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Integrins are heterodimeric transmembrane proteins that provide a bi-directional link 
between the cell’s internal biological mechanisms and the extracellular environment. 
During inside-out signalling, intracellular messages converge on the integrin 
cytoplasmic domain to induce a conformational change. This is transmitted to the 
extracellular domain where it results in an alteration in affinity for integrin ligands 
such as fibronectin and laminin. In this way the cell has developed the ability to 
modulate the critical functions of adhesion and cell movement. In outside-in 
signalling, the integrin performs a more complex function than simple adhesion; 
upon binding to ligand, the integrin extracellular domain undergoes a conformational 
change which is transmitted to the cytoplasmic domain. This alters the integrin’s 
cytoplasmic domain affinity for intracellular signalling proteins and results in the 
activation of intracellular second messenger pathways. In this way, the extracellular 
milieu is able to influence intracellular signalling including those involved in 
apoptosis. 
This thesis demonstrates data which provide original insights into bi-directional 
integrin signalling: 
Inside-out signalling: Constitutively active Notch1 increases β3-integrin affinity and 
abrogates Hras-mediated integrin suppression without increasing expression of β3-
integrin. Dominant-Negative Rras blocks Notch-mediated integrin activation and 
Notch1-mediated reversal of Hras and Raf-mediated integrin suppression and this is 
independent of erk phosphorylation. Notch1 induces Rras activation. Functional 
adhesion assays confirm that Notch1IC increases K562 adhesion in a β1-integrin 
dependent manner and this is abrogated by Dominant-Negative Rras. This data 
supports a mechanism in which Notch1 increases integrin affinity via activation of 
Rras. 
Outside-in signalling: Evidence is presented demonstrating that extracellular matrix 
proteins, laminin and fibronectin, activate β1-integrins to protect SCLC cells against 
the apoptotic effects of etoposide and ionizing radiation via PI3Kinase activation. 
This occurs in two ways: 1) PI3Kinase-dependent β1-integrin signalling resulting in 
phosphorylation of Bad and reduced caspase-9 cleavage and 2) a β1-integrin-
mediated over-riding of etoposide and radiotherapy-induced cell cycle S phase delay 
and G2/M arrest. β1-integrin-mediated outside-in survival signalling was 
investigated further in the in vivo setting; MatrigelTM, a basement membrane product 
rich in extracellular matrix proteins, promoted SCLC xenograft survival and growth 
in a β1-integrin and tyrosine kinase-dependent manner. 
This data provides novel insights into the critical functions that integrins play in 




















Inside-Out Modulation of Integrin Affinity 
1.1 Integrins 
1.2 Inside-out signalling 
1.2.1 Talin 
1.2.2 Hras, Rras and Rap 
 Cellular Factors Influencing Ras Function 
 Guanidine Exchange Factors (GEFs) 
 GTPase Activating Proteins (GAPs) 
Membrane targeting via CAAX and posttranslational modification 
1.2.3 Ras Effectors 
 GEFs 
 Raf-family serine-threonine kinases (Raf1, A-Raf, B-Raf) 
 MEKK-1 
 Phosphoinositol-3-Kinase (PI3K) 
 Nore1 
 AF-6 








Materials and Methods 
2.1 Reagents 
2.2 Antibodies 
2.3 DNA constructs 
2.4 Cell Culture 
2.5 Transformation 
2.6 DNA purification, cloning and agarose gel electrophoresis 
2.7 Transfection 
2.8 Cell lysis 
2.9 Protein Assay 
2.10 SDS polyacrylamide gel electrophoresis and Western blotting 
2.11 Integrin affinity determination by flow cytometry 
2.12 Flow cytometric analysis of β1-integrin expression on the surface of GD25 
Null and GD25 β1 cells 
2.13 Proliferation assays 
2.14 Apoptosis 
2.15 Immumnofluorescent Microscopy 
2.16 Cell Cycle Analysis 
2.17 Rras activation assay 
2.18 Cell Adhesion Assay 
2.19 SCLC xenograft experiments 
 
Chapter 3 
Notch1 increases integrin affinity via activation of Rras 
3.1 Introduction 
3.1.1 Modulators of Notch 
3.1.2 CBF-independent Notch signalling 
3.1.3 Notch signalling in lower organism development 
3.1.4 Notch – Evidence for signalling with Ras 
In lower organisms 
In higher organisms 
 6
3.1.5 Notch – Evidence for signalling with Integrins 
In lower organisms 
In higher organisms 
3.2 Confirmation of integrity of Notch1ICV1744 construct used in experiments 
3.3 Notch1ICV1744 increases integrin affinity and abrogates Hras-mediated 
integrin suppression 
3.4 Dominant-Negative Rras blocks Notch-mediated integrin activation 
3.5 Dominant-Negative Rras blocks Notch1IC reversal of (G12V)Hras-mediated 
integrin suppression and this is independent of erk phosphorylation 
3.6 Dominant-Negative Rras blocks Notch1IC reversal of Raf-mediated integrin 
suppression 
3.7 Notch1ICV1744 does not increase expression of β3-integrin 
3.8 Notch1ICV1744 induces Rras activation 
3.9 Functional assays of integrin affinity 
3.10 Characterisation of K562 transfection, viability and adhesion 
3.11 Notch1IC increases K562 adhesion in a β1-integrin dependent manner 
3.12 Dominant-Negative Rras inhibits Notch1IC-mediated Adhesion of K562 cells 




Extracellular Matrix overrides DNA-damage-induced cell cycle arrest in small 
cell lung cancer cells via β1-integrin dependent activation of PI3Kinase 
4.1 Introduction: Outside-In Integrin Signalling – Extracellular Matrix-mediated 
Multidrug Resistance 
4.1.1 Classical mechanisms of MDR 
Drug Efflux Pumps (MDR/MRP/BCRP/LRP) 
Glutathione-S-transferase (G-S-T) 
Topoisomerase II-associated Multi-Drug Resistance 
4.1.2 The role of integrins and extracellular matrix in chemoresistance 
4.1.3 Increased resistance to tumour penetration resulting in reduced drug exposure 
4.1.4 Reduced induction of DNA damage or upregulated DNA repair 
 7
4.1.5 Autocrine loops 
4.1.6 Integrin-mediated modulation of cell survival and death signalling pathways 
Outside-in signalling 
Apoptotic second-messenger systems 
Bax/Bcl-2 signalling 
Cell cycle effectors 
4.2 Extracellular matrix protects small cell lung cancer against etoposide and 
radiation-induced apoptosis 
4.3 Extracellular matrix-mediated protection is β1-integrin-dependent 
4.4 Extracellular matrix-mediated protection is Protein Tyrosine Kinase and 
Phosphoinositol-3-kinase-dependent 
4.5 Adhesion of SCLC cells to ECM proteins does not modulate initial levels of 
DNA damage or subsequent DNA repair 
4.6 ECM proteins override etoposide and radiation-induced G2/M arrest via β1-
integrin and PI3Kinase-dependent modulation of cell cycle regulatory 
proteins 
4.7 Discussion 
4.7.1 Extracellular matrix protects small cell lung cancer against etoposide and 
radiation-induced apoptosis. 
4.7.2 Extracellular matrix-mediated protection is β1-integrin-dependent 
4.7.3 Extracellular matrix-mediated protection is Protein Tyrosine Kinase and 
Phosphoinositol-3-kinase-dependent 
4.7.4 Adhesion of SCLC cells to ECM proteins does not modulate initial levels of 
DNA damage or subsequent DNA repair 
4.7.5 ECM proteins override etoposide and radiation-induced G2/M arrest via β1-









The Role of β1 Integrins and Protein Tyrosine Kinases in vivo in the 
Modulation of Extracellular Matrix-mediated Survival Signalling in Small Cell 
Lung Cancer 
5.1  Introduction 
5.2 In vivo, extracellular matrix promotes SCLC xenograft survival and growth 
5.3 Matrigel-mediated xenograft growth is β1-integrin dependent 
5.4  Genistein inhibits ECM-mediated xenograft survival in vivo only when 
delivered pre-implantation 





Assessment of a GD25 Embryonic Murine Fibroblast Model to Investigate 
Extracellular Matrix-mediated Multidrug Resistance (ECM-MDR) in vitro 
6.1 Introduction 
6.2 GD25 Null and GD25 β1 cell lines: expression of mouse β1-integrin 
6.3 Fibronectin and laminin do not mediate protection against etoposide-induced 
apoptosis in GD25 cells plated in DMEM with 10% FCS 
6.3.1 Etoposide-induced apoptosis in GD25 cells plated in serum-containing 
media: time and dose response 
6.3.2 Fibronectin and laminin do not mediate protection against etoposide-
induced apoptosis in GD25 cells cultured in DMEM with 10% FCS 
6.4 Fibronectin and laminin do not mediate protection against etoposide-induced 
apoptosis in GD25 cells plated in SITA 
6.4.1 Etoposide-induced apoptosis in GD25 cells plated in SITA: time and dose 
response 
6.4.2 Fibronectin and laminin do not mediate protection against etoposide-
induced apoptosis in GD25 cells plated in SITA 



























a.a.  amino acid 
ABC  ATP binding cassette 
Ab  Antibody  
abl   Abelson tyrosine kinase 
ADAM a disintegrin and metalloprotease 
ADMIDAS  adjacent to MIDAS 
AF-6  ALL1 fused gene from chromosome 6 
ANK   ankyrin repeats 
AP-1  c-jun/c-fos dimer 
Apaf-1  apoptotic protease activating factor 
Aph1  Artemia POU-Homeoprotein 
APX-1 ascorbate peroxidase-1 
ARG-2F16 C.elegans Notch ligand 
ATM  ataxia telangiectasia mutated 
ATR  ATM-related protein 
Aup1   Ancient Ubiquitous Protein1 
 
B12.2   C.elegans Notch ligand 
BCA  bicinchoninic acid 
bHLH  basic Helix-Loop-Helix 
BRCA1 breast cancer gene-1 
BRCP  Breast cancer resistance protein 
BSA  Bovine serum albumin 
 
C3G  guanine nucleotide exchange factor 
CAAX  cysteine, aliphatic, aliphatic, any 
CalDAG-GEF calcium and DAG-regulated GEF 
CBF   Core Binding Factor  
CBP/p300 CREB-binding protein 
cdc25  GEF for Saccharomyces.cerevisiae 
CDK  cyclin-dependent kinase 
CDKI  cyclin-dependent kinase inhibitor 
Ce  Caenorhabditis elegans 
Chk1  Checkpoint kinase 
CIB   calcium and integrin-binding protein  
CIR  CBF1-interacting corepressor 
CLL  chronic lymphocytic leukaemia  
CSL   Core Binding Factor, Su(H), Lag-1 
 
DAG  diacylglycerol  
Del-1  developmental endothelial locus-1 
DHR  discs-large homology region 
DLL  Delta-like ligand 
DMEM Dulbecco’s modified Eagle’s Medium 
DNA-PKcs DNA Protein kinase catalytic subunit 
DSL  Delta, Serrate, Lag-2 
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EBD   effector binding domain 
ECM  extracellular matrix 
EDTA  ethylenediaminetetraacetic acid 
EGF   epidermal growth factor 
EGFR   EGF receptor 
Epac  exchange protein directly activated by cAMP 
erbB2  erythroblastic leukaemia viral oncogene homolog 2 
Erk1/2  extracellular signal-related kinase 1/2 
 
F3  FERM 3  
FACS  Fluorescence-activated cell sorting 
FADD  Fas-associated protein with death domain 
FAK  focal adhesion kinase 
FBS   foetal bovine serum 
FCS  foetal calf serum 
FERM  four point one, ezrin, radixin, moesin 
FGF  Fibroblast growth factor 
FLIP  FLICE-like inhibitory protein 
FRET   fluorescence resonance energy transfer 
 
GABP-β growth-associated binding protein beta 
GAP   GTPase Activating Protein 
GAP1m mammalian homolog of Ras-GTPase activating protein 
GCN5  histone acetyl-transferase 
GDP  guanosine diphosphate 
GEFs   guanidine Exchange Factors 
GFFKR Gly-Phe-Phe-Lys-Arg 
GFP  Green Fluorescent Protein  
GLGF  gly-leu-gly-phe 
GLP-1  Germline proliferation 1 
Grb2  growth factor receptor-bound protein 2 
GSK  glycogen synthase kinase 
GST  glutathione-s-transferase 
GTP  guanosine triphosphate 
Gy  Gray (joule/kg) 
 
γH2Ax  histone H2Ax phosphorylated on Serine139 
H+E  haematoxylin and eosin 
hASH1 human Achaete-scute homolog 
HDAC  histone deacetylase 
Hes  Hairy enhancer of Split 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HERPs  Hes-related proteins 
HR  homologous recombination 
HRP   horseradish peroxidase 
HSP60  heat shock protein 60 
Hus1  DNA damage checkpoint protein 
 12
 
IAP  integrin-associated protein 
IC1n  integrin IIb 3-associated protein 
IGF-1  insulin-like growth factor 1 
ICAM  intercellular adhesion molecule 
ICAP-1α integrin cytoplasmic domain-associated protein-α 
IgG  immunoglobulin G 
Il-6  interleukin 6 
ILKBP  ILK-binding protein 
ILK  Integrin linked kinase 
 
JNK  Jun N-terminal kinase 
 
p27Kip1 cyclin-dependent kinase inhibitor, 27kDa 
Ku70  70kDa subunit of DNA-protein kinase complex 
 
Lag  Lin and GLP 
LFA1  lymphocyte function-associated antigen 
LIMBS  ligand-induced metal-binding site 
LIN-3  C.elegans EGF homolog 
LIP-1  C.elegans MAPkinase phosphatase 
LNR   Lin12/Notch repeat 
LRP  lung cancer resistance protein  
 
Mac-1/CR3 integrin αMβ2/complement receptor 3 
MAML  mastermind-like; transcriptional coactivator for Notch 
MAPK   mitogen activated protein kinase 
Mash1  mouse Achaete-scute homolog 
MDC1  mediator of DNA-damage checkpoint 
MDR  multidrug resistance 
MEK  mitogen activated protein kinase 
MEKK MEK kinase 
MHC-I major histocompatibility complex 1 
MIDAS  metal ion-dependent adhesion sites 
MKP3  mapk phosphatase 
Mre11  meiotic recombination 11 
MR-GEF Mras-regulated GEF 
mSin3A mammalian self-inactivating 3A 
mTOR  mammalian target of rapamycin 
MRP  multi-drug resistance-associated proteins 
MVP   major vault protein 
MyoD  myogenic differentiation protein 
 
Nbs1  Nojmegen breakage syndrome 1 
NcoR  nuclear corepressor 
NFκB   nuclear factor kappa B 
NGF  nerve growth factor 
NHEJ   non-homologous end-joining 
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Nore1  novel ras effector 1 
NPxY   Asn-Pro-x-Tyr  
Nrarp  Notch-regulated ankyrin repeat protein 
NSCLC non -small cell lung cancer 
 
OPA  poly-glutamine sequence 
 
p21Cip1 cyclin-dependent kinase inhibitory protein 1, 21kDa 
p56lck  leukocyte-specific protein tyrosine kinase, 56kDa 
Pac1  Platelet activation complex; αIIβ3 monoclonal antibody 
PARP   poly-ADP ribose polymerase 
PBS  phosphate buffered saline 
pCAF  p300/CBP-associated factor 
PDGF  platelet-derived growth factor 
PEA-15 phosphoprotein enriched in astrocytes 
PECAM platelet endothelial cell adhesion molecule-1 
pEGFP1 EGF-encoding expression vector 
Pen-2  presenilin enhancer-2 
PEST   Proline, Glutamate, Serine, Threonine 
PFA  phosphonoformic acid 
PgP  P-glycoprotein 
PH  Pleckstrin homology 
PI   phosphoinositol 
PI3K   phosphoinositol-3-kinase  
PI4K  phosphoinositol-4-kinase 
PI45P2  phosphoinositol-4,5-bisphosphate 
PINCH binding protein for ILK 
PIP5-kinase phosphoinositol-4-phosphate 5-kinase 
PIPKIγ90 typeI gamma phosphatidylinositol phosphate kinase isoform γ90 
PIPKIγ-661  typeI gamma phosphatidylinositol phosphate kinase isoform γ661 
PKB  Protein kinase B  
PKCε  protein kinase C epsilon 
PLCε  phospholipase C epsilon 
PLL  poly-l-lysine 
PP2A  protein phosphatase 2A 
PTB   phosphotyrosine-binding 
 
Rad50  protein involved in DNA double strand break repair 
RA-GEFII  Ras-associated guanine exchange factor 
RalGDS Ral guanine nucleotide dissociation stimulator 
RalGEF2 Ral guanine exchange factor 2 
RalGPS Ral-GEFs with PH domain and SH3-binding motif 
RAM  regulation of amino-acid metabolism 
RapI-GAPII Rap1 GTPase-activating protein 2 
RasGRF1 Ras-specific guanine nucleotide-releasing factor 1 
Rap  Ras-related protein 
RapL regulating of cell adhesion and polarisation enriched in lymphoid 
tissues 
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RasGRF1 Ras-specific guanine nucleotide-releasing factor 1 
RasGRP2/3 Ras guanyl releasing protein 2/3 
Rb  retinoblastoma protein 
RBD  ras-binding domains 
RBPJκ recombination signal binding protein for immunoglobulin kappa J 
region 
RGD   Arg-Gly-Asp 
Rgl  Ral GDP dissociation stimulator-like 
Rgr  RalGDS-related 
Rlf  RalGEF-like 
RP-A  replication protein A  
RPE  P-phycoerythrin 
RPMI  Roswell Park Memorial Institute 
RQRR  arg-gln-arg-arg 
 
SAP30  Sin3A binding protein, 30kDa 
SDS-PAGE  sodium dodecyl sulphate polyacrylamide gel electrophoresis 
Sel-10  F-Box protein 
SH2/3  Src-homology 2/3 
SITA  selenium, insulin, transferrin, albumin 
SMC   Sensory Organ Mother Cell 
smgGDS small G-protein dissociation stimulator 
SMRT  silence mediator for retinoic acid and thyroid receptors 
Sos  son of sevenless 
SPA   Rap1-GAP in lymphocytes 
Src  family of tyrosine kinases 
ST6Gal-1 beta galactosidase α-2,6-sialyltransferase 1 
Su(H)  Suppressor of Hairless 
SUP-17 suppressor 17, an ADAM protein 
 
TACE  Tumor necrosis factor-alpha-converting enzyme 
TAD  Transcriptional activation domain 
TC21  teratocarcinoma oncogene 21 
TCR  T-cell receptor 
TEMED N,N,N’,N’-tetramethylethylenediaine 
TGF Transforming Growth Factor 
Tiam-1 T lymphoma invasion and metastasis-inducing gene 1 
TLE Transducin-like enhancer of split 
TopoII  Topoisomerase 2 
TPA   tissue plasminogen activator 
 
Vav  Rho-family GEF 
V-CAM1 vascular cell adhesion molecule 1 
VEGF  vascular endothelial growth factor 
VLA-1  integrin α1β1 
VPCs  vulval precursor cells 
 
WAF1  wild-type p53-associated fragment 1 
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WEE1  cdc2 inhibitor 
 
XRCC  Xray cross complementing 
 

























 Inside-Out Modulation of Integrin Affinity 
 
1.1 Integrins 
Integrins are a family of adhesion receptors which mediate cell-extracellular matrix 
and cell-cell interactions. They consist of heterodimers containing non-covalently 
linked α and β subunits which are single-pass transmembrane proteins. The 
invertebrates Caenorhabditis.elegans (worm) and Drosophila.melanogaster (fly) 
possess 2α/1β and 5α/2β subunits respectively and the vital roles that these proteins 
play in cell development and signalling is highlighted by the frequent early non-
viable phenotype of knockout mutants (Brown et al., 2000). To date 18α/8β subunits and 24 
distinct heterodimers have been identified in vertebrates, these interacting with 
extracellular matrix (ECM) proteins and cell surface receptors/proteins with a 
varying degree of promiscuity (see Appendix: Table 1). Integrin subunits typically 
contain a large extracellular domain, a single-pass transmembrane domain and a 
short cytoplasmic tail of 20-60 amino acids (Hynes, 2002). A significant advance in the 
understanding of integrin-ligand interactions was provided by the demonstration of 
the X-ray structure of the extracellular domains of integrin αVβ3 (Xiong et al., 2001) (see 
Appendix: Fig 1). The integrin structure resembles a “head” connected to two legs. 
The head piece contains a seven-bladed β-propeller in the α-subunit closely 
juxtaposed with a von Willebrand Factor (vWF) type A domain in the β-subunit (βA 
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also referred to as the “I” domain or βI; several α subunits also contain vWF type A 
domains). A groove formed in the upper surface by the apposition of these two 
domains is able to bind peptides containing the RGD (Arg-Gly-Asp) sequence 
common to many extracellular matrix proteins. The βA domain is connected to an 
immunoglobulin-like “hybrid” domain and thence via EGF (epidermal growth factor) 
repeats and a β-tail domain to its transmembrane domain. The α-subunit is connected 
to its transmembrane domain by 3 β-sandwich modules (thigh, calf1, calf2). The top 
surface of the βA domain also contains three metal ion-dependent adhesion sites; 
MIDAS, adjacent to MIDAS (ADMIDAS) and ligand-induced metal-binding site 
(LIMBS) (Chen et al., 2006),(Xiong et al., 2002). Cation binding to all three of these sites is able 
to influence movements of the α-helices of the βA domain and thus to influence 
affinity states. Cations can increase (Mn2+/Mg2+) or decrease (Ca2+) affinity for 
ligands and can also modulate ligand specificity (Plow et al., 2000). In the inactive state 
(low affinity for ligands) the αVβ3 integrin adopts a folded structure bent at the 
“genu” which occurs at the thigh/calf1 level of the α-subunit and between the Hybrid 
domain and EGF repeats of the β-subunit (Xiong et al, 2001). In this inactive state the 
ligand-binding groove faces towards the plasma membrane and is inaccessible to 
ligands. The “legs” of this inactive integrin are stabilised by the conformation of the 
α and β-subunit cytoplasmic tails. Alterations in the conformational state of the 
cytoplasmic tail by “inside-out” signalling are propagated to the head resulting in 
shifts of α-helices in the βA domain, a swing of the hybrid domain away from the α-
subunit  and extension of the “genu” to an obtuse angle. As a result of this unfolding 
the ligand binding groove is “activated” to a higher affinity, exposed state (Takagi et al., 
2002). Recently FRET (fluorescence resonance energy transfer) has provided an 
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addition to this model which includes intermediate “primed” conformations (Chigaev et 
al., 2003). In general, higher affinity states correlate with a greater distance of head 
domain movement away from the membrane. 
A key feature of integrins is their ability to participate in bidirectional 
transmembrane signalling (Shattil et al., 2004),(Calvete, 2004). Far from being inert anchorage 
proteins, integrins are able to transmit “Inside-Out” and “Outside-In” signals by 
virtue of a transmission of conformational changes from the cytoplasmic to 
extracellular domains (inside-out) and vice-versa (outside-in). This fundamental 
feature of integrins is most well characterised in the platelet integrin, αIIbβ3. When 
platelets are activated by agonists (e.g. thrombin), intracellular signals converge on 
the αIIbβ3 integrin cytoplasmic tail and via integrin conformational change modify 
the extracellular domain from a low to a high affinity state - “Inside-Out” signalling 
(Byzova et al., 2000),(Bertoni et al., 2002). Conversely, ligand binding to the extracellular domains 
results in transmission of altered conformation to the intracellular cytoplasmic tails. 
This modifies the binding characteristics and activity of intracellular signalling 
proteins and transduces “Outside-In” signalling (Ginsberg et al., 2005). 
The membrane-proximal sequences of integrin cytoplasmic tails are highly 
conserved (Calderwood, 2004) (see Appendix: Fig 2). The α-subunits have a highly 
conserved GFFKR (Gly-Phe-Phe-Lys-Arg) amino-acid sequence that auto-inhibits 
integrin activation and deletion of this sequence results in an increase in integrin 
affinity (O'Toole et al., 1994). Deletion of membrane proximal portions of the β-integrin 
similarly increase affinity whilst deletion of membrane distal portions inhibit integrin 
activation (Lu et al., 2001). In integrin-αIIbβ3, a salt bridge between R995 of αIIb and 
D723 of β3 stabilises the integrin in a low affinity state (Hughes et al., 1996). Forced 
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association of the cytoplasmic regions of αLβ2 and αMβ2 blocks activation and 
forced dissociation promotes activation (Lu et al., 2001),(Kim et al., 2003). FRET has shown 
that higher affinity states are associated with a reduction in FRET indicative of 
cytoplasmic domain spatial separation. The high affinity state associated with 
deletions of the membrane-proximal regions is independent of cell type or metabolic 
energy whereas the more carboxy-terminal modulation of integrin affinity is both 
energy and cell-type dependent (O'Toole et al., 1994),(Hughes et al., 1995). Specific sequences in 
the β tail outside the membrane-proximal region do modulate integrin affinity; 
mutations in the conserved NPxY (Asn-Pro-x-Tyr) motif reduce binding of many 
signalling proteins (Liu et al., 2000), induce structural changes in the cytoplasmic domain 
and inhibit integrin activation (Ulmer et al., 2001). Deletion of α-chain amino acids distal to 
the GFFKR sequence inhibits inside-out affinity modulation (Tohyama et al., 2003),(Kassner et 
al., 1993). i.e. the membrane-proximal amino acids stabilize the integrins in a low 
affinity state whilst the sequence of amino acids distal to these regions regulate 
activation via interactions with inside-out signalling proteins. 
 
[In addition to integrin affinity changes, integrin clustering (or “avidity”) is a 
complementary mechanism for increasing integrin adhesion and signalling. 
Clustering may be promoted by several mechanisms including ligand binding (Loftus et 
al., 1984), ligand self-association (Simmons et al., 1996), lateral interactions of integrins with 
other membrane proteins (Hemler, 1998), integrin linkages to the cytoskeleton (Bennett et al., 
1999) and homomeric interactions of integrin transmembrane domains (Li et al., 2003). As 
this thesis is concerned with integrin affinity change, clustering changes will not be 
discussed further]. 
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1.2 Inside-out signalling 
In recent years many intracellular signalling proteins have been found to be 
implicated in inside-out integrin affinity modulation. These are summarised in 
Appendix: Table 2. The most widely studied, Talin and Ras moieties (Hras, Rras, 
Rap1), are discussed in more detail below. 
 
1.2.1 Talin 
Talin is a 235kDa protein which exists as a homodimer that links integrin 
cytoplasmic domains to the actin cytoskeleton (Kobayashi et al., 2001). Talin binds strongly 
to β1A, β1D, β2, β3, β5 and weakly to β7 integrin cytoplasmic tails via the talin head 
(Calderwood, 2004). The talin head domain contains a FERM (four point one, ezrin, 
radixin, moesin) domain composed of three subdomains (F1,2,3) (Calderwood et al., 2002). 
F3 has the highest affinity of the three fragments for the cytoplasmic tail of integrin 
β3, recognising the NPxY motif. Studies using laser tweezer microscopy showed that 
talin is essential for integrin-cytoskeletal structural linkage (Jiang et al., 2003) but as well 
as a structural role in tethering integrins to the cytoskeleton, talin also plays a key 
role in regulating integrin activation (Tadokoro et al., 2003),(Calderwood et al., 2002),(Vinogradova et al., 
2002),(Knezevic et al., 1996) by increasing integrin affinity. Talin knockdown using a RNAi 
approach directly correlated with a reduction in integrin activation that was not 
rescued by other integrin activators such as Rras confirming its role as the final 
common step in inside-out activation of integrins (Tadokoro et al., 2003). Upon binding to 
talin the α and β-cytoplasmic tails undergo a spatial separation which is transmitted 
as a conformational change in the extracellular domain resulting in increased integrin 
affinity (Kim et al., 2003). 
 21
Talin-mediated modulation of integrin affinity can be further influenced by several 
intracellular mechanisms; The talin head domain is basic (Rees et al., 1990) enabling it to 
interact with negatively charged phosphoinositides such as PI45P2 (phosphoinositol-
4,5-phosphate). Integrin-ligand binding results in increased PI45P2 synthesis (McNamee 
et al., 1993) by sequential phosphorylation of PI by PI4K and PI4P5Ks (Anderson et al., 1999). 
The integrin binding activity of talin is enhanced by its interaction with this 
membrane phospholipid PI45P2 (Martel et al., 2001). PI45P2 binding to talin induces a 
conformational change in talin which unmasks the integrin binding site within the 
FERM domain and increases its affinity for the β1 integrin cytoplasmic tail 
promoting integrin activation. Talin also binds to and activates a splice variant of the 
PI45P2-producing enzyme PIPKIγ-90 (Ling et al., 2002),(Di Paolo et al., 2002) raising the 
possibility of a positive feedback loop. However, PIPKIγ-90 and β3-integrin tails 
also compete for identical F3 binding sites on talin and may therefore act to inhibit 
integrin activation in some settings. Another phosphoinositide pathway may act in 
opposition: Integrin-ECM engagement induces focal adhesion formation. FAK-
induced (Focal Adhesion Kinase) association of Src and PIPKIγ-661 (typeI gamma 
phosphatidylinositol phosphate kinase) and subsequent Src-mediated 
phosphorylation of PIPKIγ-661 on tyrosine644 increases PIPKIγ-661’s affinity for 
talin 15-fold and consequently blocks talin binding to the cytoplasmic tail of β1 
integrin (Ling et al., 2003). i.e. Src may inhibit talin-integrin interaction to act as a switch 
in focal adhesion turnover. 
Other phosphotyrosine-binding (PTB) domains can bind NPxY motifs raising the 
possibility of competition with talin e.g. integrin cytoplasmic domain-associated 
protein-α (ICAP-1α) binds to β1A via a PTB-domain/NPxY interaction and inhibits 
 22
talin association (Bouvard et al., 2003). Calcium-calmodulin dependent protein kinase II 
phosphorylates ICAP-1α and regulates β1-integrin-mediated adhesion (Bouvard et al., 
1998). Talin binds to the first NPxY motif of β1-integrin whilst tyrosine 
phosphorylation of the second NPxY motif inhibits ICAP-1α binding (Chang et al., 2002). 
 
1.2.2 Hras, Rras and Rap 
Since its discovery in 1964, the Ras superfamily has expanded to a group of over 150 
small GTPases (distinct from the large heterotrimeric αβγ G-proteins) that are 
implicated in many signalling processes in cells. They can be assigned to 6 families; 
Ras, Rho, Ran, Rab, Arf and Rad/Rem/Kir which are closely interrelated 
phylogenetically (Ehrhardt et al., 2002) (see Appendix: Fig 3). 
Within the Ras family are 5 subfamilies: 1) p21ras proteins – Hras, Nras, Kras4A, 
Kras4B, 2) Rras/TC21 (Rras2), 3) Mras (Rras3), 4) Rap, 5) Ral. All contain a 
carboxy CAAX (cysteine, aliphatic, aliphatic, any) domain and exhibit a high degree 
of amino acid sequence homology across a wide variety of species from yeast 
Saccharomyces.cerevisiae (Haney et al., 1994), to Drosophila.melanogaster (Brock, 1987) and 
humans (Lowe et al., 1987a). 
Although the Ras superfamily members have independent and differing functions, 
the mechanism by which they signal to effectors follows a similar pattern:  In the 
inactive state Ras members are bound to GDP. To become activated, Guanidine 
Exchange Factors (GEFs) catalyse the release of GDP which is then replaced by the 
more abundant GTP (Lenzen et al., 1998). GTP-bound Ras moieties undergo activating 
allosteric changes in two regions (termed SwitchI and SwitchII) which facilitate 
binding and signalling to multiple effectors. The Ras family members possess 
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intrinsic GTPase activity. The dephosphorylation of GTP to GDP results in the 
insertion of an arginine side chain into the active site of Ras resulting in reduced 
activity. GTPase Activating Proteins (GAPs) increase the rate of dephosphorylation 
of GTP-GDP and thus play an important role in modifying the rate of conversion of 
Ras moieties to their inactive state. Several important Ras mutants have been 
developed: A (G12V)Hras mutation inhibits intrinsic GTPase activity resulting in 
failure to dephosphorylate active GTP-Hras to inactive GDP-Hras. (G12V)Hras is 
therefore constitutively active. (G38V)Rras is constitutively active in an identical 
manner. Conversely, (T43N)Rras binds GDP with higher affinity than GTP, 
rendering it Dominant-Negative (Huff et al., 1997). 
 
Cellular Factors Influencing Ras Function 
 
Guanidine Exchange Factors (GEFs) 
Nearly all GEFs activate Ras by binding via a highly conserved region termed the 
minimal Ras domain of cdc25 (the GEF for Saccharomyces.cerevisiae).  
In addition to this cdc25 domain, GEFs contain multiple other domains (see 
Appendix: Fig 4) which enable binding to protein/lipid, diacylglycerol (DAG) and 
calcium, indicating a much greater capacity for signalling complexity and crosstalk 
with other pathways. For example, receptor tyrosine kinases acting through effector 
proteins such as Grb2 can activate Sos (GEF) via interaction of SH2 and SH3 
domains (Gale et al., 1993),(Li et al., 1993). 
Structure-function studies have identified four regions of Ras that interact with 
GEFs; the switchI region (a.a. 25-40), switchII region (a.a. 57-65) and alpha helix3 
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(a.a. 92-104) plus loop7 (a.a. 105-9). However, the specificity of Ras for individual 
GEFs is poorly understood; for example, the helix3 region of Rras (a.a. 91-103) is 
responsible for binding of RasGRF1 but not Sos (two GEFs for Rras) (Tian et al., 2001). 
Each Ras moiety is able to bind to several GEFs (see Appendix: Table 3) and vice 
versa and interestingly, the only GEF that does not possess a cdc25 domain, 
smgGDS, has the broadest Ras specificity (Vikis et al,. 2002). 
Difficulty exists in the interpretation of Ras research: Nearly all studies utilise 
models which involve overexpression of Ras moieties. This overexpression may 
cause mislocalisation resulting in inappropriate recruitment of GEFs and other 
effectors. This may explain, in part, GEFs apparent marked promiscuity for multiple 
Ras members. Furthermore, overexpression of constitutively active Ras for chronic 
periods at supraphysiological levels may not represent the physiological state. 
Similarly, Dominant-Negative Rases produce their effect by inhibiting release of 
GDP which causes sequestration of GEFs. Since GEFs interact with several Ras 
members it is possible that the effect of Dominant-Negative overexpression in these 
experiments is to inhibit other Ras pathways. Many published experiments also 
utilise monoclonal antibodies considered specific to an epitope of p21Ras. However, 
the epitope consists of residues in SwitchII which are very similar to sequences in 
Mras and TC21, resulting in cross-reactivity (Ehrhardt et al., 1999),(Feig, 1999).  
 
GTPase Activating Proteins (GAPs) 
GAPs catalyse the hydrolysis of Ras-bound GTP to GDP resulting in a return of Ras 
to the inactive state. This mechanism involves the insertion of an arginine side-chain 
into the active site of Ras (Sermon et al., 1998). Known GAPs involved in Hras, Rras and 
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Rap signalling are summarised in Appendix: Table 3. Similar to GEFs, GAPs 
exhibit broad Ras-binding specificity and are able to interact with other signalling 
pathways e.g. GAP1m and GAP1IP4BP/Rras-GAP) can be regulated via binding to 
inositol phosphates and GAP1m may interact with the large heterotrimeric GTPases 
by binding directly to Gα12 (Wittinghofer, 1998),(Jiang et al., 1998b). 
 
Membrane targeting via CAAX and posttranslational modification 
The carboxy-terminal CAAX motif of Ras family members is a target for enzymic 
processing which results in the addition of a farnesyl or geranylgeranyl group (Casey, 
1995) essential for Ras localisation to the plasma membrane. Inhibitors of this process 
block Ras function. Further modifications influence the activity of Ras moieties 
(Hancock et al., 1990),(Hancock et al., 1989); for example Hras, Nras, Kras4A and TC21 become 
palmitoylated and this results in transport via the Golgi into cholesterol-rich 
membrane lipid rafts (Hancock et al., 1990). The localisation of Hras to lipid rafts is 
essential for its activation of downstream effectors, possibly by regulating the 
proximity to other signalling proteins and GEFs (Roy et al., 1999),(Jaumot et al., 2002). In 
contrast Kras4B and Mras lack palmitoylation sites but have multiple basic residues 
that stabilise non-raft membrane localisation; these moieties bypass the Golgi and 
transport to bulk plasma membrane in a tubulin-dependent manner (Apolloni et al., 
2000),(Thissen et al., 1997). 
Recently, further insights into subcellular movements of palmitoylated Ras members 
have been elucidated (Rotblat et al., 2006); palmitoylated Hras and Nras are transported 
through the cytoplasm on 80-100nm cytoplasmic “rasosomes” that are not typical 
plasma membrane or Golgi-derived vesicles. This mechanism is dependent on the 
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hypervariable region of Ras and is not inhibited by actin cytoskeleton or microtubule 
disruption. 
 
1.2.3 Ras Effectors 
Many proteins have Ras-binding Domains (RBDs) capable of interacting with Ras 
proteins (see Appendix: Table 4) though not all of these have been proven to be 
involved in Ras-mediated signalling: 
  
GEFs 
A number of Ral-GEFs (e.g. RalGDS, Rgl, Rlf/Rgl2, RPM/Rgl3, RalGPS/Ral-GEF2, 
Rgr (Albright et al., 1993),(Kikuchi et al., 1994),(Spaargaren et al., 1994),(Shao et al., 2000),(D'Adamo et al., 1997) are 
also effectors for Ras, Rap and Rit and this has been shown to result in, for example, 
Ras-mediated activation of RalA (Rosario et al., 2001). Similarly, two Rap-GEFs (MR-GEF 
and RA-GEFII) are known to function as Mras effectors; overexpression of Mras and 
RA-GEFII results in activation of Rap1A (Gao et al., 2001). Similarly, activated Hras 
stimulates PLCε-mediated hydrolysis of PI45P2 (Kelley et al., 2001). 
 
Raf-family serine-threonine kinases (Raf1, A-Raf, B-Raf) 
p21Ras members activate mitogen activated protein kinases (MAPKs) to promote 
proliferation via a cascade involving initial activation of Raf (Vojtek et al., 1993),(Zhang et al., 
1993). The precise mechanism of activation of Raf is not known though this may 
involve direct activation by Ras binding and indirect via recruitment of Raf to the 
plasma membrane (Rizzo et al., 2000). Kras and Hras are more efficient activators of Raf 
than Rras and Mras (Voice et al., 1999). The amino-acid residues of Hras critical to binding 
 27
Raf include a.a. 31-45 (which neighbours the effector region) and a.a. 56-59 (n-
terminal of switchII region) (Shirouzu et al., 1994). 
 
MEKK-1 
Another serine-threonine kinase, MEKK-1, an activator of MEK1/2 and Erk1/2, JNK 
and p38mapk (Lange-Carter et al., 1993),(Xu et al., 1996), binds directly to and is activated by the 
effector domain of active p21Hras (Russell et al., 1995). 
 
Phosphoinositol-3-Kinase (PI3K) 
This critical enzyme with lipid and protein kinase activity binds directly to the 
effector domain of GTP-bound Ras via its catalytic p110α (Rodriguez-Viciana et al., 1994) 
subunit, catalysing the activation of PI3K effectors such as PKB (Katso et al., 2001) which 
promote cell survival. Activated Rras and Mras are more efficient activators of PI3K 
than Hras (Kimmelman et al., 2000). Ras members can activate Rho via PI3K; PI3K binds to 
PH domains of Sos1/2, Vav and Tiam-1 (Nimnual et al., 1998),(Han et al., 1998),(Michiels et al., 1997) 




In a yeast two-hybrid screen a presumed adaptor protein containing several SH3-
domain binding sites and a DAG-binding site, Nore1, was identified as a protein that 





AF-6 is the mammalian homologue of the Drosophila protein Canoe and is believed 
to participate in cell-cell adhesion regulation downstream of Ras (Taya et al., 1998). Ras 
and Canoe are functionally linked in Drosophila ommatidial development (Gaengel et al., 
2003), though in Drosophila dorsal closure AF-6 binds preferentially to activated Rap1 
and acts as a Rap1 effector (Boettner et al., 2003). 
 
1.2.4 Functions of Ras  
Ras moieties have multiple well documented functions in development, 
transformation, growth stimulation and inhibition, differentiation and adhesion 
(Ehrhardt et al., 2002). Hras and Rras share approximately 55% sequence homology with 
the main region of divergence being the c-terminal 26 amino acids (Lowe et al., 1987a). 
Despite similar amino-acid sequences, Hras and Rras expression in mammalian cells 
produces significantly different responses. Though both are able to induce cellular 
transformation dependent upon conserved sequences in their effector binding domain 
(amino acids 32-40 of Hras (Huff et al., 1997)) and the integrity of their c-terminal CAAX 
domains (Buss et al., 1989), Hras is able to cause cellular transformation in a wide range of 
cells whilst Rras is much more cell type specific in this respect. Furthermore, Rras-
transformed NIH3T3 cells do not display all of the morphological features associated 
with Hras transformation (Cox et al., 1994). Amino acids 5-120 of Hras share 71% 
homology with Rras (Lowe et al., 1987a). However, amino acids 121-189 show the greatest 
divergence with only 41% homology. Lowe et al. (Lowe et al., 1988) substituted the 
aligned sequences of Hras and Rras that showed the greatest sequence divergence 
(Rras1-30/Hras1-4, Rras52-57/Hras26-31, Rras67-78/Hras41-52, Rras112-
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124/Hras86-98, Rras137-218/Hras111-end) to assess which amino acid regions were 
most important in Hras/Rras-mediated transformation and integrin affinity 
modulation. Exchanging amino-acids 1-30 of Rras for 1-4 of Hras did not alter the 
Hras transforming phenotype. It is not surprising that the first 26 amino acids of Rras 
are not involved in signalling function since Xray crystallography predicts that these 
26 amino acids extend away from the GTP binding site (McCormick et al., 1985). Only 
substitution of the c-terminal tail altered Hras transformation to an Rras phenotype, 
though it is unclear whether this relates to alterations in c-terminal-dependent 
membrane targeting. Also, replacing amino acids 137-218 of Rras with 111-189 of 
Hras does not induce a Hras-transforming phenotype. i.e. amino acids 111-189 are 
essential but not solely responsible for a Hras transformation phenotype (Lowe et al., 
1988).  
Hras and Rras also produce different responses to serum deprivation; whereas Hras 
induces survival in response to growth factor withdrawal (Chou et al., 1997), Rras 
increases apoptosis in response to serum deprivation (Wang et al., 1995). Furthermore, Rras 
differs from Hras in its failure to induce neurite outgrowth in PC12 cells (Rey et al., 1994). 
These differences may, in part, relate to differences in specificity for shared 
downstream effectors as described above. 
 
In the following section Ras-mediated integrin affinity modulation and adhesion will 
be discussed in more detail: 
Three Ras moieties have been shown to play a critical role in integrin affinity 
modulation; Hras, Rras and Rap. In most model systems Hras decreases whilst Rras 
and Rap increase integrin affinity. 
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Hras 
Hughes et al showed that constitutively active (G12V)Hras reduced integrin affinity 
in Chinese Hamster Ovary cells and this was not related to integrin phosphorylation 
or dependent on de novo mRNA or protein synthesis (Hughes et al., 1997). Hras residues 
148-171 were critical for this suppression (Hughes et al., 2002). 
Initially it was considered that the canonical ras-raf-mapk pathway was likely to be 
implicated in integrin affinity suppression. However, although Raf1, the downstream 
effector of Hras, is required for Hras-mediated integrin suppression (Hughes et al., 1997), 
erk phosphorylation and integrin suppression were able to be uncoupled using Hras 
mutants. Also α5β1 suppression by constitutively active Raf1 is not inhibited by 
MKP3 (a mapk phosphatase) or MEK inhibitors (e.g. PD98059) and overexpression 
of activated MEK does not suppress integrin affinity (Hughes et al., 2002). Thus it appears 
that Hras and Raf1 suppress integrins independent of erk/mapk activation. An 
alternative hypothesis is that erk/mapk are involved, but in specific cellular 
compartments that are not accurately assessed in experiments assessing bulk cellular 
activation. It is important to note, however, that Hras-mediated suppression is highly 
contextual; Hras suppresses integrin affinity in fibroblasts but activates in other cell 
types (Kinbara et al., 2003). For example, Dominant-Negative Hras reduces α4/5β1 affinity 
in haemopoietic Baf-3 cells (Shibayama et al., 1999) and decreases ICAM (intercellular 
adhesion molecule) binding in eosinophils (Myou et al., 2002). LFA1 (lymphocyte 
function-associated antigen, also known as αL/β2) is activated by Hras in adult T cell 
leukaemia cells (Tanaka et al., 1999). In model systems where Hras activates integrins it is 
usually via PI3K since it is blocked by inhibitors of PI3K, Ly294002 and 
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wortmannin, and reproduced by overexpression of p110α. Models demonstrating 
integrin suppression are usually mediated via Raf1. 
Also note that in some models integrin affinity modulation may occur via non-Raf 
mediated mechanisms e.g. (G12V)Hras causes α2-6 sialylation of β1-integrins due to 
altered expression of ST6Gal-1 (a sialylator) and increased sialylation modulates 
collagen binding in a HD3 colonocyte overexpression model (Seales et al., 2003). 
 
Rras 
In contrast to Hras, Rras increases integrin affinity. Ruoslahti showed initially that 
constitutively active Rras converted mouse 32D and human myeloid cells from 
suspension to adherent phenotype (Zhang et al., 1996). Dominant-Negative (S43N)Rras 
produced the opposite effect. In these models Rras increased the affinity of integrins 
αIIbβ3 and α5β1 for fibronectin. Subsequently it was shown that stably expressed, 
constitutively active Rras stimulates α2β1-dependent migration of breast epithelial 
cells across collagen (Keely et al., 1999) and this is reversed by Dominant-Negative Rras. 
Rras also induces extensive spreading in PC12 cells (Self et al., 2001), neurite outgrowth 
in embryonic retinal cells (Ivins et al., 2000) and mast cell adhesion to fibronectin (Kinashi et 
al., 2000). Rras antagonises the Hras/Raf1-mediated integrin suppression pathway, 
though this effect is not due to simple competition for the common effector Raf1 
since Rras can reverse suppression of a Raf mutant that does not possess a Ras-
binding domain (Sethi et al., 1999a), and acts independently of erk/mapk since it does not 
correlate with erk activation. Unexpectedly, mutations of the effector binding domain 
(EBD), which mediates interaction with Rras’s known effectors 
(Raf/PI3K/Nore1/RalGDS), did not correlate well with abrogation of integrin affinity 
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modulation (Sethi et al., 1999a),(Oertli et al., 2000),(Hansen et al., 2002) suggesting that known effectors 
are not involved. Using Hras/Rras chimaeras Hansen et al (Hansen et al., 2002) showed that 
the terminal 26 amino acids are sufficient to confer differential integrin affinity 
modulation, though again this may relate to alterations in subcellular localisation; 
Hras undergoes farnesylation and palmitoylation whilst Rras undergoes 
palmitoylation and geranylgeranylation (Lowe et al., 1987b) and Oertli et al showed that a 
c-terminal cysteine to serine mutation that blocked prenylation was also able to 
inhibit constitutively active (G38V)Rras-mediated affinity upregulation (Oertli et al., 
2000). 
Although little is known about the mechanisms mediating Rras’s modulation of 
integrin affinity, several groups have identified downstream mediators: In 
macrophages, Rras activates integrin αMβ2 via Rap1 resulting in increased red blood 
cell phagocytosis (Self et al., 2001),(Caron et al., 2000). In haemopoietic and epithelial cells a 
known Rras effector, PI3K, has been shown to be involved (Keely et al., 1999) in integrin 
affinity upregulation. Berrier et al (Berrier et al., 2000) also demonstrated that Rras 
propagates signals via PI3K to Rac and PKCε to regulate integrin-dependent cell 
spreading. 
Rras possesses a proline rich sequence in amino acids 199-206 that binds the SH3 
domain of Nck, a likely adaptor protein (acts via SH2 domain with 
p130Cas/PTKs/FAK). When this site was mutated in a mouse monocyte adhesion 






Rap was originally identified as a reverser of Kras phenotype (Kitayama et al., 1991); it does 
this by competing for Raf and reducing erk phosphorylation (though this may be an 
overexpression phenomenon). Rap GEFs include C3G, Epac, RasGRP2/3, RA-
GEFI/II, MR-GEF and PLCε. Rap-GAPs are Rap1-GAPII and SPA-1 and GAP1P4BP 
(see Appendix: Table 3). Rap works downstream of many cytokines and growth 
factors to increase integrin affinity e.g. Erythropoietin and Interleukin-3 cause Rap-
mediated activation of α4/5β1-integrins and this is blocked by PLCγ inhibition (Arai et 
al., 2001). Overexpression of constitutively active (G12V)Rap in macrophages increases 
αMβ2-mediated binding to C3bi-opsonised particles (Caron et al., 2000). CD98, a 
multispan transmembrane protein can reverse Hras-induced integrin suppression 
(Fenczik et al., 1997) and CD98 crosslinking causes Rap activation to sustain αLβ2-
dependent cell adhesion (Suga et al., 2001). PECAM (platelet endothelial cell adhesion 
molecule-1) in neutrophils increases αLβ2 + α4β1-mediated adhesion in a Rap-
dependent manner; Rap expression obviates the need for PECAM and Rap-GAP 
abrogates this (Reedquist et al., 2000). TCR crosslinking also causes Rap activation (Sebzda et 
al., 2002). Constitutively active Rap1 increased αIIbβ3 affinity in megakaryocytes (Bertoni 
et al., 2002) and αLβ2 affinity in Jurkat cells (Katagiri et al., 2000),(Kinashi et al., 2000). 
Indirect confirmation of Rap’s role in integrin control is provided by experiments 
manipulating Rap-GEFs and GAPs: C3G (a Rap-GEF) knockout causes reduced 
adhesion which is rescued by (G12V)Rap or other Rap-GEFs (e.g. Epac) (Ohba et al., 
2001). SPA1 (a Rap-GAP) overexpression reduces Rap activity and decreases β1-
mediated cell adhesion to fibronectin (Tsukamoto et al., 1999) and αLβ2/α4β1-mediated 
adhesion (de Bruyn et al., 2002). However, not all of Rap’s effects on adhesion and motility 
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are affinity-mediated; Rap can also affect avidity in a cell-type specific manner (Sebzda 
et al., 2002). 
Little is known about Rap’s effectors: Peterson et al (Peterson et al., 1996) showed that the 
CAAX box was not essential and hypothesised that Rap’s reversal of Hras-mediated 
integrin suppression involved EBD-dependent competition for other GEFs such as 
Rgl2. Nore1B (also known as RapL) interacts with active Rap in a yeast 2 hybrid 
screen and binds to GTP-Rap via a Ras association (RalGDS/AF-6) domain, 
resulting in hydrolysis to GDP-Rap. Nore1B coimmunoprecipitates with integrin 
αLβ2 and Nore1B overexpression causes αLβ2 clustering and increased affinity 
(Katagiri et al., 2003),(Tommasi et al., 2002). An amino terminal-truncated Nore1B inhibits TCR-
induced, Rap-dependent T cell adhesion though this may be through sequestration of 
Rap rather than direct Nore1 involvement. However, although Rras binds Nore1, an 
EBD mutation that inhibits Nore1 binding did not block Rras-mediated integrin 
activation (Oertli et al., 2000). 
 
Hypothesis: 
Extracellular matrix binding to β1-integrins prevents apoptosis in response to 
chemotherapy and radiotherapy. This is a result of β1-integrin-mediated modulation 
of classical apoptotic signalling proteins (Bax/Bcl and caspases), overriding of cell 








Materials and Methods 
 
2.1 Reagents 
Dulbecco’s Modified Eagles Medium (DMEM); penicillin; streptomycin; dialysed 
foetal bovine serum (FBS); BCA protein reagent; L-glutamine; 30% albumin (w/v); 
non-essential amino acids; 30% (w/v) acrylamide/bis solution and  
LipofectAMINETM Plus reagent were purchased from Life Technologies (Paisley, 
UK). Wortmannin and Ly294002 were purchased from Calbiochem-Novabiochem 
Corporation (Nottingham, UK). Hybond C nitrocellulose membrane and enhanced 
chemiluminescence (ECL) reagent were purchased from Amersham Life Science 
Ltd. (Cheshire, UK). JET-PEITM transfection reagent was purchased from Q-
BIOgene. Unless otherwise stated, all chemicals were purchased from Sigma 
Chemical Company (Dorset, UK). 
 
2.2 Antibodies 
Anti-HA (Y-11), anti-myc (9E10 and A14) and anti-ERK2 (C-14) were purchased 
from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Phospho-ERK1/2 (ERK-
PT115), anti-FLAG M2 monoclonal antibody, anti-actin (AC-40), anti-mouse IgG, 
mouse anti-p21Cip1/WAF1 (clone CP74) and mouse anti-p27Kip1 (clone DCS-72) 
were purchased from Sigma (Dorset U.K). All anti-species specific horseradish 
peroxidase-conjugated antibodies and RPE-Conjugated monoclonal mouse anti-
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Human CD25 Interleukin-2 receptor were purchased from DAKO (Bucks, UK). All 
anti-species specific Alexa-Fluor-conjugated antibodies were purchased from 
Molecular Probes (The Netherlands). Function-blocking β1-antibody, 4B4, was 
purchased from Coulter (Hialeah, Florida). Function-activating β1-antibody, TS2-16, 
was obtained from an in-house hybridoma. Anti-PAC1 (activation specific αIIbβ3 
antibody) and mouse anti-DNA-PKcs (p350 clone 6) were purchased from BD 
Biosciences (Oxford, UK). Rabbit anti-cleavage site-specific caspase-9 antibody 
(CCSA 315/316), rabbit anti-caspase-3 (Asp179) (5A1), anti-GSK-3α/β and rabbit 
anti-phospho-GSK-3β (pS9) were purchased from BioSource International. Mouse 
anti-cyclin A was purchased from Oncogene Research Products, USA. Mouse anti-
cyclin B was purchased from BD Transduction Labs, USA. Mouse anti-cyclin D1 
(clone AM29) was purchased from Zymed. Mouse anti-cyclin E (clone HE12) and 
mouse anti-γH2Ax were purchased from Upstate. Rabbit anti-phospho-CDK2 
(Thr160), rabbit anti-phospho-CDK1 (Tyr15), rabbit anti-phospho-Bad (Ser136) and 
rabbit anti-Bad (9292) were purchased from Cell Signaling Technology, USA. 
 
2.3 DNA constructs 
Mouse Notch1ICV1744 construct was a generous gift from R.Kopan (Washington 
University School of Medicine, St Louis, USA) and was provided carboxy-terminal 
myc-tagged in a pEGFP1 vector (with a stop codon proximal to the GFP sequence). 
To standardise controls, Notch1ICV1744 was cloned from pEGFP1 into the 
HindIII/Apa1 sites of pcDNA3.1+. For coimmunoprecipitation and 
immunofluorescence experiments which employed cotransfection of Notch1ICV1744 
and myc-tagged Ras moieties, Notch1ICV1744 was myc-untagged by digestion with 
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BamH1 and Sal1 prior to cloning into pCMV-Tag4A (which contains a Flag-tag at 
the 3-primed end). HA-tagged pDCR-(G12V)Hras and Myc-tagged pSG5-
(G38V)Rras genes were kindly donated by Dr. M.Ginsberg (Scripps Research 
Institute, La Jolla, USA). These genes were previously subcloned into pCDNA3.1+ in 
this laboratory by Dr J.Love. Myc-tagged (wt)Rras and (T43N)Rras in pSG5 were 
kindly donated by Hall (Scripps, La Jolla, CA). Interleukin-2 receptor subunit 
reporter construct, pBR322-Tac-α5 was kindly donated by S. E. LaFlamme (Centre 
for Cell Biology and Cancer research, NY, USA).  All plasmids were sequenced 
prior to use and the integrity of subsequent maxiprep products were reconfirmed by 
electrophoresis of endonuclease digested samples. 
 
2.4 Cell Culture 
Chinese Hamster Ovary cells stably expressing the chimaeric integrin αIIbβ3/α6β1 
(CHOαβpy) in association with a gene resistant to G418 were a generous gift from 
Professor Mark Ginsberg. These were cultured in CHO complete media: DMEM 
supplemented with 10%(v/v) heat-inactivated foetal calf serum (Labtec), 5mg/ml L-
glutamine, 100U/ml penicillin, 100μg/ml streptomycin (Invitrogen Ltd, UK), 
400μg/ml G418 (Invitrogen)  and 1% NEAA (Life Technologies). Cells were 
passaged on reaching confluence every three to five days.  Cells beyond passage 12 
were discarded and new stocks brought up from frozen. In experiments where CHO 
cells were quiesced, CHO quiescent media contained DMEM supplemented with 
0.25%(w/v) BSA, 5mg/ml L-glutamine, 100U/ml penicillin, 100μg/ml streptomycin 
and 1% non-essential amino acids. 
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K562 cells were cultured in K562 complete media: HEPES buffered RPMI 1640 
medium (Invitrogen Ltd, UK) supplemented with 10%(v/v) heat-inactivated foetal 
calf serum (Labtec), 5mg/ml L-glutamine (Life Technologies, Paisley, UK) , 
100U/ml penicillin and 100μg/ml streptomycin (Invitrogen Ltd, UK). 
GD25 Null cells are murine embryonic fibroblasts which do not express β1-integrin 
and GD25 β1 cells stably express β1-integrin in association with a puromycin 
resistance gene.  GD25 Null cells were cultured in GD25 complete media: DMEM 
(Life Technologies) supplemented with 10%(v/v) heat-inactivated foetal calf serum 
(Labtec), 5mg/ml L-glutamine, 100U/ml penicillin, 100μg/ml streptomycin 
(Invitrogen Ltd, UK) and 1% non-essential amino acids (NEAA-Life Technologies). 
GD25 β1 cells were cultured in the same media plus 10μg/ml puromycin (Sigma). In 
experiments where GD25 cells were quiesced, GD25 quiescent media contained 
DMEM supplemented with 0.25%(w/v) BSA, 5mg/ml L-glutamine, 100U/ml 
penicillin, 100μg/ml streptomycin and 1% non-essential amino acids. 
 
NCI-H69, NCI-H345 and NCI-H510 small cell lung cancer lines were obtained from 
American Type Tissue Culture Collection (ATCC - Rockville, Maryland, USA). 
These were cultured in SCLC complete media: HEPES buffered Rosewell Park 
Memorial Institute Medium 1640 (RPMI) 1640 medium (Invitrogen Ltd, UK) 
supplemented with 10%(v/v) heat-inactivated foetal calf serum (Labtec), 5mg/ml L-
glutamine (Life Technologies, Paisley, UK) , 100U/ml penicillin and 100μg/ml 
streptomycin (Invitrogen Ltd, UK). For experiments, cells were cultured in either 
SITA (RPMI supplemented with 30nM selenium, 5μg/ml insulin, 10μg/ml 
transferrin, 0.25%(w/v) BSA, 100U/ml penicillin and 100μg/ml streptomycin) or 
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SCLC quiescent media; RPMI medium supplemented with 0.25%(w/v) BSA, 
100U/ml penicillin and 100μg/ml streptomycin. 
 
2.5 Transformation 
Frozen Escherichia coli aliquots (TOP10, Groningen, Netherlands and DH5α, Life 
Technologies, Paisley, UK) were thawed on ice and transferred to chilled eppendorf 
tubes. Purified plasmid DNA (1-10ng) was gently mixed with the cells and incubated 
on ice for 30 minutes. Cells were then heat-shocked at 42°C in a thermomixer for 60 
seconds and returned to ice for a further 2 minutes. Transformed cells were grown in 
antibiotic free SOC media for 60 minutes at 37°C at 500rpm in a thermomixer, prior 
to spreading onto appropriate antibiotic selection plates. Plates were incubated at 
37°C overnight. Individual colonies were picked into Luria-Bertani (LB) broth 
containing selection antibiotics and grown at 37°C overnight. Appropriate plasmid 
expression was confirmed by commercial DNA sequencing analysis (Stratagene). 
 
2.6 DNA purification, cloning and Agarose Gel Electrophoresis 
Mini-prep (1-10ml) DNA purifications were performed using the Wizard SV 
Miniprep kit (Promega) as per manufacturer’s instructions. Large scale (100-500ml) 
DNA purifications were performed using the Qiagen Endotoxin Free Maxi-prep kit 
(Qiagen, Crawley, UK) as per manufacturer’s instructions. 
Diagnostic restriction digests were performed on purified DNA with the appropriate 
restriction enzymes (Promega) and resolved on 1-2% agarose (Seakem, Rockland, 
Maine, USA) gels containing 0.3µg/ml ethidium bromide to enable UV visualisation. 
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A Pharmacia Biotech Ultraspec 2000 UV spectrophotometer was used to quantify 
purified DNA. 
When cloning, restriction digest products were gel purified using the Quick Gel 
extraction kit (Qiagen), as per manufacturer’s instruction. Ligation into second 




Transient transfections of αβ-py and CHO-K1 cells were performed with 
LipofectAMINETM Plus reagent as per manufacturer’s instruction. Cells were seeded 
at a density to achieve ~50% confluency overnight in 100mm or 60mm dishes 
(Corning, High Wycombe, UK).  Purified DNA was placed in 5ml BD Falcon tubes 
(Becton Dickinson, Oxford, UK) in a volume ranging from 1–40μl.  The DNA was 
pre-complexed with 110μl of the Plus reagent mixture (comprising Plus reagent 
0.25%(v/v) diluted in DMEM containing 1%(v/v) non-essential amino acids) and 
gently mixed.  After a 15 minute incubation at room temperature, 110μl of 
LipofectAMINETM mixture (comprising LipofectAMINETM 0.25%(v/v) diluted in 
DMEM containing 1%(v/v) non-essential amino acids) was added and incubated for 
a further 15 minutes at room temperature.  The mixture was then made up to a total 
volume of 4ml with pre-warmed DMEM containing 1%(v/v) non-essential amino 
acids and placed onto the washed cells.  Cells were cultured for five hours at 37ºC, 
before addition of complete media (4ml), containing 10% FCS.  After 24 hours, 
media containing DNA was removed and replaced with fresh complete media.  For 
experiments where protein kinase activities were to be assessed, the transfection 
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media was replaced with quiescent media.  Cells were assessed 48 hours after 
transfection, either for lysis and SDS-PAGE analysis, or for integrin affinity 
determination. For some transfections JET-PEITM was used as per manufacturer’s 
guidelines. 
K562 cells were transfected by AMAXA electroporation (program P13) according to 
manufacturer’s instructions. 5μg of test DNA was used per transfection of 5 million 
cells. 
 
2.8 Cell lysis 
Cells were washed with ice cold PBS and lysed in buffer containing 50mM HEPES 
pH 7.4, 0.3M NaCl, 1.5mM MgCL2, 1.2mM EDTA, 0.5% Triton X-100, 20mM β-
glycerophosphate, 100mM sodium fluoride, 10mM sodium pyrophoshphate, 1mM 
sodium vanadate, 0.5mM dithiothreitol.  One CompleteTM protease inhibitor tablet 
(Boehringer Mannheim, Lewes, UK) was added per 50ml of lysis buffer.  Lysates 
were clarified by centrifugation at 13,000rpm for 10 minutes at 4ºC and analysed for 
protein concentration. Samples were heated in sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE) sample buffer (1 x SDS-PAGE 
sample buffer: 50mM Tris-HCl, 10%(v/v) glycerol, 2%(v/v) SDS, 0.1%(v/v) 
bromophenol blue, 10%(v/v) β-mercaptoethanol, pH 6.8) at 99ºC for 10 minutes. 
 
2.9 Protein Assay 
Protein concentrations of lysates were quantified using a BCA protein assay (Pierce, 
IL, USA).  Samples were diluted 1:5 or 1:10 in distilled H2O and 10μl incubated with 
200μl of test solution for 30 minutes at 37ºC in 96-well plates.  Plates were read 
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using an automated plate reader (MRX microplate reader, Dynatech, Chantilly, 
USA).  Samples were assayed in triplicate and graded against a standard curve (0.1–
0.5mg/ml) using bovine serum albumin. 
 
2.10 SDS polyacrylamide gel electrophoresis and Western blotting 
Samples were resolved on SDS polyacrylamide gels (Separating Gel: 0.375M Tris 
base (pH 8.8), 0.1%(v/v) SDS, 8–12%(v/v) acrylamide, 0.1%(v/v) ammonium 
persulphate, 0.02%(v/v) TEMED. Stacking Gel: 0.13M Tris base (pH 6.8), 
0.15%(v/v) SDS, 4.6%(v/v) acrylamide, 0.11%(v/v) ammonium persulphate, 
0.02%(v/v) TEMED) using a vertical electrophoresis tank Biorad Mini Protean II 
system (Biorad, Hemel Hempstead, UK).  Samples were electrophoresed at 80–150 
volts using electrophoresis buffer ( 50mM Tris base, 250mM glycine, 0.1%(v/v) 
SDS) for 1–2 hours, adjacent to pre-stained molecular weight markers (Life 
Technologies, Paisley, Glasgow).  For optimal protein separation, 8% gels were used 
for 60–120kDa proteins, 10% gels for 40–70kDa and 12% gels for 10–40kDa 
proteins. 
Proteins were transferred onto Hybond C nitrocellulose membranes in transfer buffer 
(210mM glycine, 24.7mM Tris base, 20%(v/v) methanol) at 100volts for 60–90 
minutes, in a Mini Protean II blotting tank (Biorad, UK).  Protein loading was 
confirmed by staining with 1% Ponceau S for 5 minutes to visualize protein bands.  
Non-specific binding sites were blocked by incubation with PBS-Tween 20 (PBS 
containing 0.2%(v/v) Tween) containing 5% non-fat dried milk powder for 1 hour at 
room temperature.  Membranes were probed with appropriate antibodies diluted in 
PBS-Tween 20 containing 5% non-fat dried milk powder overnight at 4ºC.  They 
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were then washed vigorously in PBS-Tween 20 for 1 hour, before exposure to 
appropriate species-specific horseradish peroxidase-conjugated (HRP) secondary 
antibodies for 1 hour, diluted in PBS-Tween 20 containing 5% non-fat dried milk 
powder.  Membranes were then washed further in PBS-Tween 20 and 
immunoreactive bands identified using enchanced chemiluminescence (ECL) 
according to the manufacturer’s instructions.  For assessment of phosphorylated 
proteins, blocking and subsequent incubation steps were carried out using 3% 
albumin in PBS. 
 
2.11 Integrin affinity determination by flow cytometry 
The integrin affinity status of transfected αβ-py cells was assessed by three-colour 
flow cytometry. Cells were transfected as described above with 0–1μg test DNAs 
(Notch, Ras, Raf) and 0.75μg Tac-α5 transfection reporter construct. After 48 hrs, 
transfected cells were trypsinised and resuspended in a total volume of 50μl of 
HEPES/NaCl buffer (20mM HEPES, 140mM NaCl, 1.8mM CaCl2, 1mM MgCl2 and 
2mg/ml Glucose, pH 7.4) containing PAC1 antibody (5μg/ml) for 30 minutes at 
room temperature. Internal controls were performed for each sample with 5mM 
EDTA (for maximal integrin suppression) or 100μM MnCl2 (for maximal integrin 
activation). Cells were washed in cold PBS and all subsequent steps were carried out 
on ice. Samples were incubated in 50μl DMEM containing 4%(v/v) anti-mouse IgM-
FITC (Biosource, Nivelles, Belgium) for 30 minutes in the dark. Cells were washed 
again with cold PBS and were incubated for 30 minutes in 50μl DMEM containing 
2%(v/v) anti-Tac-R-phycoerythrin (R-PE) (DAKO, Ely, UK).  Cells were finally 
washed and resuspended in cold PBS. 5 minutes prior to analysis on a FACS-Caliber 
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flow cytometer, ToPro3 (Molecular Probes, Leiden, The Netherlands) was added to a 
final concentration of 1μM per sample. Integrin affinity was determined by flow 
cytometric assessment of PAC1 binding in live and highly transfected cells (ToPro3 
negative and high Tac binding respectively). The integrin Activation Index (AI) was 
calculated by: Activation Index (%) AI = (FN – FI) / (FA – FI) x 100. This was then 
used to calculate the percentage integrin suppression: ((AI0-AI)/(AI0)*100). [FN: 
Geometric mean fluorescence intensity (MFI) of PAC1 binding to native integrin. FI: 
MFI of PAC1 binding in the presence of 5mM EDTA, i.e. maximally suppressed. FA: 
MFI of PAC1 binding in the presence of 100μM MnCl2, i.e. maximally activated. 
AI0 is the Activation index with the control vector and AI is the Activation index 
with DNA under test]. 
 
2.12 Flow cytometric analysis of β1-integrin expression on the surface 
of GD25 Null and GD25 β1 cells 
5x105 GD25 cells were trypsinised, washed twice with PBS, resuspended in 100μl 
PBS and incubated with 1μg of rat anti-mouse β1-integrin (9EG7 - BD PharMingen, 
San Diego, CA) or rat anti-mouse IgG1 at room temperature for 1 hour. After two 
washes with cold PBS, cells were incubated with species-specific fluorescein 
isothiocyanate-conjugated secondary antibody (1:50) for 30 min at 4°C and again 
washed twice with cold PBS. Samples were finally resuspended in PBS at 4°C and 





2.13 Proliferation assays 
GD25: GD25 β1 and GD25 Null growth curves were performed on plastic and 
fibronectin. 10,000 cells were plated per 10cm plate, suspended in 15mls of GD25 
complete media and incubated at 37oC. When counting, media was removed and the 
adherent cells were washed twice with filtered PBS. After resuspension in filtered 
PBS, cells were counted using a Coulter counter. 
SCLC: 0.5x104 H345 cells were plated into 24-well plates coated with poly-l-lysine 
(10μg/ml) or laminin (10μg/ml) and following disaggregation, cell numbers were 
counted at times indicated using a haemocytometer. 
 
2.14 Apoptosis 
GD25 cells: 96 well plates were pre-coated by incubation at 37oC for 1 hour with or 
without 10μg/ml laminin or 20μg/ml fibronectin. 2x104 GD25 cells were plated per 
well either a) in GD25 complete media and allowed to adhere for 6 hours followed 
by overnight quiescence in GD25 quiescent media or b) in SITA with cells remaining 
in SITA for the duration of the experiment. Cells were then treated with etoposide 0-
20μg/ml. The percentage of apoptotic cells was assessed 0-48 hours later a) 
morphologically by immunofluorescence microscopy after addition of 1μl of 
ethidium bromide (1mg/ml) and 1μl of acridine orange (1mg/ml) [Small orange = 
late apoptosis, large orange = necrosis, small green = early apoptosis, large green = 
healthy cell] and b) by flow cytometric analysis of AnnexinV-PE and Topro3 




SCLC cells: were quiesced overnight at 37oC in RPMI supplemented with 0.25% 
bovine serum albumin, 5mg/ml L-glutamine, 100U/ml penicillin and 100μg/ml 
streptomycin. Cells were washed twice and seeded (4x104 cells in 200μl of RPMI 
SITA per well) into 96 well plates which had been pre-coated by incubation at 37oC 
for 1 hour with poly-l-lysine (10μg/ml), laminin (10μg/ml), fibronectin (20μg/ml), or 
TS2/16 (10μg/ml). Cells were allowed to settle for 1 hour at 37oC and then treated 
with sodium orthovanadate (Na3VO4, 200μM), Ly294002 (30μM), tyrphostin-25 
(25μM) or etoposide (25μg/ml) as specified. Cells were treated with ionising 
radiation (1-16Gray) using a 6MV linear accelerator. In experiments using 4B4 to 
block β1 integrin function, cells were incubated with 4B4 (10μg/ml) at 37oC for 30 
minutes prior to seeding onto ECM. The percentage of apoptotic cells was assessed 
morphologically 0-72 hours later by immunofluorescence microscopy after addition 
of 1μl of ethidium bromide (1 mg/ml) and 1μl acridine orange (1mg/ml). Apoptosis 
was also determined using a cell death detection ELISATM kit (based on the 
quantitative detection of histone-associated DNA fragments in mono- and 
oligonucleosomes) according to the manufacturer’s instructions and by flow 
cytometric analysis of Annexin V and Topro3 staining according to the 
manufacturer’s instructions. In the Caspase-3 activity assay quiesced SCLC cells 
were adhered to poly-l-lysine (10μg/ml), laminin (10μg/ml), fibronectin (20μg/ml), 
or TS2/16 (10μg/ml) as specified and treated with sodium orthovanadate (Na3VO4) 
(200μM), Ly294002 (30μM), tyrphostin-25 (25μM), etoposide (25μg/ml) or z-VAD 
(100μM) as indicated. Cells were lysed at 48 hours and caspase-3 activity was 
assessed using a caspase-3 cellular activity kit according to the manufacturer’s 
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instructions. Specific caspase-3 activity (pmol/min/mg protein) in each experiment 
was normalised to untreated cells. 
K562 cells: 24-72 hrs after AMAXA electroporation the percentage of apoptotic cells 
was assessed morphologically by immunofluorescence microscopy after addition of 
1μl of ethidium bromide (1 mg/ml) and 1μl acridine orange (1mg/ml). 
 
2.15 Immumnofluorescent Microscopy 
Notch expression; wild-type (wt) Chinese Hamster Ovary (CHO) cells were plated 
onto alcohol-sterilised coverslips in 6 well plates and transfected with 
Notch1ICV1744 construct using jet-PEI lipofection reagents according to 
manufacturer’s instructions. After 48 hours cells were washed twice with phosphate 
buffered saline (PBS), fixed with 3% paraformaldehyde, washed with PBS, 
permeabilised with 0.1% Triton, washed with PBS and blocked with 3% fish skin 
gelatin. Cells were probed with 1:2000 anti-myc (9E10) antibody for 1 hour at room 
temperature and washed with PBS. Secondary species-specific antibody labelled 
with ALEXA-flour488 (1:500) was applied for 1 hour at room temperature. After 
washing the slides with PBS, coverslips were fixed with mowiol. Slides were viewed 
with a Zeiss Axioskop 2 microscope and image analysis was performed using 
Openlab software from Improvision. 
Visualisation of DNA double-strand breaks; SCLC Cells were quiesced overnight 
and seeded into 8 well coverslides (Nalge NUNC) at a density of 2.5x105 cells/cm2 
pre-coated with laminin or poly-l-lysine. Cells were allowed to adhere for 2 hours at 
37oC and then treated as specified. Cells were fixed at 0-24 hours after treatment 
with 3% paraformaldehyde, washed with phosphate buffered saline, permeabilised 
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with 0.1% Triton and blocked with 3% fish skin gelatin. Cells were probed with 
1:500 dilution of anti-γH2Ax for 2 hours at room temperature and washed with PBS. 
Secondary antibody labelled with ALEXA-fluor 488 (1:500) was applied for 1 hour 
at room temperature, slides were washed with PBS and coverslips were fixed. The 
slides were viewed with a Zeiss Axioskop 2 microscope. Image analysis was 
performed using Openlab software from Improvision. 
 
2.16 Cell Cycle Analysis 
SCLC cells were quiesced overnight and seeded into 6 well plates pre-coated with 
laminin, fibronectin or TS2/16 and treated as specified. In some experiments cells 
were treated with Nocodazole 2μM for 24 hours prior to seeding onto ECM. Cells 
were fixed 0-24 hours later in 70% ice-cold ethanol (for at least two hours), stained 
with propidium iodide and subjected to flow cytometric analysis (pulse processing) 
with a FACSCalibur flow cytometer. Cell cycle parameters from at least 10,000 
events were analysed using CELLQuest software. 
 
2.17 Rras activation assay 
The GST linked Ras binding domain (RBD) of Raf was expressed from pGEX-Raf 
RBD (donated by W. Kolch) and linked to glutathione-agarose beads. CHOαβpy 
cells (2 x105/well in growth media) were transfected using JetPEITM with (wt)Rras 
and test DNA as specified. As a positive control cells were transfected with 
constitutively active (G38V)Rras (0.25μg/2ml of media). After 24 hours, growth 
media was replaced with serum free DMEM (1% BSA, 1% L-Glutamine, 1% 
Penicillin/Streptomycin, 1% non-essential amino acids and G418 antibiotic at 
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400μg/ml (Invitrogen)). After a further 24 hours cells were lysed in buffer (140mM 
NaCl, 1.5mM MgCl2 15% glycerol, 1% nonidet P40 and 1x protease inhibitor) at 
4oC for 20 min, centrifuged at 13,000 rpm for 10 min and protein balanced by BCA 
protein assay (Pierce, USA). An aliquot of the whole cell lysate was retained and 
boiled in Laemmli sample buffer. The remainder of the cell lysate was incubated 
with RBD-agarose beads (30μl/lysate of a 1:1 slurry beads:lysis buffer) for 2 hours at 
4oC. The beads were washed twice in lysis buffer and twice in ice cold PBS and 
protein was eluted by boiling in Laemmli sample buffer. The RBD pulldown and 
whole cell lysate were analysed by Western blotting with anti-myc (9E10) antibody. 
 
2.18 Cell Adhesion Assay 
24-well cell culture plates were coated with poly-l-lysine (10μg/ml) or fibronectin 
(10μg/ml) in PBS for 60 min at 37°C. Wells were washed and blocked with 3% 
(w/v) bovine serum albumin in PBS for 60 min at room temperature. 2x105 K562 
cells, treated as specified, were resuspended in 500μl of HEPES/NaCl buffer and 
seeded into the wells. EDTA (5mM final concentration) or Mn2+ (100μM final 
concentration) was added as indicated. Where specified K562 cells were treated with 
4B4 (10μg/ml 45 min 37oC) or MW167 (50μM 4 hours 37oC) prior to seeding. Cells 
were allowed to adhere for 30 min at 37°C. Non-attached cells were then removed by 
gentle washing with PBS x2. Adhered cells were fixed with 3% paraformaldehyde (5 
min) and stained with 0.4% methylene blue (5 min). Intracellular methylene blue was 
eluted with 0.1M HCl and the optical density (OD) (λ 560nM) of each sample was 
determined using an automated plate reader. Cell adhesion for each condition was 
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expressed as a percentage of total cellular adhesion to poly-l-lysine (i.e. OD sample / 
OD poly-lysine x 100). 
2.19 SCLC xenograft experiments 
5x106 H345 or H69 SCLC cells suspended in PBS or Matrigel (1:1 vol of 
cells:Matrigel/PBS mixed at 40C, total volume 200μl) were implanted 
subcutaneously in contralateral flanks of Nude nu/nu:Balb(c) mice (10 mice per 
condition) suspended in PBS or Matrigel (1:1 vol of cells:Matrigel mixed at 40C), 
laminin (20μg/ml), fibronectin (40μg/ml) or collagen (20μg/ml) with or without pre-
incubation with mouse anti-human function-blocking β1-integrin antibody (4B4), 
IgG1-isotype antibody, genistein (50μM with the Matrigel/cells at the time of 
implantation) or genistein vehicle (10% DMSO in PBS). Some mice subsequently 
received 50mg/kg/day i.p. genistein or Vehicle in 200μl injections day2-8. Tumour 
size was assessed manually with calipers every 3-4 days and xenograft volume 
calculated by: Volume = (Width2 x Length)/2. Mean ± s.e. shown. Statistical 
analysis: 2-way Anova. At the time of sacrifice, xenografts were dissected, halved 
and parallel samples were stored in formalin (haematoxylin and eosin staining and 
immunohistochemical staining for Ki67, CD34 and CD56 was kindly performed by 
Dr W.Wallace in the pathology department, New Royal Infirmary of Edinburgh) and 
liquid nitrogen (lysates were protein equilibrated and submitted to Western blot 








Notch1 increases integrin affinity 
via activation of Rras. 
 
3.1 Introduction 
Notch proteins are large (~2500 amino acids), highly conserved, single-pass 
transmembrane proteins that play a vital role in cell differentiation and development. 
The major components of the Notch signalling pathway were originally recognised 
genetically following the discovery of loss of function mutant 
Drosophila.melanogaster fruit flies which possessed notches within their wing 
outlines (Morgan, 1917) and exhibited excessive neuronal differentiation (Poulson DF, 1945). 
i.e. Notch represses neuronal differentiation. The core members of the Notch 
signalling pathway are 1) a Delta-type Notch ligand, 2) a Notch-type receptor (Kopan et 
al., 1993) and 3) a transcription factor of the CBF1/Su(H)/Lag-1 family (see Appendix: 
Table 5). Notch is initially produced as a single protein strand but undergoes three 
cleavages during its metabolic lifetime (see Appendix: Fig 5): After production in 
the nucleus, S1 cleavage occurs in the Golgi by a furin convertase after recognition 
of a RQRR sequence (Logeat et al., 1998). The two fragments are held together by a 
calcium-coordinated bond (Rand et al., 2000) and Notch is then presented at the cell 
surface as a heterodimeric molecule (Blaumueller et al., 1997). Notch ligands of the Delta and 
Serrate/Jagged family are transmembrane proteins with a small intracellular domain 
and a large extracellular domain containing epidermal growth factor-like repeats and 
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an amino-terminal DSL (Delta, Serrate, Lag-2) region specific to this class of 
proteins (Lendahl, 1998). Notch ligands interact with the extracellular domain of Notch 
receptors via the EGF repeats and DSL domain (Rebay et al., 1991),(Kopan, 2002), resulting in 
the S2 cleavage, by a protease of the ADAM (a disintegrin and metalloprotease) 
family, TACE (Tumor necrosis factor-alpha-converting enzyme), at a site 
immediately external to the transmembrane domain (Mumm et al., 2000),(Brou et al., 2000). The 
extracellular cleaved portion of the Notch receptor is transendocytosed into the 
Notch ligand-bearing cell (Parks et al., 2000),(Kramer, 2001) and the removal of the inhibitory 
LNR (Lin12/Notch repeat) sequence enables the remaining membrane-tethered 
Notch receptor fragment to be cleaved constitutively (Kimble et al., 1998),(Kopan et al., 1996) 
within its transmembrane domain at valine 1744 (Schroeter et al., 1998) by a 5-600kDa γ-
secretase protein complex containing presenilin (Kaether et al., 2002),(Bergman et al., 2004), 
nicastrin, Aph1 and Pen2 (Song et al., 1999),(Struhl et al., 1999),(De Strooper et al., 1999),(De Strooper, 
2003),(Shirotani et al., 2003) in a process termed Regulated Intramembrane Proteolysis (RIP). 
This process can be inhibited by a substitution at amino acid 1744 or the use of 
biochemical inhibitors of γ-secretase (Struhl and Greenwald, 1999),(Mizutani et al., 2001). This S3 
cleavage results in release of the intracellular portion (NotchIC) which translocates to 
the nucleus (Kopan et al., 1996),(Schroeter et al., 1998) where it acts at subdetectable levels. 
NotchIC lacks intrinsic enzymatic or DNA binding capacity but influences 
transcription of many genes by modulating the balance of corepressor complexes 
(e.g. SMRT(silence mediator for retinoic acid and thyroid receptors)/NCoR(nuclear 
receptor corepressor)/HDAC1 or CIR/HDAC2/SAP30 (Espinosa et al., 2003),(Kao et al., 
1998),(Hsieh et al., 1999) and coactivator complexes (e.g. p300, pCAF and MAML1) via 
binding to CSL (Core Binding Factor, Su(H), Lag-1) proteins in the nucleus (Henkel et 
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al., 1994). Several nuclear localisation sites have been identified and using deletion 
mutants (Dumont et al., 2000) it has been shown that the RAM domain (Tamura et al., 1995),(Chu et 
al., 2004) is the major domain involved in binding to RBPJ but also that the ankyrin 
repeats are essential for Hes1+5 activation. In addition other c-terminal sequences 
termed the OPA and PEST (Proline, Glutamate, Serine, Threonine) domains further 
enhance nuclear signalling. Coactivator complexes contain histone acetylases such as 
pCAF and GCN5 (Kurooka et al., 2000) which promote nucleosome disruption and 
chromatin relaxation resulting in upregulated transcription of target genes. Only a 
limited number of Notch effectors have been identified; the best described of these 
being the basic Helix-Loop-Helix (bHLH) repressor proteins Hes (Artavanis-Tsakonas et al., 
1999) (Hairy/Enhancer of Split) and Hes-related proteins (HERPs) initially identified 
in Drosophila from the Enhancer of split Complex (E(spl)-C) gene region (Bailey and 
Posakony, 1995) that encodes many proteins that cause neural repression. Hes and HERP 
(Parks et al., 1997),(Bailey and Posakony, 1995),(Lecourtois et al., 1995),(Iso et al., 2003) transcription is switched 
on by Notch by virtue of CSL binding sites in their promoters. They function as 
suppressors of neurogenic differentiation in Drosophila by silencing proneural genes 
such as Achaete-scute (Ball, 2004) (Mash1 and HASH1 are mouse and human 
homologs). Hes can repress actively by recruiting corepressor complexes (e.g. 
Groucho (Dras/TLE/HDAC) for Hes or NCoR/mSin3A/HDAC1 for HERP) (Iso et al., 
2003) or passively by sequestration of proteins e.g. Hes1 can heterodimerise with E47 
(which is a MyoD and Mash homodimer partner) and thus MyoD/Mash signalling is 
reduced (Kopan et al., 1994). Several other downstream effectors have been identified: 
Notch1IC also represses AP-1-mediated transactivation (Chu et al., 2002). AP-1 are Jun 
homodimers or Jun-Fos heterodimers that act as transcriptional modulators. AP-1 can 
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be activated by Ras-JNK or p38-Ser63+73 phosphorylation which then allow binding 
of CBP/p300 and its associated transcriptional complexes. Notch strongly represses 
(G12V)Hras-induced AP-1-mediated transactivation and this effect was highly 
dependent on an intact Notch RAM domain and nuclear localisation. The reversal of 
(G12V)Hras effect was not due to alteration of erk/jun/p38/mapk/jnk 
phosphorylation. In hepatocellular carcinoma Notch1IC overexpression inhibits 
growth by reducing cyclinA, D and E, CDK2, phosphorylated retinoblastoma protein 
(Rb) and increasing p21cip1waf1, JNK and p53 (Qi et al., 2003). However, in another 
system Notch was seen to upregulate cyclinD1 (Ronchini et al., 2001). In T cells Notch1IC 
inhibits apoptosis by increasing Bcl-2 and FLIP via a src-p56lck-PI3K-PKB pathway 
(Sade et al., 2004). Interestingly, in this system Notch1 was coimmunoprecipitated with 
PI3K and p56Lck suggesting direct interaction. 
In Small Cell Lung Cancer Notch1 and 2 were overexpressed resulting in G1 arrest, 
p21cip1/waf1 and p27kip1 upregulation, Erk1 and 2 phosphorylation and reduced 
hASH though in this model these effects were Hes1-independent (Sriuranpong et al., 2001). 
In invasive cervical cancer Notch1 causes PKB phosphorylation and reduced anoikis 
(Rangarajan et al., 2001).  In epithelial Mv1Lu cells Notch1 overcomes TGF-β-induced G1 
arrest by upregulation of c-myc (Rao et al., 2003) and in K562 cells Notch1IC is associated 
with YingYang1 via Notch ankyrin repeats (Yeh et al., 2003). YingYang1 has zinc finger 
domains and reduces Hes-1 luciferase expression via CBF-1. 
A small number of other downstream Notch targets have been identified including 
Nrarp, an evolutionarily conserved small ankyrin repeat-containing protein that 
functions as a negative regulator of Notch signalling (Krebs et al., 2001),(Pirot et al., 2004), acid 
 55
α-glucosidase, a lysosomal enzyme that degrades glycogen (Yan et al., 2002a), mapk 
phosphatase, LIP-1, p21cip1waf1, cyclinD1/CDK2, MAMLs1-3 (Iso et al., 2003). 
In addition, a number of other proteins have been shown to have RBPJκ binding sites 
similar to those seen in Hes/HERP but have not yet been shown to act directly as 
downstream Notch effectors (e.g. MHC-I, CD23, Il-6, erbB2, NFκB) (Iso et al., 2003). 
 
3.1.1 Modulators of Notch 
Delta/Notch levels do not correlate well with levels of proneural precursor proteins 
suggesting that post-translational signalling/feedback are important (Parks et al., 1997). 
Several modulators of Notch function have been identified: 
Fringe is a glycosyl transferase that glycosylates EGF repeats of Notch resulting in 
altered ligand binding affinity and increased signalling from Delta/reduced signalling 
via Serrate/Jagged (Blair, 2000). Numb, a phosphotyrosine binding domain adaptor 
protein that binds Notch directly recruits Itch, an E3 ubiquitin ligase, which 
ubiquitinates Notch1 at the cell surface, increasing proteasomal degradation and 
reducing its translocation to the nucleus (McGill et al., 2003). Ubiquitination involves three 
steps via ubiquitin activating enzyme (E1), ubiquitin conjugating enzyme (E2) and 
ubiquitin ligase (E3). E3 provides selectivity and specificity. Ubiquitination can 
result in proteosomal degradation, receptor internalisation and trafficking to vesicle 
microorganelles. Mammalian Itch (Qiu et al., 2000) ubiquitinates at the cell membrane 
whilst the invertebrate homolog Sel-10 (Wu et al., 2001b) and Drosophila Suppressor of 
Deltex (Cornell et al., 1999) do so at the nucleus. Notch1IC increases antiapoptotic Bclx(L) 
and FLICE-like inhibitor (FLIP) in T cells and these effects were antagonised by 
Numb (Sade et al., 2004). Numb has also been implicated developmentally in “inherited” 
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Notch control (Bray, 1998); i.e. when daughter cells are formed only one of the pair 
receives the Numb gene. In this setting the Notch daughter cell differentiates into a 
socket cell whilst Notch-depleted, Numb-expressing cells form hair cells. Numb 
knockout or NotchIC overexpressing cells both become socket cells (Rhyu et al., 
1994),(Posakony, 1994). Ubiquitination also modulates Notch ligand function: Neuralised 
and Mindbomb are ring-type E3 ubiquitin ligases that ubiquitinate the Notch ligand, 
Delta, causing internalisation of Delta from the membrane promoting its ability to 
activate Notch in neighbouring cells by virtue of increased transendocytosis (Itoh et al., 
2003). 
MINT binds to the intracellular portion of Notch and directly inhibits binding to 
RBPJ protein via its RAM domain to reduce Hes signalling (Kuroda et al., 2003).  
Mastermind (a transcriptional activator recruited to the CSL complex) also stimulates 
phosphorylation and turnover of NotchIC resulting in cessation of Notch signal (Fryer et 
al., 2002). 
Two groups have shown that different mammalian Notch subtypes produce different 
levels of Hes activation and may antagonise each other’s activity. e.g. Notch2 
antagonises Notch1 and Notch3 (Shimizu et al., 2002), Notch3 antagonises Notch1 (Beatus et 
al., 1999). In embryonal brain tumour cell lines Notch1 reduces cell growth whilst 
Notch2 increases growth and is associated with a worse survival in medulloblastoma 
(Fan et al., 2004). 
There is also evidence of rapid negative feedback loop involvement; Kuroda et al 
demonstrated a 10-fold reduction in Hes1-mRNA in cells that have intact translation 
machinery compared with those in which translation is inhibited (Kuroda et al., 1999). 
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3.1.2 CBF-independent Notch signalling 
Although the majority of Notch-mediated signalling has been shown to dependent on 
S3 cleavage and nuclear localisation, several groups have reported cleavage-
independent Notch signalling. Notably, genetic analysis of novel Notch alleles in 
Drosophila has clearly demonstrated that Notch can signal independently of Su(H) in 
a Deltex-dependent manner (Ramain et al., 2001). Zecchini et al showed in Drosophila 
development that although dorsal closure was Notch-dependent, it was cleavage- 
independent (Zecchini et al., 1999) and acts via the JNK (c-Jun N-terminal kinase) 
signalling pathway. Two regions of the intracellular domain of Notch were critical 
for this function; the cdc10/ankyrin repeats and a region carboxy-terminal to this. 
Giniger demonstrated that Notch1 can directly regulate the actin cytoskeleton via the 
tyrosine kinase, abl (Giniger, 1998). In mammals, Notch has been shown to inhibit mouse 
myogenesis without cleavage or interaction with CBF-1 (Shawber et al., 1996),(Bush et al., 2001). 
 
3.1.3 Notch signalling in lower organism development 
Notch signalling in development can be summarised as inductive, lateral and 
inherited. 
The most well recognised example of (positive) inductive signalling is Drosophila 
wing development. Here a Notch ligand-bearing cell signals to a Notch receptor-
bearing cell to induce wing margin growth via increased expression of vestigial. Loss 
of function mutants (Kim et al., 1996) produce the typical notched wing phenotype. 
Lateral inhibition was first identified as the mechanism by which neural 
differentiation is controlled in Drosophila; Notch ligand-bearing cells signal to Notch 
receptor-bearing cells causing Hes-induced repression of neurogenic Achaete-Scute 
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Complex which results in inhibition of neural differentiation in the Notch receptor-
bearing cells (Guillemot et al., 1993). Using these signalling techniques Notch-mediated 
signalling has been shown to be crucial at multiple stages of Drosophila development 
(Bray, 1998). 
The most well described example of inherited signalling involves Numb (Guo et al., 1996); 
in early embryogenesis, during mitosis one daughter cell inherits Numb via 
assymetric segregation. This negatively regulates Notch in the Numb-bearing cell 
and downregulates the expression of Notch-dependent proteins. In contrast, the cell 
which does not inherit Numb expresses higher levels of Notch-dependent proteins. In 
this way cell fate is defined by the presence or absence of Notch signalling. 
 
3.1.4 Notch – Evidence for signalling with Ras 
In lower organisms 
In C.elegans vulval development, 6 vulval precursor cells (VPCs P3.p-P8.p) are 
initially equivalent in developmental potential and equally capable of forming one of 
three primary fates (Wilkinson et al., 1994),(Christensen et al., 1996),(Eisenmann et al., 2000). The anchor 
cell of the developing gonad stimulates the closest cell (P6.p) via a LIN-3 signal (an 
EGFR homolog) to induce a receptor tyrosine kinase (Let-23) → ras → mapk 
pathway which instructs the cell to adopt a primary cell fate. The P6.p cell then 
signals laterally to P5.p and P7.p instructing them to adopt an alternative, secondary, 
cell fate. This lateral signal is mediated by a Lin-12/Notch pathway that is dependent 
upon SUR-2-mediated Ras signalling in the P6.p cell (Singh et al., 1995). Whereas Notch 
signalling is activated in P5.p and P7.p, the P6.p cell downregulates its own Notch 
signalling via a post-translational Notch modification which results in altered 
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endocytic routing dependent on a di-leucine intracellular domain situated between 
the transmembrane domain and the first ankyrin repeat (Shaye et al., 2002). In addition, the 
lateral Notch signal to P5.p and P7.p results in upregulation of Lip-1 which is a mapk 
phosphatase, indirectly downregulating the primary cell fate-determining mapk 
signal in p5.p and p7.p (Berset et al., 2001). C.elegans vulval development is one example 
of Notch and Ras interacting to influence cell development. In this setting Ras 
signalling from one cell results in serial Notch signalling in another. 
A comparable system exists in Drosophila mesothorax development (Culi et al., 2001). 
Here, each Drosophila mesothorax bristle is derived from a single Sensory Organ 
Mother Cell (SMC) which arises as a result of high cellular levels of the proneural 
gene product achaete-scute complex (AS-C) which is dependent upon an EGFR/Ras 
pathway. In order to limit the number of cells adopting bristle fate these SMCs direct 
Notch-mediated lateral inhibitory signals to adjacent cells which blocks AS-C via the 
repressive E(spl)-C bHLH mechanism described earlier. 
In Drosophila dorsal mesoderm development, wingless and decapentaplegic (TGF-
beta homolog) signals induce early mesodermal cells to become competent to 
respond to EGFR/FGF-mediated Ras activation which causes them to adopt Founder 
myoblast (FMC) status (Artero et al., 2001),(Carmena et al., 2002),(Dierick et al., 1999). These cells 
express surface Delta to signal via Notch receptors to adjacent cells instructing them 
to adopt “Fusion-competent cell” , rather than FMC status. Notch further blocks 
EGF/FGF signalling within Fusion-competent cells via inhibition of pathway 
intermediates, heartless and rhomboid (Artero et al., 2003). Interestingly, in this study a 
screen identified Hbs (Echinoid) to be downstream of Notch. In Drosophila eye 
development Echinoid antagonises the Ras pathway at the level of transcription of a 
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target gene tramtrack (Bai et al., 2001), representing a further possible mechanism for 
Notch antagonism of Ras signalling. 
In Drosophila ommatidia development, Notch and Ras signalling converge in the 
same cell to define cell fate. The R7 ommatidial photoreceptor cell receives signals 
via both a Ras pathway (via Sevenless, a receptor tyrosine kinase, from R8) and a 
Notch pathway (Delta signal from R1+6) to define cell differentiation. i.e. Notch and 
Ras act here in parallel, exclusively but cooperatively (Tomlinson et al., 2001). 
A further potential mechanism for Notch and Ras interaction may involve AF-6, a 
180kDa mammalian protein (Drosophila homolog Canoe) which is the fusion partner 
of ALL-1/AF-6 which causes human leukaemia. Canoe acts downstream of Notch in 
Drosophila eye development and has a GLGF/DHR motif which is thought to 
function to localise a number of proteins to sites of cell-cell contact where it may 
regulate adhesive cell-cell interactions (Miyamoto et al., 1995),(Matsuo et al., 1999). In addition to 
acting downstream of Notch, the C.elegans homolog Ce-AF-6 was also identified as 
a putative Ras effector which binds GTP-Hras but not GDP-Hras or inactivated A38-
GTP-Hras (Watari et al., 1998),(Kuriyama et al., 1996). Thus, Notch may influence Ras signalling 
via Canoe. 
Warthog was found in a screen for modifiers of activated Notch phenotype and is a 
Ras-like GTPase (Drosophila homologue of rab6, Drab6) involved in vesicular 
trafficking (Purcell et al., 1999). The authors postulate that delayed presentation of Notch or 





In higher organisms 
Very few studies have investigated the interaction of Notch and Ras in higher 
organisms. In 3T3-L1 cells Hras causes adipogenesis only if Notch signalling is also 
present (Ruiz-Hidalgo et al., 1999). Individually, Notch and Ras have well-described roles in 
oncogenesis: In a transgenic mouse model Notch4 is dependent upon downstream 
Ras signalling to sustain anchorage-independent growth (Fitzgerald et al., 2000). Weijzen et 
al have demonstrated in human embryonic kidney cells and human foreskin 
fibroblasts that Notch1 is a downstream effector of oncogenic (G12V)Hras (Weijzen et 
al., 2002). (G12V)Hras increased nuclear levels of Notch1IC and also increased delta1 
and presenilin1 via a p38/MEKK6-mediated pathway.  
Another potential level of Notch/Ras signalling overlap is ADAMs (a Disintegrin 
and Metalloprotease) (Yan et al., 2002b). As well as being membrane metalloproteases that 
modulate Notch S2 cleavage and Notch ligand cleavage (Schlondorff et al., 1999) they are 
also involved in EGFR transactivation by G-proteins that can result in downstream 
Hras signalling. 
 
3.1.5 Notch – Evidence for signalling with Integrins 
In lower organisms 
There is some indirect evidence that integrins and Notch may be involved in 
coordinated signalling in lower organisms. In Drosophila, Blister wing, where fluid 
accumulates between the dorsal and ventral wing surfaces due to a failure of integrin-
mediated fusion is a common phenotype to both Notch and integrin loss-of-function 
mutants (Brown et al., 2000),(Brabant et al., 1996). A screen for other autosomal mutations that 
cause the Blister wing phenotype also identified other key Notch pathway members, 
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Delta and Mastermind (a CSL activator) (Prout et al., 1997). Additionally, data from 
Zebrafish somitogenesis suggests that mutations in the Notch pathway and integrin 
α5 subunit can produce a complementary disruption in somite formation possibly 
implicating Notch in integrin regulation (Julich et al., 2005),(Chong et al., 2005). 
In neural stem cells the intracellular domain of Notch was coimmunoprecipitated 
with β1-integrin inferring a direct interaction (Campos et al., 2006).  
 
In higher organisms 
There is only one report of Notch-mediated modulation of integrin affinity in higher 
organism experiments. Leong at al showed that Notch4IC inhibits endothelial 
sprouting, VEGF-induced angiogenesis and migration of cells through collagen via 
increased β1-integrin-mediated adhesion (Leong et al., 2002) dependent upon the ankyrin 
repeats (MacKenzie et al., 2004).  
Other evidence that Notch-mediated signals may influence integrin affinity is only 
indirect:  e.g. Integrin beta cytoplasmic tails contain NPxY motifs that can form beta 
turns which recognise protein tyrosine binding domains e.g. Talin-PTB:NPxY-β1-
integrin. Calderwood et al showed that Numb interacted directly with β1-integrin 
domains and coimmunoprecipitated with β3 and β5 integrin but not β1A, β2 or β7 
(Calderwood et al., 2003).  
ADAMs (a disintegrin and metalloprotease) offer a further potential pathway for 
Notch and integrin crosstalk. ADAMs such as TACE (TNFα-converting enzyme) 
and Kuzbanian are involved in ectodomain processing of proteins including the 
Notch ligand, Delta. In addition ADAMs contain snake venom-like domains capable 
of acting as integrin ligands and this feature may be important in adhesion events of 
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sperm-ova interactions (Schlondorff and Blobel, 1999),(Blobel et al., 1992). To date there is no 
evidence supporting a direct link between ADAMs, integrins and Notch signalling. 
Del-1 (developmental endothelial locus-1) is a Delta-like protein which is a 
component of early endothelial cell extracellular matrix (Hidai et al., 1998). It contains a 
RGD motif that binds αvβ3 integrins and it also has EGF-repeats that interact with 
other EGF-repeat-containing molecules such as Notch and Delta. Although there is 
no direct evidence of interaction, it presents a possible mechanism of Notch/integrin 
pathway crossover. 
GABP-β is a protein with Notch homology that forms a heterotetrameric complex 
with GABP-α on the CD18 (β2-integrin) promoter to increase expression (Rosmarin et al., 
1995). This supports the possibility of Notch-mediated CBF-independent modulation 
of integrin transcription. 
In view of this direct and indirect evidence supporting interactions of Notch with 
integrins and Ras, the following experiments were performed to investigate the role 
of Notch1 in integrin affinity modulation. 
 
3.2 Confirmation of integrity of Notch1ICV1744 construct used in 
experiments 
Notch1ICV1744 is a constitutively active Notch1 mutant that is amino-truncated at 
valine 1744 and thus lacks the transmembrane and extracellular domains. It is 
constitutively active and translocates to the nucleus where it activates transcription 
factors such as Hes1 (Schroeter et al., 1998). The mouse Notch1ICV1744 construct was 
provided with a carboxy-terminal myc-tag in a pEGFP1 vector (with a stop codon 
proximal to the GFP sequence). To standardise controls, Notch1ICV1744 was cloned 
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from pEGFP1 into the HindIII/Apa1 sites of pcDNA3.1+. The authenticity of all 
constructs used in the following experiments was confirmed by miniprep digest of 
the resultant construct, DNA sequencing analysis, immunoblotting of the protein 
product and immunofluorescence microscopy of the appropriate tag (myc or Flag). 
For coimmunoprecipitation and immunofluorescence experiments which employed 
cotransfection of Notch1ICV1744 and myc-tagged Ras moieties, the myc-tag of 
Notch1ICV1744 was removed by digestion with BamH1 and Sal1 prior to cloning 
into pCMV-Tag4A (which contains a Flag-tag at the 3’ end). An untagged negative 
control, pcDNA3.1+NotchICV1744(EcoRV), was produced by digesting 
pEGFPNotch1ICV1744 with EcoRV to produce a truncated moiety which retains the 
amino terminal sequence but lacks some of the ankyrin repeats (ANK (6)), distal 
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Figure 3.1  Production and authentication of Notch1 constructs used in experiments. A Ethidium 
bromide-stained 2% agarose gel electrophoresis demonstrating HindIII/Apa1 Notch1 cleavage product 
(left) from pEGFP-NotchICV1744 and confirmation of insertion of NotchICV1744 cleavage product in 
pcDNA3.1+ (right). B Western blot of Notch1 constructs probed with anti-myc antibody. C 
Immunofluorescence microscopy of Chinese hamster ovary (wt) cells transfected with NotchICV1744 
stained with rhodamine-phalloidin (red) and nuclear Alexa-Fluor488 (green) staining of myc-tagged 
Notch1ICV1744. 
 
Results. DNA agarose gel electrophoresis (Fig 3.1A) and DNA sequencing 
confirmed the accurate cloning of Notch1 constructs into pcDNA3.1+ (and 
pCMVTag4A; not shown). After transfection into Chinese Hamster Ovary (CHO) 
cells, protein expression was confirmed by immunoblotting with anti-myc (9E10) 
antibody (Fig 3.1B) and appropriate nuclear localisation was demonstrated by 
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3.3 Notch1ICV1744 increases integrin affinity and abrogates Hras-
mediated integrin suppression 
(G12V)Hras is a constitutively active Hras mutant which decreases integrin affinity 
(Sethi et al., 1999a). I tested the hypothesis that Notch1IC increases integrin affinity and 
reverses (G12V)Hras-mediated integrin suppression. 
 























Figure 3.2  Notch1IC increases integrin affinity and reverses Hras-mediated integrin 
suppression. Chinese hamster ovary cells stably expressing the chimaeric integrin αIIbβ3α6β1 were 
transiently transfected with interleukin-2 receptor (Tac-α5, 0.75μg) and Notch1ICV1744 (1μg), 
(G12V)Hras (1μg) or Notch1ICV1744 and (G12V)Hras. After 48 hours cells were stained with Pac-1 
(specific for the active confirmation of αIIbβ3), anti-Tacα5 and Topro-3. Antibody binding on single, 
viable, cells was analysed by 3-colour flow cytometry. A αIIbβ3 integrin affinity was measured by flow 
cytometric assessment of Pac-1 binding and % integrin suppression normalised to Tac-alone values. 
Mean ± s.e. of n=16 experiments shown. B Representative dot-plots showing right-shift (increased 
Pac-1 binding due to increased integrin affinity) of highly transfected cells (black) transfected with 
Notch and reduced binding left shift by (G12V)Hras. C Western blot for transfected Notch1ICV1744 and 
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Results: The chimaeric integrin is in a relatively high affinity state and so 
(G12V)Hras was used to reduce integrin affinity (Fig.3.2A+B). Hras reduced 
integrin affinity by 54.2 ± 5.2% (s.e.) (p<0.01) demonstrated by a left shift of highly 
transfected cells (upper dark dots Fig3.2B) in this model as previously described 
(Hughes et al., 1997). Notch1ICV1744 induced an increase in integrin affinity above vector 
control of 88.8 ± 18.3% (s.e.) (p<0.001) associated with a right shift of Pac binding 
and also reversed (G12V)Hras-mediated integrin suppression (p<0.01, Fig 3.2A+B). 
Western blots (Fig 3.2C) demonstrated that these effects were not produced by 
alterations in the expression of (G12V)Hras, Notch or αIIbβ3-integrin. (G12V)Hras 
increased erk phosphorylation as previously shown (Sethi et al., 1999a). Notch expression 
had no effect on erk phosphorylation when transfected alone or with (G12V)Hras. 
 
3.4 Dominant-Negative Rras blocks Notch-mediated integrin 
activation 
To date, few candidate proteins have been shown to mediate increases in integrin 
affinity and to reverse Hras-mediated suppression of integrin affinity. The best 
described is Rras (Zhang et al., 1996),(Sethi et al., 1999a) and thus I postulated that Notch1IC 
mediates its effect on integrin affinity via activation of Rras. This postulate was 
initially tested by assessing the effect on integrin affinity of Rras inhibition in 





















Figure 3.3  Dominant-Negative Rras blocks Notch-mediated integrin activation. Chinese hamster 
ovary cells stably expressing the chimaeric integrin αIIbβ3α6β1 were transiently transfected with 
interleukin-2 receptor (Tac-α5, 0.75μg) and Notch1ICV1744 (1μg), Dominant-Negative (T43N)Rras 
(1μg) or Notch1ICV1744 and (T43N)Rras. A αIIbβ3 integrin affinity was measured by 3-colour flow 
cytometric assessment of Pac-1 binding shown as % integrin activation. Mean ± s.e. of n=19 
experiments shown.   B Representative dot-plots showing right-shift of highly transfected cells (black) 
indicating increased integrin affinity of Notch-transfected cells and reversal of this by Dominant-
Negative (T43N)Rras. 
 
Results: Notch1IC increased integrin activation above vector control from 36.0 ± 
1.0% (s.e.) to 59.4 ± 4.5% (s.e.) (p<0.001). Whilst Dominant-Negative (T43N)Rras 
had no significant effect on integrin affinity alone (p>0.05), it completely abrogated 
Notch1IC-mediated integrin activation (integrin activation index 33.5 ± 1.5% (s.e.), 
p<0.001). 
 
3.5 Dominant-Negative Rras blocks Notch1IC reversal of 
(G12V)Hras-mediated integrin suppression and this is 
independent of erk phosphorylation 
Hras decreases integrin affinity (Hughes et al., 1997),(Hughes et al., 2002). Following the 
demonstration that DNRras abrogates Notch1IC-mediated integrin activation I sought 
100 101 102 103 104
PAC 1 BINDING
100 101 102 103 104
PAC 1 BINDING
100 101 102 103 104
PAC 1 BINDING
100 101 102 103 104
PAC 1 BINDING









































to show that DNRras also abrogates Notch1IC-mediated reversal of Hras-mediated 
integrin suppression. Since Hras-mediated integrin suppression has been shown to be 
dependent on erk activation, western blots of total and phosphorylated erk were 
performed to assess whether Notch modulates levels of this downstream effector. 
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Figure 3.4  Dominant-Negative Rras blocks Notch1IC reversal of (G12V)Hras-mediated integrin 
suppression and this is independent of erk phosphorylation. Chinese hamster ovary cells stably 
expressing the chimaeric integrin αIIbβ3α6β1 were transiently transfected with interleukin-2 (Tac-α5, 
0.75μg) and combinations of Notch1ICV1744 (1μg), (G12V)Hras (1μg) and Dominant-Negative 
(T43N)Rras (1μg). A αIIbβ3 integrin affinity was measured by 3-colour flow cytometric assessment of 
Pac-1 binding and % integrin suppression normalised to Tac-alone values. Mean ± s.e. of n=8 
experiments shown. B Western blot confirming balanced expression of transfected constructs, equal 
β3-integrin expression and integrin suppression independent of erk phosphorylation. 
 
Results: Notch1ICV1744 increased integrin affinity compared with vector control by 
60.9 ± 11.7% (s.e.) (p<0.001) and this was inhibited by DNRras (Notch1IC +DNRras 
4.3 ± 4.5% (s.e.) (p<0.001). (G12V)Hras reduced integrin affinity by 56.9 ± 3.6% 
(s.e.) (p<0.001) and Notch1IC abrogated this effect (Notch1IC+(G12V)Hras 10.5 ± 
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suppression was blocked by DNRras (Notch1IC+(G12V)Hras vs 
Notch1IC+(G12V)Hras+DNRras, p<0.05) supporting the hypothesis that the effects 
of Notch1IC are mediated via Rras (Fig 3.4A). Expression of all constructs was 
confirmed by western blot (Fig 3.4B). Alterations in Pac-1 binding were not due to 
alterations in the expression of αIIbβ3 integrin assessed by western blot analysis (Fig 
3.4B) Furthermore, as expected, although (G12V)Hras was shown to induce erk 
phosphorylation, this phosphorylation was independent of Notch and DNRras 
expression. 
 
3.6 Dominant-Negative Rras blocks Notch1IC reversal of Raf-
mediated integrin suppression 
Since Hras-mediated integrin suppression is dependent on downstream Raf activation 
(Hughes et al., 1997),(Hughes et al., 2002) the effect of (T43N)Rras and Notch1ICV1744 on 
constitutively active Raf-CAAXBXB-mediated integrin suppression (Sethi et al., 1999a) as 

































Figure 3.5  Dominant-Negative Rras blocks Notch1IC reversal of Raf-mediated integrin 
suppression. Chinese hamster ovary cells stably expressing the chimaeric integrin αIIbβ3α6β1 were 
transiently transfected with interleukin-2 receptor (Tac-α5, 0.75μg) and combinations of Notch1ICV1744 
(1μg), Raf-CAAXBXB (1μg) and Dominant-Negative (T43N)Rras (1μg). A αIIbβ3 integrin affinity was 
measured by 3-colour flow cytometric assessment of Pac-1 binding and % integrin suppression 
normalised to Tac alone values. Mean ± s.e. of n=7 experiments shown. B Representative dot-plots 
demonstrating summed data in A. C Western blot confirming expression of transfected constructs. 
 
Results: Fig 3.5A+B: Notch1ICV1744 increased integrin affinity (p<0.001) and this 
was inhibited by DNRras (p<0.001). RafCAAXBXB reduced integrin affinity 
(p<0.001) and Notch1ICV1744 completely abrogated this (p<0.001). The effect of 
Notch1ICV1744 on Raf-CAAXBXB-mediated integrin suppression was blocked by 
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3.7 Notch1ICV1744 does not increase expression of β3-integrin 
Most of the known cellular effects of Notch1 are a result of alterations in protein 
expression via CBF1-dependent transcriptional modulation. To assess whether 
increased Pac1 binding in the flow cytometry experiments was due to increased 
integrin expression rather than increased integrin affinity, highly transfected cells 
(Tac-PE FL2  signal intensity ≥600) were cell sorted using a FACSCalibur flow 
cytometer and western blot analysis of αIIb and β3 integrin expression performed. 
 











Figure 3.6  Notch1ICV1744 does not increase expression of β3-integrin. Chinese hamster ovary 
(CHO) cells were transiently transfected with Tac (0.75μg) +/- pcDNA3.1+ (1μg), Notch1ICV1744 (1μg), 
(G12V)Hras (1μg) or Dominant-Negative (T43N)Rras (1μg). After 48 hours cells exhibiting high levels 
(FL2 >600) of Tac-PE (a marker of transfection efficiency) were sorted using a FACS-Calibur flow 
cytometer. 0.5 million cells were lysed and total protein levels balanced. Western blots were probed for 
actin, αIIb and β3 integrin. A Representative histograms and dotblot of PE binding of sorted cells 
(Tac/Notch transfected cells shown). B Western blot probed for actin, αIIb and β3-integrin. 
 
Results: Chinese hamster ovary cells highly transfected with Tac +/- pcDNA3.1+, 
Notch1ICV1744, (G12V)Hras and Dominant-Negative (T43N)Rras express equal 
amounts of αIIb and β3 integrin (Fig 3.6B). Thus, differences in flow cytometric 













































3.8 Notch1ICV1744 induces Rras activation 
Since the above data shows that Notch1IC increases integrin affinity via Rras it was 
anticipated that Notch1IC would produce an increase in the activated, GTP-bound, 
Rras moiety. The effect of Notch1ICV1744 transfection on levels of total and GTP-
bound Rras was assessed using an Rras activation assay (Poulson DF, 1945). 
 













Figure 3.7  Notch1ICV1744 induces Rras activation. Chinese hamster ovary cells stably expressing 
the chimaeric integrin αIIbβ3α6β1 were plated into 6 cm plates in DMEM complete media. Cells were 
transfected with wild type Rras (myc tagged) (0.5μg/well) plus pcDNA3.1+, (G38V)Rras or 
Notch1ICV1744, (all 1μg/well) as indicated. Cells were incubated for 36 hours in complete media and 
then quiesced for 12 hours prior to lysis. Cell lysates were incubated at 40C with Ras-Binding-Domain-
Raf:GST agarose beads to bind active GTP-bound Rras. Washed beads were boiled at 950C for 5 
minutes and Rras expression was determined by Western blot analysis. A Representative western blot 
of active Rras in RBD-Raf:GST pulldown and wildtype Rras in whole cell lysates probed with anti-
myc(9E10) antibody. B Representation of GTP-Rras binding to agarose bead-GST-linked Raf domain. 
 
Results: Equal levels of (wt)Rras were present in whole cell lysate loading controls. 
In the pulldown samples, the positive control (G38V)Rras, a constitutively active, 
GTP-bound mutant, demonstrated high levels of myc-tagged GTP-Rras bound to the 
RBD-Raf:GST-agarose beads. (wt)Rras alone did not induce high levels of GTP-




















































































































































bound Rras levels further supporting the evidence that Notch1 mediates increased 
integrin affinity via activation of Rras (Fig 3.7A). 
 
3.9 Functional assays of integrin affinity 
In order to further substantiate the hypothesis that Notch1 increases integrin affinity 
it was necessary to demonstrate functional changes in cells transfected with Notch1 
or treated with Notch ligands (Jagged or Delta) or inhibitors of the Notch signalling 
pathway (e.g. γ-secretase inhibitor MW167). K562 human leukaemic cells were 
chosen for assessment since i) they are highly transfectable using electroporation, ii) 
they express exclusively α5β1 integrins (Jarvinen et al., 1993) which bind fibronectin and 
iii) Many other cell lines have integrins in a maximally activated, high affinity state; 
however, under resting conditions, K562 cells are only weakly adherent to 
extracellular matrix and thus increases in integrin affinity were considered to be 
achievable and measurable with functional assays. 
 
3.10 Characterisation of K562 transfection, viability and adhesion 
Transfection of K562 cells was performed using an AMAXA electroporator. 
Transfection efficiency was assessed by flow cytometric analysis of Green 
Fluorescent Protein (GFP) expression. Viability of cells was assessed 24-72 hours 
later by acridine orange/ethidium bromide morphological assessment. Expression of 
transfected constructs was confirmed by western blotting. An adhesion dose response 





























Figure 3.8  Characterisation of K562 transfection, viability and adhesion. A Using an AMAXA 
electroporator 5 million K562 cells were transfected with 5μg pEGFP3 or control plasmid and GFP 
expression assessed after 72 hours using a FACSCalibur flow cytometer. B 5 million K562 cells were 
transfected with 10μg of control pcDNA3.1+ or 5μg pcDNA3.1+/5μg Notch1ICV1744 or 5μg 
pcDNA3.1+/5μg DNRras or 5μg Notch1ICV1744/5μg DNRras using an AMAXA electroporation system. 
Viability of cells was assessed 24-72 hours after AMAXA electroporation by acridine orange/ethidium 
bromide morphological assessment. Mean ± s.e. of 3 experiments shown. C Concomitantly, expression 
of transfected constructs and β1-integrin was confirmed 72 hours after electroporation by Western 
blotting. D 96-well plates were precoated by incubation at 370C with fibronectin (0-80μg/ml) or poly-l-
lysine (10μg/ml).105 K562 cells were plated per well and cells were allowed to adhere for 30 min at 
37°C. Non-adherent cells were then removed by gentle washing with PBS x2. Adhered cells were fixed 
with 3% paraformaldehyde (5 min) and stained with 0.4% methylene blue (5 min). After washing, 
intracellular methylene blue was eluted with 0.1M hydrochloric acid and the optical density (OD) (λ 
560nM) of each sample was determined using an automated plate reader. Mean ± s.d. of n=3 
experiments shown. 
 
Results: K562 cells exhibit high GFP transfection efficiency (80-90%) 72 hours after 
AMAXA electroporation. >90% of these cells are viable at 72 hours after AMAXA 

































































































































































confirmed (Fig 3.8C). Transfection of Notch1 and DNRras did not alter surface 
expression of β1-integrin (Fig 3.8C). K562 adhesion to fibronectin was 
concentration-dependent with maximal adhesion at 20μg/ml (Fig 3.8D). 
 
3.11 Notch1IC increases K562 adhesion in a β1-integrin dependent 
manner 

























Figure 3.9  Notch1IC increases K562 adhesion to fibronectin in a β1-integrin dependent manner. 
A K562 cells were transiently transfected with empty vector (pcDNA3.1+) or Notch1ICV1744 (1μg/106 
cells). Cells were harvested 72 hours later and assessment of adhesion to fibronectin performed. 96 
well plates were precoated with 20μg/ml fibronectin. Harvested cells were washed with PBS and 
adhered for 1 hour at 370C in triplicate. Wells were gently agitated to dislodge non-adhered cells, 
washed twice with PBS, fixed with 3% PFA, stained with methylene blue, washed and lysed with 0.1% 
hydrochloric acid. Absorbance was measured on a plate-reader at 560nm and values normalised to 
poly-l-lysine values. B Stable cell lines expressing Notch1ICV1744 were developed by G418-selection 
of K562 cells transfected with pcDNA3.1+Notch1ICV1744. Adhesion to fibronectin (20μg/ml) was 
compared with stable pcDNA3.1+ lines and values normalised to poly-l-lysine. Mean ± s.e. of n=4 
experiments shown. C Western blot confirming Notch1 transfection and equal β1-integrin expression in 
stable lines. D K562 cells were transfected as indicated. 72 hours later cells were harvested and 
incubated with or without function-blocking β1-integrin antibody (4B4 10μg/ml 370C for 30 mins). A 


























































































































Results: K562 cells transiently and stably transfected with Notch1ICV1744 exhibit 
increased adhesion to fibronectin compared to vector-only control (Fig 3.9A+B). 
K562 cells pre-treated with function-blocking β1-integrin antibody (4B4) exhibited 
significantly reduced adhesion to fibronectin (Fig 3.9C) supporting previously 
published data showing that K562 cells express predominantly α4β1 and α5β1 
integrins (Turner et al., 1998),(Kikkawa et al., 2000), the integrins responsible for adhesion to 
fibronectin. K562 cells transfected with Notch1ICV1744 exhibited a significant 
increase in adhesion to fibronectin (p<0.01) from 9.9 ± 1.3% (s.e.) to 18.9 ± 3.2% 
(s.e.) of cells adherent compared with poly-l-lysine. This effect was completely 
abrogated by function-blocking β1-integrin antibody (4B4) (Fig 3.9D) but not 
isotype control (data not shown) confirming that this increase in adhesion was 
secondary to increased β1-integrin-mediated adhesion. 
 
3.12 Dominant-Negative Rras inhibits Notch1IC-mediated Adhesion 
of K562 cells to Extracellular Matrix 
To corroborate the earlier FACS data showing that Dominant-Negative (T43N)Rras 
inhibited Notch-mediated increases in integrin affinity, assays of K562 adhesion to 























Figure 3.10 Dominant-Negative Rras inhibits Notch1IC-mediated adhesion of K562 cells to 
fibronectin. A K562 cells were transiently transfected with empty vector (pcDNA3.1+), Notch1ICV1744, 
Dominant-Negative Rras or both (1μg/106 cells). Cells were harvested 72 hours later and assessment 
of adhesion to fibronectin performed. Briefly, 96 well plates were precoated with 20μg/ml fibronectin. 
Harvested cells were washed with PBS and adhered for 1 hour at 370C in triplicate. Wells were gently 
agitated to dislodge non-adhered cells, washed twice with PBS, fixed with 3% PFA, stained with 
methylene blue, washed and lysed with 0.1% hydrochloric acid. Absorbance was measured at 560nm 
and values normalised to pcDNA3.1+ values. Mean ± s.e. of n=7 experiments shown. 
 
Results: Compared with vector control, Notch1IC increased adhesion of K562 cells to 
fibronectin by 26.99 ± 6.7% (s.e.) (p<0.001).  Dominant-Negative Rras alone did not 
significantly affect adhesion compared with control vector but it did completely 
abrogate the Notch1IC-mediated increase in adhesion (p<0.01). 
 
3.13 Discussion 
After confirmation that constitutively active mouse Notch1ICV1744 constructs were 
accurately cloned into pcDNA3.1+ (Fig 3.1) it was demonstrated that 
Notch1ICV1744 induced an increase in integrin affinity in CHO cells expressing an 
active chimeric integrin (αIIbβ3/α6β1) measured by increased binding of Pac1, an 























































has the ligand binding properties of αIIbβ3 but is activated through the α6Aβ1 
cytoplasmic domains (Fenczik et al., 1997). Furthermore, transfection of (G12V)Hras alone 
caused marked inhibition of PAC1 binding and cotransfection of Notch1ICV1744 
completely reversed this (G12V)Hras-mediated integrin suppression (Fig3.2A+B). 
Suppression of integrin activation by Hras is dependent on downstream erk1/2, 
though is not related to overall levels of erk phosphorylation (Hughes et al., 2002). 
Notch has previously been shown to have differing effects on erk phosphorylation in 
different model systems (Sriuranpong et al., 2001),(Eagar et al., 2004) and thus the effect of Notch 
on erk phosphorylation was assessed by western blotting for total and phosphorylated 
erk (Fig 3.2C). Whilst, as expected, Hras induced an increase in erk phosphorylation, 
this was unaffected by concomitant Notch expression. This supports data from 
genetic experiments in lower organisms which has previously provided indirect 
evidence of coordinated signalling between Notch and integrins. 
To date, few intracellular signalling proteins have demonstrated the capability to 
increase integrin affinity and reverse (G12V)Hras-mediated integrin suppression; 
these include Rras and Rap (described previously), PEA-15 and CD98. The increase 
in integrin affinity produced by PEA-15 (Protein Enriched in Astrocytes) is blocked 
by Dominant-Negative Rras (Ramos et al., 1998) and PEA-15 may, in part, reverse Hras-
mediated integrin suppression by sequestering mapk in the cytoplasm preventing 
erk/mapk-dependent transcription (Chou et al., 2003). CD98 (heavy chain) mediates β1-
integrin-mediated cell spreading and migration and is required for adhesion-induced 
activation of PKB-survival signalling (Fenczik et al., 1997),(Feral et al., 2005). In lower 
organisms, Notch and Ras have been shown to exhibit multiple levels of interaction; 
in C.elegans vulval development Ras signalling from one cell results in upregulated 
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Notch signalling in the adjacent cell (Shaye and Greenwald, 2002). A similar Ras-mediated 
lateral inhibition signal exists in Drosophila mesothorax development (Culi et al., 2001). In 
Drosophila ommatidia development (Tomlinson and Struhl, 2001), Notch and Ras signalling 
converge in the same cell to define cellular differentiation, i.e. acting cooperatively 
rather than sequentially. AF-6 (also known as Canoe and Ce-AF-6) may provide a 
further mechanism for Notch/Ras interaction since it acts downstream of Notch in 
Drosophila eye development but also binds GTP-Hras and is thought to localise 
proteins to sites of cell-cell adhesion (Miyamoto et al., 1995),(Matsuo et al., 1999). In addition to 
acting downstream of Notch, the C.elegans homolog Ce-AF-6 was also identified as 
a putative Ras effector (Watari et al., 1998) and Notch may alter Ras signalling via Canoe. 
Further evidence that Notch and Ras cooperate in lower organisms is provided by the 
demonstration that Notch and Drosophila Rras (Dras2/Ras64B) loss and gain-of-
function mutants share similarities in phenotype  including rough eye (Hori et al., 
2005),(Schreiber et al., 2002),(Aplin et al., 1997). 
It is perhaps not surprising that there has, as yet, been no demonstration of direct 
Notch to Rras signalling in Drosophila or C.elegans. Although Drosophila has 
developed discrete Hras and Rras entities, human Hras and Rras have limited 
homology with their invertebrate counterparts; for example human Rras has only 
~63% amino acid homology with Drosophila Rras.. The fact that Notch and Ras 
interact at all in lower organisms makes it likely that more refined and complex 
systems exist in higher animals. Few studies have addressed the interaction of Notch 
with Ras in higher organisms. In 3T3-L1 cells Hras induces adipogenesis only if 
Notch signalling is also present (Garces et al., 1997). Individually, Notch and Ras have 
well-described roles in oncogenesis: Fitzgerald et al (Fitzgerald et al., 2000) showed that 
 81
Notch4 is dependent upon Ras signalling to sustain anchorage independent growth. 
A further potential level of Notch/Ras signalling overlap is ADAMs (a Disintegrin 
and Metalloprotease) (Yan et al., 2002b); membrane metalloproteases that modulate Notch 
S2 cleavage since,  in addition, they are involved in EGFR transactivation by G-
proteins that results in downstream Hras signalling. In view of this indirect evidence 
for Notch/Ras interaction and since Rras is the most well characterised positive 
modulator of integrin affinity it’s role in Notch-mediated integrin affinity modulation 
was investigated further here. 
(T43N)Rras is a mutant of Rras that has a much higher affinity for GDP than GTP 
and thus is constitutively inactive. Cotransfection of (T43N)Rras with 
Notch1ICV1744  completely inhibited Notch1IC-mediated integrin activation (Fig 
3.3). It also abrogated (G12V)Hras-mediated (Fig 3.4A) and Raf-CAAXBXB-
mediated integrin suppression (Fig 3.5A) inferring that Notch’s effect on integrin 
affinity is mediated via Rras downstream of, or parallel to, the Hras-Raf pathway. 
Western blotting again confirmed that the influence of Notch did not relate to altered 
erk phosphorylation or levels of expression of β3-integrin. 
An alternative explanation for the increase in Pac-1 binding caused by Notch1 is 
increased expression of the target for Pac-1, integrin  αIIbβ3. Western blot analysis 
of whole cell lysates as shown above demonstrated no difference in overall 
expression but since these lysates contained all transfected cells (rather than only the 
highly transfected cells that exhibit these integrin affinity changes) they may not 
accurately reflect the expression of integrins on the surface of highly transfected 
cells. Therefore highly transfected cells (Tac-PE FL2  signal intensity ≥600) were 
cell sorted using a FACSCalibur flow cytometer and Western blot analysis of αIIb 
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and β3 integrin expression performed. This again confirmed no difference in integrin 
expression between the pcDNA3.1, Notch1ICV1744, (G12V)Hras or Dominant-
Negative (T43N)Rras-transfected cells (Fig 3.6B). (T43N)Rras can sequester GEFs 
when overexpressed. It is therefore possible that the effect of (T43N)Rras is a result 
of blocking GEF-dependent events shared by both Hras and Rras. However, previous 
data has shown that this mutant of Dominant-Negative Rras does not affect Hras 
signalling (Ramos et al., 1998). 
If Notch activates integrins via a Rras-mediated mechanism then it was felt likely to 
be due to activation of Rras from GDP-bound to the GTP-bound form. 
To determine whether Notch signalling could directly activate Rras to the GTP-
bound form, CHO cells were transfected with myc-tagged wild-type Rras and either 
Notch1ICV1744 or empty vector (pcDNA3.1+). After 48 hours the Ras-binding-
domain (RBD) of Raf linked via GST to agarose beads, was used to pulldown GTP-
bound Rras from cell lysates. Western blot assessment of GTP-Rras levels was then 
performed. Notch transfection reproducibly produced an increase in the amount of 
Rras pulled down in this assay confirming Notch-mediated Rras activation. 
(G38V)Rras, a constitutively active, GTP-bound  mutant was transfected as a 
positive control. (Initial attempts, using this assay, were made to identify the increase 
in GTP-Rras of innate Rras in CHO cells by western blotting using anti-Rras 
antibody. However, as a result of poor antibody specificity and low overall levels of 
Rras no increase was identified). 
After demonstrating a Notch-mediated increase in GTP-bound Rras, it was 
hypothesised that Notch may interact directly with Rras to produce this effect. 
However, using myc-tagged (wt)Rras/(G38V)Rras and Flag-tagged Notch1ICV1744 
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(by subcloning into pCMV Tag4B – Stratagene) it was not possible to show a direct 
association using a coimmunoprecipitation technique or with confocal microscopy 
(data not shown). Thus, Notch1 increases integrin affinity via activation of Rras 
though it appears that Notch mediates Rras activation via an indirect mechanism. 
This may be via direct interaction with second messengers; for example Calderwood 
et al co-immunoprecipitated Numb, an inhibitor of Notch activity, with β3 and β5 
integrin (Calderwood et al., 2003). Another possible mechanism may involve the modulation 
of subcellular localisation of Rras. 
CHOαβpy cells are a useful tool to investigate integrin affinity but express high 
levels of a non-physiological chimaeric integrin which is in a relatively high affinity 
state (and thus the use of Hras to initially reduce affinity in many experiments). In 
order to demonstrate a functional outcome from Notch-mediated integrin activation 
in a human cell line system with physiological levels of integrin expression, adhesion 
assays were performed following cotransfection with Notch1ICV1744 and DNRras 
using human leukaemic K562 cells expressing β1-integrin in association with α4 and 
α5 subunits. 72 hours after transfection by electroporation, high levels of cell 
viability and protein expression of transfected products were confirmed by 
morphological assessment and western blotting respectively (Fig 3.8A+B). 
Furthermore, western blotting for β1-integrin showed equal expression in control, 
Notch1ICV1744 and DNRras-transfected cells (Fig 3.8C) confirming that alterations 
in adhesion are not due to differences in surface expression of  β1-integrin. In the 
absence of activation by TPA or hemin, K562 human myeloid leukaemia cells exist 
in a pluripotential resting state expressing only α4β1 and α5β1 integrins (Jarvinen et al., 
1993). 18.5% of cells transiently transfected with vector-only (pcDNA3.1+) adhered to 
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fibronectin and this increased to 23.2%  (Fig 3.9A) in cells transiently transfected 
with Notch1ICV1744 (paired “t” test, p=0.0006). A similar increase in adhesion was 
seen when comparing stable cell lines transfected with pcDNA3.1+ and 
Notch1ICV1744 (Fig 3.9B). Confirmation that this  adhesion to fibronectin occurred 
via β1-integrins was provided by experiments in which adhesion induced by 
Notch1ICV1744 (and K562 adhesion per se) was completely inhibited by 
preincubation of K562 cells with function-blocking antibody 4B4 (Fig 3.9D) but not 
by 4B4 isotype antibody. Thus, the Notch-mediated increase in integrin affinity 
demonstrated in FACS experiments in CHO cells also results in a functionally 
measurable outcome in a human leukaemic cell line. Yeh at al previously 
demonstrated in K562 cells that Notch1IC is associated with YingYang1 via Notch 
ankyrin repeats (Yeh et al., 2003). YingYang1 has zinc finger domains and reduces Hes-1 
luciferase expression via CBF-1. Interestingly, in a human osteosarcoma cell line, de 
Nigris et al showed that myc and YingYang1 together bind to DNA to cooperate in 
reducing expression of α3-integrin (de Nigris et al., 2007). However, K562 cells do not 
express α3-integrin and expression levels of β1-integrin were unchanged in these 
experiments precluding the above YingYang1-mediated mechanism as a contributor 
to the above results. 
Importantly, the Rras-dependent nature of this phenomenon was also reproduced in 
this human cell line model with the demonstration that Notch-mediated increase in 
adhesion was completely abrogated by cotransfection with DNRras (Fig 3.10A). 




In conclusion, the data here show that Notch1 activates integrins and reverses Hras-
mediated suppression of integrins via activation of Rras. Interactions such as this 
have previously been suggested by indirect genetic data in invertebrates and mouse 
developmental models but this is the first direct evidence that Notch, integrins and 
Rras interact simultaneously to produce alterations in β1-integrin-mediated adhesion. 
The mechanisms underlying this may be important in cell-fate decision-making 
during embryogenesis and explain some of the overlap in phenotypes observed in 
Notch, integrin and Ras mutants in Drosophila and C.elegans. It implicates Notch in 
many integrin-mediated events that are critical in cellular behaviour related to 
adhesion and motility. Furthermore this data may provide a link to begin to explain 
the observation that Notch can act as a tumour suppressor: There is some evidence 
that integrins can become “blind” to the extracellular milieu and in doing so 
anchorage independence is promoted. By activating integrin affinity, Notch may 
inhibit this anchorage independence and via concomitant antagonism of Hras-
mediated cell cycle promotion, prevent disordered cell growth. 
 
[More recent data (not shown here) produced in this lab (Dr P.Hodkinson) has shown 
that: 
1) Low dose Notch1IC1744 (0.25μg/well) and low dose (wt)Rras (0.375μg/well) 
produce no significant effect on integrin activation/reversal of suppression when 
transfected alone but did produce complete reversal of (G12V)Hras suppression 
when both were transfected. This is consistent with increased levels of (wt)Rras 
being activated to GTP-Rras causing reversal of (G12V)Hras-mediated integrin 
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suppression, providing further support for a role for Rras activation downstream of 
Notch1 signalling  
2) Although Notch-mediated effects on integrin affinity are dependent on γ-
secretase intramembranous cleavage, they are not CBF-dependent; a Notch mutant 
which is S3-cleavable but lacks the ability to transactivate the CSL complex reversed 
(G12V)Hras integrin suppression without producing Hes activation. These 
experiments were supported by similar results using MINT, a Notch antagonist. 
Deletion mutants implicated Notch ankyrin repeats in Notch-mediated integrin 
activation. 
3) The Notch ligand, Delta-like ligand-4 (Dll-4) significantly increased adhesion 
of K562 cells to fibronectin in a β1-integrin-dependent manner and MW167, a γ-














Extracellular Matrix overrides DNA-damage-induced 
cell cycle arrest in small cell lung cancer cells via β1-
integrin dependent activation of PI3Kinase. 
 
4.1 Introduction: Outside-In Integrin Signalling – Extracellular Matrix- 
  mediated Anti-apoptotic Signalling 
Over the last 50 years cytotoxic chemotherapy and radiotherapy has been the 
mainstay of cancer treatment for patients with haematological and metastatic 
tumours. In some solid tumour sites they have replaced surgery as the treatment 
modality for primary-site tumour control (e.g. anus, small cell lung cancer, some 
head and neck cancers and non-melanomatous skin cancers). In addition, adjuvant 
chemotherapy can also produce significant survival benefits to selected patients 
following the treatment of localised disease presumably by eliminating undetectable 
minimal or microscopic residual tumour. Complete, sustained tumour responses 
resulting in cure are frequently obtained in patients with haematological 
malignancies, trophoblastic tumours and germ cell tumours. Often, however, in 
haematological malignancies and ovarian/germ cell/small cell lung/breast cancer 
although impressive initial responses to chemotherapy are seen, in a significant 
number of patients residual and recurrent disease refractory to further therapy results 
in treatment failure, tumour relapse and ultimately death. Subpopulations of tumour 
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cells survive the initial drug treatment and become unresponsive to a wide spectrum 
of anti-cancer agents in a phenomenon known as multi-drug resistance or MDR (it is 
important to note that this is distinct from mechanisms of single-drug resistance, e.g. 
gene amplification of the methotrexate target-dihydrofolate reductase, which will not 
be considered further in this thesis). The molecular mechanisms underlying the 
development of this multi-drug chemotherapy resistance are the object of intense 
research activity and offer the potential to provide novel therapeutic targets to 
improve the response to chemotherapy and ultimately impact on survival in cancer 
patients. 
Many forms of chemotherapy primarily exert their cytotoxic effect by inducing 
apoptosis (Airas et al., 2000). It has generally been considered that drug-resistant cells arise 
from genetic changes that either occur spontaneously because of inherent genetic 
instability in cancer cells or as a result of chemotherapy-induced genetic damage 
(Obara et al., 2002),(Duensing et al., 1996),(Struski et al., 2001). Factors that allow cell survival following 
acute cytotoxic drug exposure may differ from mechanisms selected for by chronic 
drug exposure. The inheritable nature of the drug resistant phenotype in 
transplantable mouse leukaemia models (Hayakawa et al., 2000),(Ader et al., 2002) together with 
the understanding of the biochemical action of certain anti-metabolites led to the 
early focus on genetic features of tumour cells as the determinant of drug sensitivity 
and resistance. Classically, investigations of drug resistance have focused on the 
single cell by selecting for drug resistant cells following exposure to cytotoxic 
agents. These studies have revealed a number of mechanisms such as a) Drug efflux 
via ATP binding cassette (ABC) cotransporters such as the P-glycoprotein (PgP) 
drug pump, b) Upregulation of drug detoxification mechanisms such as the 
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glutathione-S-transferase system and c) Topoisomerase II downregulation and 
mutation. Despite extensive research the clinical, in vivo relevance of these 
mechanisms is unclear and no significant clinical benefit has yet accrued. The search 
for novel mechanisms of MDR responsible for chemotherapy failure therefore 
continues. Recently it has become apparent that extracellular matrix-binding to 
integrins results in resistance against chemotherapy-induced apoptosis. Furthermore, 
this phenomenon has been demonstrated in a wide variety of cell types and results in 
resistance to anticancer agents that induce cell death via a variety of unrelated 
mechanisms. Phenomena which may explain this significant discovery include a) 
Increased resistance to tumour penetration resulting in reduced drug exposure, b) 
Reduced induction of DNA damage or upregulated DNA repair, c) Potentiation via 
autocrine loops and d) Modulation of cell survival and death signalling pathways.  
 
4.1.1 Classical mechanisms of MDR 
Drug Efflux Pumps 
Reduced intracellular drug concentration can result from increased efflux of drug 
from resistant cells due to the presence of P-glycoprotein (PgP/MDR-1), multi-drug 
resistance-associated proteins (MRP2-7), breast cancer resistance protein and the 
lung cancer resistance protein drug pumps in the plasma membrane (Biedler et al., 
1970),(Kartner et al., 1983). The genes for P-glycoprotein and MRP have been cloned and it 
has been demonstrated that these ATP-driven pumps have broad substrate specificity 
(Roninson et al., 1986),(Cole et al., 1992). As well as playing an important role in transport of 
endogenous substances (e.g. Leukotriene C4) they reduce intracellular drug 
accumulation thereby conferring resistance to a broad range of structurally and 
 90
mechanistically diverse chemotherapeutic agents (Gerlach et al., 1986). P-glycoprotein-
mediated drug resistance has been well characterised in haematological malignancies 
(Dalton et al., 1989) and P-glycoprotein expression has correlated with chemotherapy 
response and outcome in some clinical series (Jiang et al., 1998a),(Webb et al., 1998). However, 
this mechanism alone cannot account for all drug resistance found in vivo or in vitro, 
nor is it likely to explain cell survival following acute cytotoxic drug exposure. The 
picture is less clear in solid tumours and though P-glycoprotein upregulation has 
been identified in many cell types e.g. bladder (Tada et al., 2002), breast (Takamura et al., 
2001),(Faneyte et al., 2001) and colon cancer (Sinicrope et al., 1994) the relationship of expression to 
clinical chemoresistance and therefore the true clinical relevance of this 
phenomenon, remains unclear. In small cell lung cancer (SCLC) lines P-glycoprotein 
phenotype is easy to develop in vitro but it appears to be infrequently expressed in 
vivo (Lai et al., 1989). P-glycoprotein specific mRNA expression was elevated in only 4 
out of 23 SCLC cell lines and 3 out of 6 primary tumours. In no instance was 
elevation of P-glycoprotein expression to the very high levels sometimes seen in 
colon cancer (Duensing et al., 1994). In addition there was no correlation between P-
glycoprotein expression and response to chemotherapy or whether the tumour was 
derived from previously treated or untreated patients. This suggests that the 
expression of P-glycoprotein is not a dominant mechanism of drug resistance in 
SCLC. 
Breast cancer resistance protein (BRCP) (Doyle et al., 1998),(Lage et al., 2000a), a 72kDa ATP 
binding cassette (ABC) cotransporter of the P-glycoprotein/MRP family has been 
shown to be associated with mitoxantrone, topotecan, methotrexate (Doyle et al., 1998),(Lage 
et al., 2000a),(Volk et al., 2000) and (in most studies) adriamycin resistance in breast (Volk et al., 
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2000),(Faneyte et al., 2002),(Scheffer et al., 2000) colon, gastric and ovarian cancer, fibrosarcoma 
and myeloma (Ross et al., 1999). The major vault protein (MVP)/lung cancer resistance 
protein (LRP) is a further 110kDa ABC drug cotransporter (Scheffer et al., 1995) that is 
upregulated in chemoresistant cell lines in non-small cell lung cancer (NSCLC) (Berger 
et al., 2000),(Volm et al., 1997), acute myeloid leukaemia (List et al., 1996), prostate (van Brussel et al., 
2001) and ovarian cancer (Arts et al., 1999). It localises to nuclear pore complexes and may 
influence intracellular drug transport and localisation, possibly diverting drugs from 
their nuclear target. We do not yet know the clinical importance of these more 
recently discovered drug transporters. 
 
Glutathione-S-transferase 
An alternative mechanism of drug resistance is upregulation of drug detoxifying 
enzymes such as the G-S-Transferases, a group of multigene isoenzymes that 
detoxify both xenobiotic and endobiotic compounds via conjugation with glutathione 
prior to further metabolism and excretion (Hall, 1999),(Salinas et al., 1999). Resistance to cis-
platinum and doxorubicin is associated with increased G-S-T levels and this has been 
shown to result in protection against DNA damage (Goto et al., 2001). G-S-T levels are 
upregulated in a number of cancers including breast (Perquin et al., 2001),(Buser et al., 1997), 
colon (Redmond et al., 1991) and non-small cell lung cancer (NSCLC) (Nakanishi et al., 1999). 
Again, however, although this mechanism is important in many in vitro cancer cell 
lines it appears that it may only have minor clinical relevance (Buser et al., 1997),(Nakanishi et 




Topoisomerase II-associated Multi-Drug Resistance 
Several important chemotherapeutic agents including etoposide, teniposide and 
doxorubicin induce apoptotic cancer cell death via interaction with topoisomerase-II 
(TopoII). TopoII regulates the three-dimensional structure of DNA by binding to a 
DNA molecule, cleaving both strands of that DNA and passing a second DNA 
duplex through the first before re-annealing the cleavage site (Kaufmann, 1989). Etoposide 
blocks the re-annealing action of TopoII at a step in its catalytic cycle after the 
enzyme has created a double-strand break, the so-called “cleavage complex”, and 
ultimately leads to activation of apoptosis (Kaufmann, 1998). Most investigators show that 
cancer cell lines selected for resistance to TopoII poisons escape cell death by 
reducing the level of target TopoII enzyme (Koshiyama et al., 2001),(Nielsen et al., 2000),(Lage et al., 
2000b). This is usually associated with a concomitant reduction in TopoII activity 
(resistant cells are able to survive with a three to four-fold reduction in TopoII 
content (Kobayashi et al., 2001) though subsequent recovery in expression (Matsumoto et al., 2001b) 
or mutation (Matsumoto et al., 2001a) resulting in a maintained overall enzyme activity 
despite reduced enzyme concentration have been identified as mechanisms to counter 
this. NSCLC is intrinsically much more resistant to etoposide than SCLC and this 
may be due to the fact that NSCLC cells have significantly less TopoII target for 
etoposide to bind than SCLC (de Jong et al., 1990). However, worse prognosis (van Brussel et al., 
2001),(Dingemans et al., 2001) and lower chemotherapy response rates (Dingemans et al., 1999) have 
also been obtained in the presence of increased levels of TopoII enzyme and again 
the clinical importance of this well-researched phenomenon is unclear. 
Several mechanisms have been described whereby cancer cells, upon exposure to 
one chemotherapeutic agent, can develop multi-drug resistance to several other 
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agents. It is not uncommon for these mechanisms to co-exist. For example a SCLC 
line made resistant in vitro by graded exposure to doxorubicin was found to show 
collateral resistance to vincristine, etoposide, cis-platinum and x-irradiation but not 
to melphalan, colchicine or actinomycin-D (Zijlstra et al., 1987). This drug resistance was 
explained on the basis of a combined decrease in intracellular levels of doxorubicin, 
reduced TopoII activity and increased DNA repair. 
Whereas these mechanisms may ultimately cause multi-drug resistance in previously 
chemosensitive tumours in vitro, both pre-clinical and clinical studies indicate that 
these mechanisms are unlikely to promote tumour cell survival in the initial 
aftermath of chemotherapy in chemosensitive tumours in vivo. Therefore the search 
has continued for alternative mechanisms of multi-drug resistance. 
 
4.1.2 The role of integrins and extracellular matrix in chemoresistance 
Most studies into multi-drug resistance have concentrated on the cancer cell in 
isolation without accounting for factors in the extracellular milieu. There is good 
evidence that soluble factors in the extracellular environment can modulate 
chemosensitivity, e.g. the cytotoxicity of vincristine, adriamycin and 
cyclophosphamide is inhibited by haemopoietic cytokines such as granulocyte 
macrophage colony stimulating factor, granulocyte colony stimulating factor or 
interleukin-6 (Lotem et al., 1992). Etoposide-induced apoptosis in pancreatic carcinoma cell 
lines is increased by interleukin-1β (Arlt et al., 2002). Interferon-alpha 2b sensitises HCT-
15 cells to doxorubicin (Lucero Gritti et al., 2001) and type I interferon increases cell death in 
melanoma lines in response to cis-platinum (Matarrese et al., 2002). 
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Further support for the role of extracellular factors in multi-drug resistance is given 
by the finding that certain resistance mechanisms may only be functional in vivo (Raff, 
1992). For example mammary tumours made resistant to alkylating agents in vivo were 
sensitised to cytotoxic drugs once removed from the animal (Teicher et al., 1990). In 
addition, studies have revealed differences in tumour cell response to drugs when 
assayed in monolayer versus spheroid culture (Kobayashi et al., 1993), a model that 
replicates some of the in vivo cellular and extracellular matrix architecture. The 
spheroid model has been shown to approximate the in vivo microenvironment with 
the formation of cell-cell junctions and activation of intracellular signalling cascades. 
Possible mechanisms of spheroid-associated resistance include; inhibition of 
apoptosis, a preponderance of quiescent cells, modulation of growth and repair 
enzymes, reduced drug permeability, central hypoxia/necrosis and alterations in 
subcellular localisation of TopoII (Desoize et al., 2000),(Oloumi et al., 2000).(Desoize et al., 1998). The 
recent concept that factors in the extracellular environment may protect against 
chemotherapy, enabling cells to survive the primary chemotherapy insult and then go 
on to develop more random and chemotherapy-induced DNA damage which render 
the cells multi-drug resistant has been the object of significant study in recent years. 
A finding of particular significance is that integrin-mediated adhesion to extracellular 
matrix protects cells from chemotherapy-induced apoptosis. In normal cells ligand 
binding to integrins is responsible for a multiplicity of cell functions including 
adhesion and motility (Hauser et al., 1993), angiogenesis (Carpizo et al., 2000),(Brooks et al., 1994), 
differentiation (Chenard et al., 2000), growth and cell survival (Frisch et al., 2001),(Zhang et al., 1995). 
Integrins regulate many intracellular signalling pathways including tyrosine 
phosphorylation and inositol lipid metabolism that are central to regulation of 
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essential effectors of apoptosis (Meredith, Jr. et al., 1993),(Bates et al., 1994),(Frisch et al., 1994). The 
potential role of integrin binding and signalling in cancer cell anchorage-
independence, invasion, motility, metastasis and cancer cell survival has 
understandably provided the stimulus for many interrelated avenues of investigation.  
In 1972 Durand and Sutherland showed that intercellular contact promotes tumour 
cell survival following cytotoxic damage such as radiation (Durand et al., 1972), an early 
clue to the role of extracellular protection-signalling. Two decades later Fridman 
(Fridman et al., 1990) demonstrated that adhesion of SCLC cells to laminin resulted in 
increased resistance to chemotherapy-induced apoptosis, the dominant form of cell 
death in response to chemotherapy (Hannun, 1997). Further work in SCLC has confirmed 
that an extensive ECM that includes fibronectin, laminin and collagen IV surrounds 
SCLC cells in vivo. Adhesion of SCLC cells to these matrix proteins via β1-integrins 
confers resistance to apoptosis induced by etoposide, cis-platinum and doxorubicin 
and this protection can be completely abrogated by a function-blocking β1 integrin 
antibody (Damiano et al., 1999). 
ECM-mediated protection against chemotherapy-induced apoptosis has been 
demonstrated in a number of haemopoietic cell lines. Direct in vitro evidence comes 
from the demonstration that myeloma cell lines expressing α4β1 and α5β1 integrin 
are resistant to doxorubicin and melphalan when adhered to fibronectin compared to 
cells grown in suspension. In these cells adherence to fibronectin resulted in no 
difference in intracellular doxorubicin concentration or expression of ABC 
cotransporters ruling out the induction of drug efflux pumps as a possible mechanism 
of cytoprotection (Damiano et al., 1999),(Damiano et al., 2000). U937 human histiocytic lymphoma 
cells become resistant to doxorubicin, etoposide and mitoxantrone when adhered to 
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fibronectin (Hazlehurst et al., 2001b). In a lymphoma model that mimics the germinal centre 
by provision of CD40 and interleukin-4, adherence to V-CAM1 (a ligand for α4β1 
integrin) resulted in resistance to etoposide-induced apoptosis (Taylor et al., 2000),(Taylor et al., 
1999). Also, B-cell chronic lymphocytic leukaemia (CLL) cells in vitro were protected 
against fludarabine by α4β1-mediated binding to fibronectin (de la Fuente et al., 2002). 
There is also evidence for the presence of this MDR pathway in several solid 
tumours. Adriamycin MCF-7 breast lines have increased expression of α6β1 integrin 
and adhesion to laminin compared with the parental line (Narita et al., 1998). In addition 
α4β1 and α5β1 integrins are expressed on doxorubicin resistant lines but not on 
parental lines (Nista et al., 1997) and α5β1 expression enables these cells to derive a 
growth and survival advantage from fibronectin binding. MDA-MB-231 and 435 
breast cancer lines in vitro demonstrated a significant reduction in paclitaxel and 
vincristine-induced apoptosis following ligation of β1 integrins by their ECM ligands 
(Aoudjit et al., 2001). Breast cancer, fibrosarcoma and osteosarcoma lines were all protected 
against radiation and doxorubicin following incubation with basement membrane gel 
(Pogany et al., 2001). Vitronectin, but not fibronectin, protects human glioma cell lines 
against etoposide-induced death (Uhm et al., 1999). Similar protective effects have also 
been seen in colon cancer lines (Kouniavsky et al., 2002). Indirect evidence of ECM-
mediated chemoresistance is available for a broader spectrum of solid cancers. In 
head and neck cancer a melphalan-resistant nasal carcinoma cell line shows 
upregulation of integrin subunits α2, α5, α6, β1 and β2 compared with drug-sensitive 
parent lines. As well as chemoresistance phenotype this was associated with a 
significantly stronger binding to ECM and increased invasiveness (Liang et al., 2001). A 
vinblastine-resistant subline of renal carcinoma cells showed increased expression of 
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α1β1/α2β1 and decreased expression of α6β1 integrin in association with increased 
attachment to collagen and fibronectin (Duensing et al., 1996). Similar indirect evidence 
exists in drug-resistant sublines of glioma (Hikawa et al., 2000),(Gladson et al., 1995) and ovarian 
cancer (Sedlak et al., 1996),(Maubant et al., 2002). 
Evidence is accumulating that ECM induces this important phenomenon of 
multidrug chemoresistance by a number of mechanisms which include: 
 
4.1.3 Increased resistance to tumour penetration resulting in reduced 
drug exposure 
There is some evidence to support the intuitive notion that ECM provides a physical 
barrier to chemotherapy thus blocking its delivery to cancer cells. In a multicellular 
layer model, mouse mammary and human bladder cancer cells were grown to a depth 
of 200μm. These cells developed an ECM of laminin and collagen and penetration of 
cis-platinum, etoposide, gemcitabine, paclitaxel and vinblastine through the matrix 
was diminished (Tannock et al., 2002). A reduced macromolecule diffusion coefficient was 
noted in tumours with extensive collagen networks (Netti et al., 2000) and collagenase 
treatment of these tumours reversed this physical resistance. It is postulated that 
collagen influences macromolecule transport by binding to and stabilizing the 
glycosaminoglycans component of ECM. Early clinical trials using hyaluronidase 
have, however, failed to show synergy with chemo-irradiation (Baumgartner et al., 1998). It is 
important to reflect that though this mechanism may genuinely occur in vivo there is 
good evidence, in vivo, that drug delivery is in fact adequate on many occasions 
(denoted by the occurrence of complete responses). Furthermore integrin-mediated 
MDR is present in in vitro models where drug intracellular drug delivery is 
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guaranteed (Damiano et al., 1999),(Damiano et al., 2000). It is therefore very unlikely that reduced 
drug penetration is responsible for all ECM-related chemoresistance in vivo. 
 
4.1.4 Reduced induction of DNA damage or upregulated DNA repair 
It is possible that ECM confers drug resistance by limiting the amount of DNA 
damage induced by chemotherapy. Although in a SCLC study (Sethi et al., 1999b) TopoII-
induced DNA damage measured by a decatenation assay was similar in ECM and 
plastic-plated cells there have been other positive reports of diminished DNA 
damage in the presence of ECM. Dalton et al identified a 40-60% reduction in 
etoposide-induced DNA double-strand breaks measured by a neutral comet assay 
when U937 lymphoma cells were adhered to fibronectin (Hazlehurst et al., 2001a),(Hazlehurst et 
al., 2001b). It appears that this was due to a reduction in TopoII activity secondary to 
alterations in the nuclear distribution of enzyme. The mechanisms responsible for 
this are, as yet, unknown. In a study which used mouse lung endothelial cells 
adherence to collagen, laminin and soluble (or coated) α5, β1, β3 integrin antibodies 
resulted in integrin clustering and a reduction in bleomycin-induced DNA damage 
measured by DNA sedimentation and in-situ nick translation (Hoyt et al., 1997). Further 
investigation showed that this DNA protection was PARP-dependent suggesting that 
an alteration in chromatin structure may be important (Jones et al., 2001). 
 
4.1.5 Autocrine loops 
It is well recognised that cancer cells are capable of production and secretion of 
ECM. Immunohistochemical staining of archival SCLC tissue demonstrated not only 
extensive ECM but also the presence of ECM proteins within cancer cells (Sethi et al,. 
 99
1999b). Vitronectin mRNA is increasingly expressed in glial cells as they progress 
from normal → low-grade → high-grade astrocytoma and vitronectin binding 
integrins were detected throughout these tumours (Gladson et al., 1995). Human myeloma 
cell lines expressed fibronectin mRNA and fibronectin secretion was detectable by 
ELISA (van, I et al., 1994). 7/10 of these myeloma lines showed subsequent adherence to 
this fibronectin via α4β1 integrins raising the possibility of an autocrine loop 
mediating increasing chemoresistance. 
 




In this process intracellular biochemical pathways controlling cellular proliferation 
and apoptosis are modulated by integrin-mediated signals. Several intracellular 
signalling proteins are known to associate with the cytoplasmic domain of integrins. 
The most well characterised include FAK (Schaller, 2001), integrin-linked kinase (ILK) 
(Wu et al., 2001a) and integrin-associated protein (IAP) (Juliano, 2002) though increasing 
information is accruing on integrin cytoplasmic domain-associated protein-1 (ICAP-
1), cytokesin-1, calcium and integrin-binding protein (CIB) and calreticulin (Coppolino et 
al., 2000). These integrin-binding proteins then signal to second-messengers that include 
protein kinases, e.g. protein kinase B (Nicholson et al., 2002), protein kinase C, 
phosphoinositide-3-kinase (Jones et al., 2000), mitogen activated protein kinase (Coppolino et 
al., 2000), mapk kinase/MEK, glycogen synthase kinase, Jun-N-terminal kinase and 
GDP/GTP binding proteins (e.g. Ras, Rho (Parise et al., 2000)) sometimes in association 
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with adaptor/docking proteins such as Cas (O'Neill et al., 2000), Grb2/7. These cascades 
result in control of crucial enzyme systems such as the caspase system, Bax/Bcl-2 
family of proteins and regulators of the cell cycle. Interestingly, until recently, 
unligated integrins were considered to be relatively inert and to contribute minimally 
to intracellular signalling. However, work by Stupack et al (Stupack et al., 2001) 
necessitates further consideration of this premise. They show, using carcinoma cells 
in a 3-dimensional matrix model, that unligated αvβ3 integrins actively recruit 
caspase-8 to the membrane and activate apoptosis in a death receptor/FADD 
independent manner. 
It is postulated that ECM-binding to integrins results in upregulation of survival and 
downregulation of apoptotic pathways to prevent chemotherapy-induced apoptosis. 
To date very few studies have addressed the challenging task of identifying which of 
the above effectors are the key mediators in ECM-mediated drug-resistance. 
However, initial steps have been made. 
 
Apoptotic second-messenger systems 
There is an enormous literature describing intermediate effectors of apoptosis from 
cell surface to nucleus. Very few of these have addressed the specific pathways 
involved in ECM-dependent MDR. In small cell lung cancer ECM inhibits 
etoposide-induced caspase-3 cleavage and apoptosis (Sethi et al., 1999b),(Rintoul et al., 2002). 
This mechanism was protein tyrosine kinase-dependent as shown by reversal by 
tyrphostin, a tyrosine kinase inhibitor. In breast cancer (Aoudjit et al., 2001) integrin-
mediated protection from paclitaxel/vincristine was shown to be a result of inhibition 
of mitochondrial cytochrome-c release (a key activator of the caspase system) in a 
 101
mechanism dependent upon PI3K activation of Protein Kinase B. Interestingly the 
inhibition of PI3K in an in vitro pancreatic cancer cell line (Ng et al., 2000) and an in vivo 
(athymic mouse xenogeneic transplant) ovarian cancer model (Hu et al., 2002) resulted in 




The Bax/Bcl-2 system is central to cell fate decision-making. Bax family members 
are pro-apoptotic acting via the mitochondrial caspase-activating pathway whilst Bcl-
2 family members are anti-apoptotic (Inoue et al., 2001). The ratio of these competing 
moieties determines the cell's fate (Appendix: Fig 6). Indirect evidence supports the 
role of Bax/Bcl-2 proteins in ECM-mediated MDR. In Chinese hamster ovary cells 
(Zhang et al., 1995) adhesion to fibronectin via the α5β1 (but not αvβ1) integrin prevents 
cells from undergoing apoptosis on serum starvation. This requires the cytoplasmic 
domain of the α5β1 integrin and was dependent on tyrosine phosphorylation of Focal 
Adhesion Kinase (FAK). Anti-β1 integrin antibodies and anti-sense oligonucleotides 
enhanced apoptosis as measured by nuclear condensation and nucleosomal laddering. 
In an in vitro melanoma cell line BclX(L) upregulation was shown to induce cis-
platinum chemoresistance and antisense oligonucleotide treatment was shown to 
reverse this effect (Heere-Ress et al., 2002). Studies in B lymphoma cells have shown that in 
a model mimicking conditions in a germinal centre activation of α4β1 integrins 
resulted in elevated levels of BclX(L) gene transcription and protein levels in a 
NFκB-dependent manner. This resulted in etoposide resistance and ligand binding to 
α4β1 diminished conformational changes in Bax proteins to prevent etoposide-
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induced disruption of constitutive Bax/Bcl-2 binding (Taylor et al., 2000). Similarly, 
fludarabine resistance in B-cell chronic lymphocytic leukaemia was associated with 
α4β1 integrin-induced upregulation of BclX(L) (de la Fuente et al., 2002). Ligation of αvβ3 
integrin in endothelial cells results in intracellular signals that leads to increased 
expression of Bcl-2 with a coordinate reduction in the levels of Bax. This 
stoichiometric change consequently increases the Bcl-2/Bax ratio thereby tipping the 
intracellular balance in favour of cell survival through the inhibition of apoptosis 
(Brooks et al., 1994). The αvβ3 integrin, as well as αvβ5, the other receptor for vitronectin, 
is also expressed on the surface of malignant glioma cells in vivo (Gladson et al., 1995). 
Ligation of either vitronectin receptor is associated with enhanced survival of 
glioblastoma cells. Moreover the enhanced survival conferred by these two 
vitronectin receptors translates into the phenotype of chemoresistance, a feature that 
typifies high-grade gliomas. Activation of vitronectin receptors in glioma cells is 
associated with increased expression of the anti-apoptotic proteins Bcl-2 and 
BclX(L). As levels of the pro-apoptotic protein Bax did not change, the net effect was 
to promote survival by apoptotic inhibition (Uhm et al.,1999). However, in an in vitro 
myeloma model (Damiano et al., 1999), although a doxorubicin/melphalan-resistant subline 
was shown to express increased α4β1 receptors that rendered them chemoresistant 
when adhered to fibronectin, this drug resistance was not mediated via Bax/Bcl-2 
changes suggesting cell-type specificity for this phenomenon. 
 
Cell cycle effectors 
The cell cycle is regulated by cascades of cyclins/cyclin-dependent kinases (CDKs) 
and cyclin-dependent kinase inhibitors (CDKIs) that respectively promote and inhibit 
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the cell cycle. Manipulation of cell cycle activity represents another mechanism by 
which the ECM-mediated chemoprotective effect could be explained. For example, it 
may be hypothesised that promotion of the cell cycle through arrest points may avert 
DNA-damage checkpoint analysis and thereby prevent DNA damage-recognition 
and apoptotic decision-making. Integrin signalling has been shown to have multiple 
effects on the cell cycle: Integrin-mediated cyclin D1 upregulation, CDKI (p21cip1 
and p27kip1) downregulation and hyperphosphorylation of the retinoblastoma protein 
results in progression of the cycle from G1 into S phase (Zhu et al., 1996). This 
mechanism is intimately linked to the activity of intracellular biochemical cascades 
and growth factor signalling. Most studies identify a positive influence from ECM on 
the cell cycle though there are reports of cell-type-specific cell cycle inhibition for 
αvβ8 (Cambier et al., 2000) and α2β1 (Coppolino et al., 2000). The evidence regarding cell-cycle 
effects in the setting of ECM chemoresistance is scarce and contradictory. In 
adriamycin-resistant MCF-7 breast cancer cells α5β1 binding to fibronectin 
promotes G1-S progression and prevents them from undergoing serum deprivation-
induced apoptosis (Nista et al., 1997). However, upon adherence to fibronectin, myeloma 
cells develop drug-resistance but concomitantly undergo G1 cell cycle arrest 
associated with increased p27kip1 levels and inhibition of cyclin A/E kinase activity 
(Hazlehurst et al., 2000). 
 
This laboratory has previously shown that adhesion of small cell lung cancer (SCLC) 
cells to extracellular matrix (ECM) via β1-integrins (α2β1, α3β1, α6β1 and αvβ1 – 
see Appendix: Table 6) protects against chemotherapy-induced apoptosis (Sethi et al., 
1999b) and this novel mechanism of drug resistance has been shown to exhibit a broad 
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cell type and chemotherapeutic agent specificity (Elliott et al., 2002). However, the 
intracellular signalling responsible for this cell survival is poorly understood. 
Although small cell lung cancer primary site and metastatic tumours consist of 
closely packed cells, they are surrounded by an extensive stroma rich in ECM 
proteins and high levels of extracellular matrix expression around cells correlate with 
poorer patient prognosis (Sethi et al., 1999b),(Rintoul et al., 2001),(Rintoul et al., 2002). 
In this body of work I initially confirmed reproducibility of the previous model used 
in SCLC in this laboratory for assessing ECM-mediated chemoprotection. 
Subsequently, experiments were performed to assess the hypotheses: 
 
a “ECM mediates survival signalling in SCLC via β1-integrin-dependent 
modulation of DNA damage and repair”. 
b “ECM mediates β1-integrin-dependent survival signalling in SCLC by 
overriding cell cycle checkpoints and thus evades programmed cell death”. 
 
4.2 Extracellular matrix protects small cell lung cancer against 
etoposide and radiation-induced apoptosis 
Experiments described here sought to reproduce previous results demonstrating 
matrix-mediated chemoprotection and further, since radiotherapy plays a central role 
in the clinical management of SCLC, to show that ECM-mediated antiapoptosis also 

















Figure 4.1 A Fibronectin and laminin protect against etoposide-induced apoptosis in SCLC 
cells. H345 SCLC cells were quiesced overnight and seeded into 96 well plates pre-coated with poly-l-
lysine (10μg/ml), laminin (10 μg/ml) or fibronectin (20 μg/ml) and treated with or without etoposide 
(25μg/ml). The percentage of apoptotic cells was determined after 48 hours by flow cytometric 
assessment of AnnexinV binding. Results are presented as absolute % increase in apoptosis 
compared with non-treated cells (mean ± s.e. of n=4 experiments). Data analysis: matched 1-way 
ANOVA with Bonferroni post-test. B Laminin protects against radiation-induced apoptosis in 
SCLC cells. H345 SCLC cells were quiesced overnight and seeded into 96 well plates pre-coated with 
poly-l-lysine (10μg/ml) or laminin (10μg/ml) and treated with or without megavoltage radiotherapy (0-
16Gy). The percentage of apoptotic cells was determined by morphological assessment of acridine 
orange/ethidium bromide-stained cells. Results are presented as absolute % increase in apoptosis 
compared with non-treated cells (mean ± s.e. of n=5 experiments). Data analysis: matched 1-way 
ANOVA with Bonferroni selected post-test. C Extracellular matrix does not modulate SCLC growth 
rates. 0.5x104 H345 cells were plated into 24-well plates coated with poly-l-lysine (10μg/ml) or laminin 
(10μg/ml) and following disaggregation, cell numbers were counted at times indicated using a 
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Results: After 48 hours of plating on poly-l-lysine, etoposide induced an increase in 
apoptosis in H345 cells measured by AnnexinV staining of 70.3 ± 7.6% (s.e.). This 
was significantly reduced by plating cells on laminin (8.5 ± 10.6%; p<0.01) and 
fibronectin (12.4 ± 6.8%, p<0.01) (Fig 4.1A). This protective effect was first seen at 
36 hours and persisted to 72 hours and was confirmed by a) acridine orange/ethidium 
bromide staining assessment and b) a cell death detection ELISA kit which is based 
on the quantitative detection of histone-associated DNA fragments (Hodkinson et al., 2006). 
This effect was not due to a direct physical interaction between etoposide and ECM, 
since etoposide-treated cell culture media incubated in wells plated with ECM for 48 
hours was still able to induce apoptosis when transferred onto SCLC cells adhered to 
poly-l-lysine (data not shown (Hodkinson et al., 2006)). 
Laminin (and fibronectin, data not shown) also protected H345 cells (and H69 cells, 
data not shown) against radiation-induced apoptosis (Fig 4.1B). This was statistically 
significant up to a dose of 8Gray (Gy) but was non-significant at higher radiation 
dose levels. Since radiation induces apoptosis via direct DNA damage this further 
supports the assumption that laminin-mediated protection against etoposide is not 
due to a direct physical interaction or reduction of entry of etoposide into SCLC 
cells.  
Cells grown on laminin (and fibronectin, data not shown) proliferated at the same 
rate as cells grown on poly-l-lysine (Fig 4.1C) confirming that differences in 




4.3 Extracellular matrix-mediated protection is β1-integrin-
dependent 
Previous experiments in this laboratory have shown that the β1-integrin is highly 
expressed in SCLC cells (Sethi et al., 1999b). To test the hypothesis that ECM-mediated 
protection against etoposide-induced apoptosis in SCLC is due to β1-integrin-
mediated signalling, experiments were performed using function-blocking β1-
integrin antibodies (4B4) and function-activating antibodies (TS2/16). 
  









Figure 4.2 A Laminin protects against etoposide-induced apoptosis in a β1-integrin-dependent 
manner in SCLC cells. H345 SCLC cells were quiesced overnight, preincubated with or without 
function blocking β1-integrin antibody (10μg/ml 4B4) for ½ hour and seeded into 96 well plates pre-
coated with poly-l-lysine (10μg/ml), laminin (10 μg/ml). or function-activating antibody (10μg/ml TS2/16). 
They were treated with or without etoposide (25μg/ml) and the percentage of apoptotic cells was 
determined after 48 hours by morphological assessment of acridine orange/ethidium bromide-stained 
cells (A) and a cell death ELISA kit based on the quantitative detection of histone-associated DNA 
fragments (mean ± s.e. of n=4 experiments) (B). Results are presented as % increase in apoptosis 
compared with non-treated cells on poly-l-lysine (mean ± s.e. of n=6 experiments). Data analysis: 



















































































































Results: When H345 (and H69, data not shown) SCLC cells were plated on poly-l-
lysine, etoposide induced an increase in morphologically assessed apoptosis of 46.44 
± 4.3% (s.e.). This was significantly reduced to 5.73 ± 4.4% (p<0.001) by adhesion 
to laminin (Fig 4.2A). However, although treatment of H345 SCLC cells with 
function-blocking β1-integrin antibody 4B4 did not induce a significant increase in 
apoptosis (PLL-4B4), it did abrogate laminin-mediated etoposide protection 
(p<0.001). 4B4-isotype antibody (anti-IgG1) did not produce this effect (data not 
shown). TS2/16, a function-activating β1-integrin antibody replicated the laminin-
mediated protection against etoposide-induced apoptosis, further supporting the 
evidence that extracellular matrix protects against apoptosis via a β1-integrin-
mediated mechanism. These results were confirmed in similar experiments where the 
technique of assessment of apoptosis was a cell death ELISA kit based on the 













4.4 Extracellular matrix-mediated protection is Protein Tyrosine 
Kinase and Phospho-Inositol-3-Kinase-dependent 













Figure 4.3 Etoposide-induced apoptosis in SCLC is reversed by laminin in a PI3Kinase and 
tyrosine kinase-dependent manner. Quiesced H345 cells were seeded into 96-well plates pre-coated 
with poly-l-lysine (10μg/ml) or laminin (10μg/ml) and treated with (+) or without (-) etoposide (25μg/ml), 
Ly294002 (30μM), Tyrphostin-25 (25mM) or z-VAD (100μM) as indicated. Apoptosis was measured 
after 48 hours using A morphological assessment of acridine orange/ethidium bromide stained cells 
and (mean ± s.e. of n=6 experiments shown). B Caspase-3 activity assay (as described in materials 
and methods), results normalised to untreated cells on poly-l-lysine (mean ± s.e. of n=6 experiments 
shown). Data analysis: matched 1-way ANOVA with Bonferroni selected post-test. C Quiesced H345 
cells were seeded into six-well plates precoated with poly-l-lysine (10mg/ml) or laminin (10 mg/ml) and 
treated with (+) or without (-) etoposide (25 mg/ml) or Ly294002 (30mM) as indicated. After 24hrs the 
cells were lysed and the expression of phospho-Bad (p-Bad), Bad, cleaved caspase-9 (p10) and 









































































































Results: Using morphological assessment (Fig 4.3A), laminin protected against 
etoposide-induced apoptosis. Treatment of H345 cells (and H69, data not shown) 
with the PI3Kinase inhibitor, Ly294002 alone (and wortmannin, data not shown) did 
not induce a significant increase in apoptosis but it did completely inhibit laminin-
mediated etoposide protection (p<0.001). This effect of PI3Kinase blockade was 
confirmed using an ELISA assessment of apoptosis based on the quantitative 
detection of histone-associated DNA fragments in mono- and oligonucleosomes (Fig 
4.3B). In addition, treatment of H345 cells (and H69, data not shown) with a broad 
spectrum tyrosine kinase inhibitor, Tyrphostin-25, alone did not induce a significant 
increase in apoptosis but did completely abrogate laminin-mediated protection 
against etoposide-induced apoptosis.  
PKB is a downstream target of PI3Kinase which phosphorylates proapoptotic factors 
such as caspase-9 and Bad resulting in inhibition of programmed cell death (Diehl et al., 
1998),(Buss et al., 2004). Adhesion of H345 SCLC cells to laminin increased 
phosphorylation of Bad (without modulating total Bad levels) and reduced etoposide-
induced cleavage of caspase-9 (Fig 4.3C). These effects were inhibited by treatment 
with the PI3Kinase inhibitor Ly294002. Caspase-9 activation results in cleavage of 
the ‘effector’ caspase-3, which stimulates apoptosis. Etoposide induced caspase-3 
cleavage in H345 cells adhered to poly-l-lysine, but this cleavage was abrogated in 
cells adhered to laminin. Furthermore, Ly294002 did not affect caspase-3 cleavage in 
cells adhered to poly-l-lysine but did inhibit laminin-mediated blockade of caspase-3 
cleavage. Coinvestigators in this laboratory confirmed this result by direct assay of 
caspase-3 activity (Hodkinson et al., 2006). 
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These data confirm that extracellular matrix-mediated protection against etoposide-
induced apoptosis is mediated via a β1-integrin-dependent pathway that signals via 
second messenger systems involving tyrosine kinase and PI3Kinase signalling. 
Furthermore, PI3Kinase signalling is implicated in ECM-mediated resistance to 
etoposide-induced apoptosis in SCLC cells via phosphorylation of Bad and 
modulation of caspase activity. 
 
4.5 Adhesion of SCLC cells to ECM proteins does not modulate 
initial levels of DNA damage or subsequent DNA repair 
Etoposide and x-rays induce apoptosis via the initial production of double-strand 
DNA breaks (Vincent, 1995),(Mathieu et al., 1999),(Verheij et al., 2000). Cells identify these sites of 
DNA damage, undergo cell cycle arrest at checkpoints and either repair the DNA 
breaks or undergo apoptosis (Jackson, 2001). I hypothesised that ECM binding to β1-
integrin cell surface receptors results in a) decreased levels of initial DNA damage or 
b) upregulation of DNA repair to reduce the number of cells instructed to undergo 
programmed cell death. 
To determine the amount of DNA damage induced by etoposide and radiation the 
number of DNA double-strand breaks in cell nuclei were determined by 
immunofluorescence staining of phosphorylated H2Ax (γH2Ax). The foci of γH2Ax 
represent individual DNA double-strand breaks and have been shown to correlate 
closely with apoptosis in response to DNA damage (Olive, 2004). Double-strand breaks 
were further confirmed by Western blotting for γH2Ax and DNA-dependent protein 
kinase catalytic subunit (DNA-PKcs), another enzyme involved in double-strand 
break repair. 
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Figure 4.4 A Quiesced H345 cells were adhered to poly-l-lysine (10μg/ml) or laminin (10μg/ml) and 
treated with or without 6MV X-rays (2Gy) or 2 hours of etoposide (25μg/ml).  Cells were washed twice 
and the media replaced with complete media containing 10% FCS. Cells were fixed 0-24 hours later, 
stained with anti-γH2Ax antibody and foci viewed by fluorescence microscopy. Representative images 
of γH2Ax foci from n=4 experiments. B The intensity of γH2Ax staining in 10 high-power fields was 
quantified with Openlab image analysis software and normalised to untreated cells (mean relative 
γH2Ax foci ± s.e. of n=3 experiments). C Concomitantly, parallel experiments in 6cm plates were 
submitted to western blot analysis for γH2Ax and DNAPKCS. A representative blot from n=4 etoposide-
treated plates is shown. 
 
Results: In H345 cells, treatment with radiation and etoposide induced a marked 
increase in γH2Ax foci (Fig 4.4A+B) which was detectable 2 hours after etoposide 
treatment and immediately after radiotherapy (data not shown). Over the next 24 
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performed. Adherence to laminin (and fibronectin, data not shown) did not reduce 
the initial number of γH2Ax foci induced or the rate of double-strand break repair. It 
is notable that at 24 hours there were still a significant number of γH2Ax foci, 
suggesting persistence of unrepaired DNA damage. Western blot analysis for γH2Ax 
and DNA-PKcs (Fig 4.4C) demonstrated a parallel increase in expression of 
phosphorylated H2Ax and DNA-PKcs following etoposide exposure and subsequent 
reduction with time. Thus, extracellular matrix protection against etoposide and 
radiotherapy is not due to a reduction in initial DNA damage (and thus does not 
influence drug entry into small cell lung cancer cells) or subsequent modulation of 
DNA repair. 
 
4.6 ECM proteins override etoposide and radiation-induced G2/M 
arrest via β1-integrin and PI3Kinase-dependent modulation of 
cell cycle regulatory proteins 
When cells are exposed to DNA damage they characteristically undergo cell cycle 
arrest at either the G1/S or G2/M checkpoints (Kastan et al., 2004),(Guadagno et al., 1993),(Fang et al., 
1996),(Massague, 2004). This enables cells to repair damaged DNA or initiate programmed 
cell death to prevent the production of daughter cells with damaged DNA. 
Modulation of cell cycle checkpoints could therefore provide a mechanism for 
modifying a cell’s response to chemotherapeutic or radiation insult.  
It has previously been shown that protein ligand binding (e.g. Growth Factors) to cell 
surface receptors can regulate cell cycle progression via modulation of cyclins, 
cyclin dependent kinases and cyclin dependent kinase inhibitors (Musgrove, 2006),(Danen et 
al., 2001). It was hypothesised that integrins induce comparable changes in cell cycle 
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signalling in small cell lung cancer to promote cell cycling and override G1/S and 
G2/M cell cycle checkpoints. By driving cells with DNA damage through these 
checkpoints, cells with treatment-induced DNA damage may circumvent apoptosis 







































Figure 4.5 ECM proteins override etoposide- and radiation-induced G2/M arrest via β1-integrin 
and PI3Kinase-dependent modulation of cell cycle regulatory proteins. A H345 cells were 
quiesced overnight, washed twice and seeded into 6 well tissue culture plates uncoated (plastic) or 
pre-coated with poly-l-lysine (10μg/ml) or laminin (10μg/ml). Cells were treated as indicated: no further 
treatment (-), etoposide (25 μg/ml) or ionising radiation (2 Gy) (XRT). Progression through the cell cycle 
was assessed 24 hours later by flow cytometric analysis of DNA content using CELL Quest software. 
Representative histograms are shown from n=5 independent experiments (table of actual percentage 
of cells in G1/S/G2-M phases of cell cycle included in Appendix: Table 7). B Quiesced H345 SCLC 
cells were seeded into 6 well tissue culture plates pre-coated with poly-l-lysine (10 μg/ml) or laminin 
(10μg/ml) and treated with etoposide (25 μg/ml). In addition cells were treated as indicated: blockade of 
β1 integrin function with 4B4 (10 μg/ml), inhibition of PI3Kinase with Ly294002 (30μM), activation of 
tyrosine kinase with sodium orthovanadate (Na3VO4) (200μM) or stimulation of β1 integrins with TS2/16 
(10 μg/ml). Progression through the cell cycle was assessed 24 hours later by flow cytometric analysis 
of DNA content using CELL Quest software. Representative histograms are shown from n=4 
independent experiments (table of actual percentage of cells in G1/S/G2-M phases of cell cycle 
included in Appendix: Table 8). C H345 SCLC cells were seeded into 6 well plates pre-coated with 
poly-l-lysine (10 μg/m l) (PLL), laminin (10 μg/ml) or TS2/16 (10 μg/ml). Cells were treated with (+) or 
without (-) etoposide (25 μg/ml), Ly294002 (30μM) or sodium orthovanadate (Na3VO4) (200μM) as 
indicated. Cells were lysed after 24 hours and the expression of p21Cip1/WAF1, p27Kip1, phosphorylated 
CDK1 (p-CDK1), phosphorylated CDK2 (p-CDK2) and cyclins D, E, A and B were determined by 

























































Results:  H345 cells demonstrated similar cell cycle profiles when grown in 
suspension or plated on poly-l-lysine or plastic. When treated with etoposide 
(25μg/ml) or radiotherapy (2Gy), cells plated on poly-l-lysine (or plastic – data not 
shown) underwent a significant change in DNA content profile. 24 hours after 
treatment with etoposide and radiotherapy 46.2 ± 1.5% (s.e.) and 47.8 ± 2.1% of 
cells respectively were in the G2/M phase of the cell cycle (with a reciprocal 
reduction in  the percentage of cells in G1) compared with 8.8 ± 1.0% of untreated 
cells. However, when plated on laminin only 16.8 ± 2.0% (etoposide) and 16.1 ± 
1.9% (XRT) of cells were arrested in the G2/M phase. Similar results were observed 
when plated on fibronectin (results not shown) (Fig 4.5A). Inhibition of β1-integrin 
signalling with 4B4 completely inhibited laminin-mediated protection from G2/M 
cell cycle arrest induced by etoposide in H345 SCLC cells without affecting cell 
cycle arrest in cells adhered to poly-l-lysine (Fig 4.5B). Also, laminin-mediated 
protection from etoposide-induced G2/M cell cycle arrest was blocked by the 
PI3Kinase inhibitor Ly294002. Stimulation of β1-integrins on H345 SCLC cells with 
TS2/16 or activation of tyrosine kinases with sodium orthovanadate (Na3VO4) 
reduced etoposide-induced G2/M cell cycle arrest and  replicated the effects of ECM. 
These results indicate that protection of SCLC cells from etoposide-induced cell 
cycle arrest by ECM proteins is mediated via β1-integrin activation of PI3Kinase and 
tyrosine-kinase signalling. 
After 24 h of etoposide treatment, H345 SCLC cells demonstrated a reduction in 
expression of cyclins E, A and B (Fig 4.5C). In parallel, the CDK inhibitors 
p21Cip1/WAF1 and p27Kip1 exhibited increased expression. Phosphorylated CDK1 
(inactive form) was increased  and expression of phosphorylated CDK2 (active form) 
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decreased. Adhesion of H345 SCLC cells to laminin both increased cyclin D 
expression and inhibited the etoposide-induced modulation of  cyclins E, A and B, 
phosphorylated CDK1 and 2, p21Cip1/WAF1 and p27Kip1. The effects of ECM 
were reproduced by function-activating TS2/16 antibodies. These laminin and 
TS2/16-mediated effects on etoposide-induced changes in cell cycle regulators was 
blocked by the PI3Kinase inhibitor Ly294002. These results indicate that ECM 
proteins can override etoposide-induced G2/M cell arrest via β1-integrins by 




4.7.1 Extracellular matrix protects small cell lung cancer against 
etoposide and radiation-induced apoptosis. 
Lung cancer in the most common cause of death from malignancy in the developed 
world (Parkin et al., 2005). The small cell variety constitutes 25% of all lung cancers and 
has poor prognosis with 2-year survivals less than 5% in many series. Surgery plays 
no significant role in SCLC therapy and radiotherapy/chemotherapy are the mainstay 
of treatment. Although response rates of up to 80% are seen with initial etoposide-
based chemotherapy, local and metastatic disease relapse characteristically develops 
several months later and this recurrent disease is frequently resistant to subsequent 
chemotherapeutic agents. This phenomenon is known as acquired multidrug 
resistance (MDR) and represents the major barrier to successful cure in the majority 
of cancer patients who present with overt or occult metastatic disease. Classical 
mechanisms of MDR such as overexpression of the multi-drug resistance gene 
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MDR1 are not implicated in SCLC MDR (Lai et al., 1989). New therapeutic targets are 
urgently needed and a comprehensive understanding of the mechanisms of MDR will 
be required to enable the development of new anticancer agents based on plausible 
biological hypotheses. 
This laboratory has previously demonstrated that SCLC is surrounded by a stroma 
rich in extracellular matrix proteins; laminin, fibronectin and collagen. SCLC cells 
bind to these proteins in a β1-integrin-dependent manner and this ECM-integrin 
interaction stimulates second messenger pathways that promote cell survival and 
protection against etoposide-induced cell death (Sethi et al., 1999b). No previous data 
informs on the mechanisms involved in MDR in SCLC and the experiments 
presented here provide novel insights into SCLC biology and therapeutic resistance. 
In vitro experiments using H345 and H69 SCLC cells plated into 96-well plates 
precoated with poly-l-lysine, laminin and fibronectin showed that ECM proteins 
protected SCLC cells against etoposide (Fig 4.1A) and radiation-induced (Fig 4.1B) 
apoptosis. Since morphological assessments of apoptosis can be subject to bias, 
results were confirmed by blinding and apoptosis was also measured by non-
morphological techniques including Annexin V staining and an ELISA kit based on 
the quantitative detection of histone-associated DNA fragments. Etoposide and 
radiotherapy are the two most important therapeutic tools in SCLC treatment and this 
finding may have great significance in the mechanisms underlying treatment 
resistance. A possible explanation for ECM-mediated protection against apoptosis in 
vitro is a direct interaction of etoposide with ECM proteins (i.e. sequestration of 
active drug in the extracellular media). However two lines of evidence refute this: 1) 
etoposide-treated cell culture media incubated in wells plated with ECM for 48 hours 
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was able to induce apoptosis when transferred onto SCLC cells adhered to poly-l-
lysine (data not shown (Hodkinson et al., 2006)) and 2) this criticism would not explain 
protection against radiation where the genetic insult occurs directly. Another possible 
mechanism by which ECM could modulate sensitivity to DNA-damaging agents is 
via modulation of proliferative rate; evidence shows that rapidly proliferating cells 
are more sensitive to DNA-damaging agents and thus an integrin-mediated reduction 
in proliferation would be expected to be protective against apoptotic insult. However, 
cells grown on laminin (and fibronectin, data not shown) proliferated at the same rate 
as cells grown on poly-l-lysine (Fig 4.1C) confirming that differences in apoptosis 
were not due to altered rates of proliferation, but to altered rates of apoptosis. 
 
4.7.2 Extracellular matrix-mediated protection is β1-integrin-
dependent 
The dominant integrin expressed in H345 and H69 SCLC cell lines is β1-integrin 
(see Appendix: Table 8). Here, function-blocking β1-integrin antibodies (4B4), but 
not isotype antibodies, completely abrogated laminin and fibronectin’s ability to 
prevent etoposide-induced apoptosis (Fig 4.2) and furthermore function-activating 
β1-integrin antibodies (TS2/16) replicated the ECM-mediated protective effect (Fig 
4.2). Taken together this provides these results indicate that ECM proteins prevent 





4.7.3 Extracellular matrix-mediated protection is Protein Tyrosine 
Kinase and Phospho-Inositol-3-Kinase-dependent 
It has previously shown that integrin-dependent adhesion induces an increase in 
tyrosine phosphorylation and PI3Kinase activation (Downward, 2004),(Kang et al., 
2005). Activated PI3Kinase phosphorylates inositol lipids, resulting in the activation 
of downstream serine/threonine kinase PKB that can phosphorylate caspase-9 and 
BAD to promote cell survival (Downward, 2004). PI3Kinase has also been shown to 
sustain ECM-mediated survival in epithelial cells (Khwaja et al., 1997) and so the effect of 
blockade of tyrosine kinase pathways with a broad-spectrum inhibitor (Tyrphostin-
25) and the PI3Kinase pathway with Ly294002 was investigated. Acridine 
orange/ethidium bromide morphological assessment confirmed that laminin protects 
against of etoposide-induced apoptosis (Fig 4.3A). However, whilst Ly294002 alone 
caused only a minimal increase in apoptosis in SCLC cells at 48 hours, it completely 
abrogated laminin-mediated protection. This data was confirmed by a caspase-3 
activity assay (Fig 4.3B). It is well established that Ly294002 inhibits other enzymes 
of the PI3Kinase family (e.g. DNA-PKcs ATM, ATR, and mTOR) at the 
concentrations used in these experiments (Okayasu et al., 2003) and more recently direct 
Ly294002-mediated inhibition of voltage-gated potassium channels has been 
demonstrated (El Kholy et al., 2003). However, another PI3Kinase inhibitor, wortmannin, is 
much more selective (IC50 of 0.003, 3.6, 5.8 and 100μM for PI3K, DNA-PKcs ATM 
and ATR respectively (Sak et al., 2002)) and this also inhibited ECM-mediated protection 
against etoposide-induced apoptosis at a dose of 0.1μM (data not shown). 
Furthermore, additional experiments (see below) demonstrating modulation of 
downstream effectors of PI3Kinase, most notably the inhibition of ECM-mediated 
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protection by Dominant-Negative PKB (Hodkinson et al., 2006) provide further 
substantiation for the role of PI3Kinase in this process. 
 
In this experiment, Tyrphostin-25, a broad spectrum tyrosine kinase inhibitor was 
also shown to abrogate laminin-mediated protection against etoposide-induced 
apoptosis implicating tyrosine kinases in the chemoprotective pathway. Similar 
results were obtained in H69 and H510 SCLC cells and results were also replicated 
by flow cytometric annexin V staining (Hodkinson et al., 2006). z-valine-alanine-aspartate 
(z-VAD), a potent, broad spectrum, irreversible inhibitor of caspases was used as a 
negative control and effectively inhibited etoposide-induced apoptosis in these 
experiments. 
A downstream effector of PI3Kinase, the serine-threonine kinase PKB, has been 
shown previously to phosphorylate proapoptotic effectors including caspase-9 and 
Bad and this phosphorylation prevents apoptosis (Diehl, 1998),(Buss et al., 2004),(Troussard et al., 
1999). During the apoptotic process a cascade of caspase cleavage events occurs: 
Caspases exist as latent precursors (procaspases) composed of heterotetramers of p10 
and p20 subunits. Upstream caspases 2, 8, 9, and 10 are activated in an amplifying 
cleavage cascade resulting in activation of downstream “executioner” caspases 6, 7 
and 3 which initiate destruction of key cellular substrates and degradation of DNA 
(Friedlander, 2003). Using western blot analysis it was shown that in H345 cells, etoposide 
induced an expected increase in cleaved caspase-9 and cleaved caspase-3 (cleavage 
indicates apoptosis) when plated on poly-l-lysine (Fig 4.3C). However, these 
cleavages were inhibited by adhesion to laminin. This laminin-mediated anti-
apoptotic effect was shown to be PI3Kinase dependent by virtue of its abrogation by 
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Ly294002. The Bcl-2 family of proteins consist of pro-apoptotic members (e.g. Bax, 
Bad, Bid) and anti-apoptotic members (e.g. Bcl-2, Bclx(L)) which exist in an 
equilibrium. The anti-apoptotic members maintain mitochondrial integrity to prevent 
cytochrome “c” release (Yang et al., 1997) and also inhibit the association of Apaf-1 with 
caspase-9 (Hu et al., 1998) to inhibit the initiation of apoptosis, whilst pro-apoptotic 
members do the reverse. Phosphorylation of Bad results in inability to heterodimerise 
with Bcl-2 members and sequestration in the cytoplasm shifting the Bcl equilibrium 
to a the anti-apoptotic state (Hayakawa et al., 2000). Here, laminin adhesion of H345 SCLC 
cells resulted in anti-apoptotic phosphorylation of Bad. Again, this effect was shown 
to be PI3Kinase dependent by inhibition with Ly294002. These results indicate that 
ECM mediates Bad phosphorylation and inhibition of caspase cleavage via 
PI3Kinase and tyrosine kinases resulting in protection against etoposide-induced 
apoptosis. 
[Further work performed in this laboratory by Dr P.Hodkinson has subsequently 
confirmed a direct laminin-mediated upregulation of PI3Kinase activity and 
downstream upregulation of PKB phosphorylation in SCLC cells in vitro, further 
supporting this data (Hodkinson et al., 2006)]. 
 
4.7.4 Adhesion of SCLC cells to ECM proteins does not modulate 
initial levels of DNA damage or subsequent DNA repair 
A previously raised concern regarding the model of SCLC cells plated on ECM is 
that of direct sequestration of etoposide by matrix proteins resulting in lower 
intracellular doses of drug. In order to test whether the anti-apoptotic effects of ECM 
were due to this or to ECM-mediated alterations in DNA-damage repair, double-
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strand break formation and repair was assessed directly by a) the detection of 
immunofluorescence stained foci of phosphorylated γH2Ax and b) western blotting 
for γH2Ax and DNA-repair enzymes such as DNA-protein kinase. H2Ax is a histone 
that is rapidly phosphorylated at Ser139 to form γH2Ax following DNA double-strand 
break formation. Within minutes of DNA damage, discrete foci of γH2Ax are formed 
and each focus of γH2Ax represents a single double-strand break. The number of  
γH2Ax foci correlate closely with cell death in response to DNA damage (Olive, 2004). 
The role of γH2Ax foci is to recruit double-strand break repair enzymes (such as 
BRCA1, DNA-PKcs) to form repair complexes and γH2Ax is removed from the 
complexes after repair following dephosphorylation by protein phosphatase 2A 
(PP2A) (Chowdhury et al., 2005). In eukaryotes double-strand breaks are repaired by two 
distinct pathways (for detailed reviews see Valerie and Povirk (Valerie et al., 2003) and 
Lisby and Rothstein (Lisby et al., 2004)); non-homologous end-joining (NHEJ) and 
homologous recombination (HR). NHEJ is error-prone and involves simple ligation 
of cut ends using the ku70/80 heterodimer, DNA-PKcs (DNA protein kinase 
catalytic subunit), the Artemis nuclease and LigaseIV/XRCC4 ligase. HR uses the 
homologous sister chromatid as a template for recovery of genetic information and is 
thus error-free though does result in loss of heterozygosity. HR uses replication 
protein A (RP-A), Rad52 group (Rad 51, 52 and 54) and the Mre11/Rad50/Nbs1 
complex (Lisby et al., 2004). Mammalian cells utilise both pathways though for HR to 
occur a sister chromatid needs to be present and thus is not possible prior to S phase 
(Houtgraaf et al., 2006). 
In the experiments shown in Fig 4.4, etoposide and radiation both induced multiple 
γH2Ax foci almost immediately after exposure (Fig 4.4A+B). There was no 
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difference in the number of initial double-strand breaks or the rate of double-strand 
break repair over the next 24 hours between poly-l-lysine and laminin-plated cells. 
Similarly, western blotting for DNA-PKcs and γH2Ax in nuclear extracts of 
radiotherapy-treated cells showed no differences when plated on poly-l-lysine or 
laminin (Fig 4.4C). The mechanisms by which DNA-PKcs are upregulated in 
response to double-strand breaks has not been fully elucidated but an increase in 
expression levels has previously been described (Shintani et al., 2003) (in view of the 
inability to demonstrate differences in double-strand break repair kinetics, formal 
assessment of DNA-PKcs enzymatic activity was not performed). Thus, extracellular 
matrix protection against etoposide and radiotherapy treatment  is not due to a 
reduction in initial DNA damage (and thus does not influence drug entry into small 
cell lung cancer cells) or subsequent modulation of DNA repair. This supports 
previous data from this laboratory showing no difference in etoposide-induced DNA 
double-strand breaks when measured by ATP-dependent decatenation of high 
molecular weight DNA (Hodkinson et al., 2006). 
 
4.7.5 ECM proteins override etoposide and radiation-induced G2/M 
arrest via β1-integrin and PI3Kinase-dependent modulation of 
cell cycle regulatory proteins 
In eukaryotic cells, the cell cycle consists of four phases; gap1 (G1), synthesis (S), 
gap2 (G2) and mitosis (M). In G1, the cell increases in size and increases 
transcription and translation of many genes. In S phase, DNA is replicated. During 
G2 the cell grows and produces extra proteins in preparation for division in the M 
phase. When cells are exposed to DNA damage they characteristically undergo cell 
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cycle delay or arrest at cell type-specific checkpoints (Lisby et al., 2004),(Valerie et al., 
2003),(Yoshida et al., 2004),(Samuel et al., 2002). The three major sites for checkpoint inhibition of 
the cell cycle are G1/S, inter-S-phase and G2/M. In all cases DNA damage sensor 
proteins transduce signals to effector proteins which result in cell cycle arrest. 
Sensors include the Rad50/Mre11/Nbs1 (which are also critically involved in DNA 
repair), Rad9/Hus1/Rad1 (proliferating cell nuclear antigen (PCNA)-like) and 
Rad17/RFC (replication factor C) protein complexes. These complexes enlist and 
phosphorylate transducers such as ATM and ATR, two PI3Kinase-like kinases 
closely related to DNA-PKcs. ATM is critically involved in repair of radiation-
induced double-strand breaks downstream of Rad50/Mre11/Nbs1. ATR is more 
important in the response to UV damage and replication inhibitors such as 
hydroxyurea. ATM and ATR phosphorylate intermediate signalling proteins such as 
BRCA1, p53 binding protein (53BP) and mediator of DNA-damage checkpoint 
(MDC1) which signal to effector proteins such as Chk1 and Chk2. These are 
serine/threonine kinases which modulate key cell cycle proteins such as Cdc25A,B 
and C. For example, in the G1/S phase, non-phosphorylated Cdc25A promotes G1/S 
transition by dephosphorylation of CDK2. Phosphorylation of Cdc25A by Chk1 or 
Chk2 causes inactivation and ubiquitin-mediated degradation resulting in G1 arrest. 
Furthermore, ATM and ATR also phosphorylate p53 which inhibits CDK2 via p21 
causing G1/S cell cycle arrest. A similar ATM/ATR-Chk1/2-Cdc25A-CDK2 
pathway exists in the intra-S-phase and G2/M checkpoint. In addition, in the G2/M 
checkpoint Chk1 and Chk2 phosphorylate WEE1 to inactivate the Cdc2/CyclinB 
complex. Since Cdc2/CyclinB promotes the G2/M transition, this results in arrest in 
G2. Interestingly although the G1/S checkpoint is dependent upon intact p53, G2/M 
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arrest occurs despite p53 knockout suggesting a p53-independent mechanism (Lisby et 
al., 2004). 
The paradigm of a soluble protein ligand binding to a cell surface receptor to regulate 
cell cycle progression has been well described for many growth factors. There is also 
an abundance of literature describing integrin-mediated alterations in cell cycle 
signalling: Most non-transformed cells need growth factor stimulation, integrin-
mediated adhesion to ECM and cytoskeletal integrity for cell cycle progression (Walker 
et al., 2005). Cell-cell adhesion normally provides a stimulus to inhibit proliferation and 
dysfunction of this association results in loss of contact inhibition which contributes 
to tumorigenesis. Growth factors (GFs) alone are usually insufficient for the 
stimulation of cellular proliferation and concomitant binding to and signalling from 
integrin-mediated adhesion is needed. Loss of adhesion in non-transformed cells 
usually results in complete G1 phase cell cycle arrest and apoptosis (Giancotti et al., 1999). 
Dysregulation of this relationship results in anchorage-independent cell growth, an 
important step in cell transformation to a malignant phenotype. Mitogenic lipids and 
inflammatory cytokines provide further influencing controls in the biological 
management of the cell cycle (Schwartz et al., 2001a) and it is clear that complex 
interactions between multiple signalling pathways converge to define cell cycle 
activity. G1 phase regulation involves cyclins D and E), CDKs (2 and 4) and the 
CDKIs (p21cip1 and p27kip1). Integrins induce cyclinD1 which binds to and activates 
CDK4/6. Integrins also downregulate p21cip1 and p27kip1 blocking CDKI-mediated 
inhibition of cyclinE-CDK2 and cyclinA-CDK2 complexes (Roovers et al., 2000). Thus, 
activated CDK4/6 and CDK2 lead to phosphorylation of the Rb protein and the cell 
progresses through  the G1 phase to the S phase. 
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When considering integrin-mediated effects on the cell cycle, transiently plating cells 
on ECM proteins has been considered analogous to acute stimulation of starved cells 
with Growth Factors (Schwartz et al., 2001b) and transiently stimulates many pathways 
including Rac, cdc42, tyrosine kinases and downstream effectors Src and Shc, Ras, 
JNK and PI3K (Giancotti and Ruoslahti, 1999). This transient stimulation is usually not 
sufficient to drive cells into S phase entry and more prolonged adhesion throughout 
the G1 phase is required (Bohmer et al., 1996). Prolonged adherence stimulates tyrosine 
phosphorylation of p130Cas and paxillin and PIP5-kinase activity (Schwartz et al., 1995) 
though there has been minimal direct evidence supporting links between many of 
these second messengers and cell cycle control. Integrins potentiate growth factor 
signalling at multiple levels to influence cell cycle progression; they can increase the 
density of surface growth factor receptors (GFRs) by reducing ubiquitin-dependent 
degradation (Baron et al., 2000) and directly associate with Growth Factors to increase 
Growth Factor-mediated signalling (Jones et al., 1997). In fact, Moro et al (Moro et al., 1998) 
showed that the EGFR intrinsic kinase activity is increased by association with β1-
integrin even in the absence of EGF stimulation. Additionally integrins can modulate 
second messengers downstream of Growth Factor signalling e.g. integrin binding to 
fibronectin results in decreased association of Ras-GAP to PDGFR leading to 
increased Ras and Erk activation (DeMali et al., 1999). Growth factor stimulation of the Rac 
pathway is also dependent on integrin-mediated regulation of Rac subcellular 
localisation (del Pozo et al., 2000). EGF-mediated PI3Kinase and PKB activation (Khwaja et al., 
1997), PDGF-mediated activation of PKC (McNamee et al., 1993) and growth factor activation 
of JNK signalling (Short et al., 1998) are all reduced in cells deprived of integrin-mediated 
signalling by detachment. ILK and two associated proteins PINCH and ILKBP 
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localise to sites of integrin adhesion to ECM (Guo et al., 2002) and inhibition of this 
interaction prevents progression into the S phase of the cell cycle. The most well 
studied area is integrin-mediated regulation of the G1 phase and G1/S checkpoint: 
Bill et al (Bill et al., 2004) demonstrated that integrin-dependent activation of EGFR 
results in upregulation of cyclinD1, Rb phosphorylation and activation of CDK4 . 
Integrins do transiently activate erk1 and erk2 (Morino et al., 1995). However, induction of 
cyclinD1 mRNA, which drives cells through the G1/S checkpoint, occurs as a result 
of sustained erk1/2 activation (Weber et al., 1997). It is the combination of sustained erk 
activation and adhesion-mediated signalling which drives the upregulation of 
cyclinD1 (Zhu et al., 1996) and G1 progression. Several potential mechanisms may 
explain this adhesion dependence: erk transport from cytoplasm to nucleus has been 
shown to require adhesion (Danilkovitch et al., 2000) and integrins may influence 
downstream events by alterations in the subcellular localisation of other proteins.  A 
downstream effector of integrins, PI3Kinase potentiates cyclinD1 stability (Gille et al., 
1999) since downstream PKB phosphorylates Glycogen synthase kinase3β (GSK3β) 
and this results in stabilization of  cyclinD1 (Kang et al., 2005),(Su et al., 2002),(Phillips-Mason et al., 
2000). In endothelial cells integrin-mediated Rac-signalling is required for 
upregulation of cyclinD1 translation (Mettouchi et al., 2001). FAK is another important 
downstream effector of integrin in outside-in signalling and there appear to be FAK-
dependent and FAK-independent pathways regulating erk potentiation and cyclinD1 
activation: Integrin-mediated FAK signalling has been shown to be essential for 
sustained erk activation, enhanced cyclin D1 expression and progression of the cell 
cycle from G1 to S phase (Zhao et al., 2001),(Buss et al., 2004). FAK has been also shown to 
interact with growth regulatory pathways involving JNK (Oktay et al., 1999),(Lebrun et al., 2000) 
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and produces enhancement of GF signalling via Ras, Raf, MEK and Erk (Renshaw et al., 
1999). However, a FAK-independent mechanism involving caveolin and Fyn has also 
been demonstrated (Wary et al., 1998). FAK has also been shown to influence levels of p27 
(a CDKI) by altering degradation by ubiquitination (Bond et al., 2004). The actin 
cytoskeleton and cell shape also appear to play important roles in regulation of 
cyclinD1 and the G1/S checkpoint (Walker et al., 2005); cytoskeletal tension provided by 
cell adhesion is required for G1-S phase progression providing one explanation for 
cell cycle arrest in many cells in suspension. As well as effects on cyclinD1, 
integrins have been shown to be involved in the downregulation of CDKIs (p21/p27) 
in late G1, coincident with activation of cyclinE-CDK2 (Roovers and Assoian, 2000). 
I hypothesised that integrins induce changes in cell cycle signalling in small cell lung 
cancer to promote cell cycling and override G1/S and G2/M cell cycle checkpoints. 
By driving cells with DNA damage through these checkpoints, cells with treatment-
induced DNA damage may circumvent apoptosis and go on to survive with 
additional DNA damage. 
In these experiments, quiesced H345 cells were adhered to 96-well plates uncoated 
or coated with poly-l-lysine, laminin (or fibronectin; data not shown). After treatment 
with or without etoposide (25μg/ml) or radiotherapy (2Gy) cell cycle profile was 
assessed by flow cytometric analysis of propidium iodide staining (whole cell and 
nuclear preparations were performed with similar results). When treated with 
etoposide or XRT, H345 cells adhered to poly-l-lysine showed a significant increase 
in the proportion of cells in the S and G2/M phases of the cell cycle (Fig 4.5A). This 
S phase and G2/M delay is characteristic of the effect of etoposide in other small cell 
lung cancer lines (Soues et al., 2001) and is predictable with the knowledge that etoposide 
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is a phase-dependent cytotoxic that acts during late S and early G2/M phase by 
stabilising the topoisomerase “cleaved complex” to produce a double-strand break. 
Similarly, XRT has well-documented effects on the cell cycle; G2 arrest is seen in 
almost all cell lines whilst G1 arrest and S phase delay are more variable (Choudhury et al., 
2006),(Maity et al., 1994). However, when H345 cells were plated on laminin and treated 
with etoposide or XRT there was only a small increase in the percentage of cells in S 
and G2/M. Furthermore, this etoposide-induced over-riding of etoposide/XRT-
induced S phase delay and G2/M arrest is abrogated by concomitant treatment with 
4B4 (function blocking β1-integrin antibody) and the PI3Kinase inhibitor Ly294002 
and is replicated by function activating β1-integrin antibody implying that ECM-
mediated protection from S phase delay and G2/M arrest is mediated by β1-integrin 
signalling via PI3Kinase (Fig 4.5B). Also sodium orthovanadate, a broad spectrum 
tyrosine phosphatase mimicked the effects of ECM indicating that this effect of ECM 
also involves tyrosine kinase activation. 
Assessment of expression of cyclins (D, A, E and B), CDKs (1 and 2) and CDKIs 
(p21 and p27) by western blotting provided further insights into the mechanism of 
action of ECM signalling in cell cycle modulation in SCLC cells (Fig 4.5C). After 
24 hours of etoposide treatment, H345 SCLC cells demonstrated a reduction in 
expression of cyclins E, A and B (Fig 4.5C). In parallel, the CDK inhibitors 
p21Cip1/WAF1 and p27Kip1 exhibited increased expression Phosphorylated CDK1 
(inactive form) was increased  and expression of phosphorylated CDK2 (active form) 
decreased. These results are consistent with the flow cytometric experiments 
described above where etoposide-induced increases in the S phase and G2/M 
fractions were identified. Plating H345 SCLC cells on laminin both increased cyclin 
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D expression and inhibited the etoposide-induced modulation of  cyclins, CDKs and 
CDKIs, again consistent with the over-riding of etoposide-induced cell cycle 
delay/arrest identified in the flow cytometry experiments. These effects of ECM on 
cell cycle modulators were reproduced by function-activating TS2/16 antibodies, and 
the laminin and TS2/16-mediated effects on etoposide-induced changes in cell cycle 
regulators were abrogated by the PI3Kinase inhibitor Ly294002. Thus, ECM proteins 
override etoposide-induced S phase delay and G2/M cell arrest via β1-integrins by 
modulating expression of cyclins, CDKs and CDKIs in a PI3Kinase dependent 
manner. 
[Activated PKB has been shown to regulate cellular proliferation by interaction with 
cell cycle regulators governing G1/S and G2/M checkpoints (Phillips-Mason et al., 2000) 
PI3Kinase has also previously been shown to induce expression of D-type cyclins in 
part by increasing the stability of cyclin-D1 through PKB-dependent phosphorylation 
of GSK3β (Diehl et al., 1998). Subsequent experiments performed in this laboratory have 
confirmed that the ECM → β1-integrin → PI3K → Cell Cycle modulation pathway 
in SCLC cells described here also involves PKB and GSK3β (an upstream regulator 
of cyclinD1). Constitutively active and Dominant-Negative PKB mutants were able 
to respectively replicate and inhibit  ECM-mediated protection against apoptosis and 
ECM-mediated over-riding of cell cycle arrest (Hodkinson et al., 2006)]. 
 
4.8 Summary 
These results show for the first time that ECM proteins activate β1-integrins to 
protect SCLC cells against the apoptotic effects of etoposide and ionizing radiation 
via PI3Kinase activation. This occurs in two ways: 1) PI3Kinase-dependent β1-
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integrin signalling resulting in phosphorylation of Bad and reduced caspase-9 
cleavage and 2) a β1-integrin-mediated over-riding of etoposide and radiotherapy-
induced cell cycle S phase delay and G2/M arrest. 
In concert these two processes promote cancer cell survival and proliferation. This 
may lead to the survival of clones with increased treatment-related DNA aberrations 
that could contribute to a multidrug-resistant phenotype. ECM-mediated resistance to 
pro-apoptotic DNA damaging agents has been shown to exist across a broad 
spectrum of cancers (see introduction) and this data describes an example of cell 
type-specific mechanisms by which this process occurs. Only by identifying the 
cancer-specific intracellular pathways responsible for treatment failure can we hope 















The Role of β1 Integrins and Protein Tyrosine  
Kinases in vivo in the Modulation of  
Extracellular Matrix-mediated Survival  
Signalling in Small Cell Lung Cancer. 
 
5.1  Introduction 
Earlier data presented in this thesis showed in SCLC cells that, in vitro, resistance 
against DNA-damaging agents is mediated via β1-integrin cell surface adhesion 
molecules (Sethi et al, 1999b),(Hodkinson et al, 2006). ECM binding to β1-integrin activates a 
second messenger pathway involving protein tyrosine kinases, PI3Kinase, PKB and 
GSK-3β. This pathway inhibits cell cycle arrest by downregulating cell cycle-
dependent kinase inhibitors p21Cip1/WAF1 and p27Kip1, reducing phosphorylation 
of CDK1 and maintaining expression of cyclins D/E/A/B and phosphorylation of 
CDK2. Concomitantly ECM, via PI3Kinase, results in phosphorylation of Bad and 
reduced caspase-9 cleavage preventing apoptosis. This in vitro data provided the 
impetus to strive towards identifying active in vivo biochemical inhibitors of this 
pathway to ultimately proceed to assessment in clinical Phase I/II trials. Initial 
experiments were devised to identify the presence of a similar, β1-integrin and 
protein tyrosine kinase-dependent survival signalling pathway in vivo. Small cell 
lung cancer xenografts were implanted into the flanks of nude mice and the effects of 
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a) β1-integrin blockade with function inhibiting antibody (4B4) and b) Tyrosine 
kinase inhibition, were investigated. The broad spectrum tyrosine kinase inhibitor 
genistein was chosen for investigation in vivo because: a) Previous dosing 
experiments in nu/nu nude mice were available in the literature obviating the need 
for dose finding experiments (Wietrzyk et al., 2000), b) It has been shown to have activity in 
human cancers in vitro; melanoma (Tamura et al., 2003),(Record et al., 1997), hepatoma (Chang et al., 
2004), NSCLC (Wei et al., 2001), breast (Shao et al., 1998), prostate (Hillman et al., 2001) and in vivo; 
melanoma (Tamura et al., 2003), breast (Shao et al., 1998), bladder (Zhou et al., 1998), c) It is a 
naturally occurring, orally bioavailable soy bean extract that is well tolerated (in 
humans) and there is some in vitro and animal model evidence that genistein 
prevents cancer initiation, inhibits cancer progression (Arliss et al., 2002) and potentiates 
systemic therapy (Tamura., 2003),(Hillman et al., 2001),(El Rayes et al., 2006) d) Broad spectrum 
inhibitors may be superior to presently-available specific inhibitors in tumour growth 
inhibition either because multiple PTKs are implicated in carcinogenesis or the 
specific target/inhibitor combination is not achieved (Roussidis et al., 2002).  In addition, 
genistein may also inhibit Multidrug Resistance (MDR) transporter pumps (Bogush et al., 
2003) and topoisomerase-II (Bandele et al., 2007) which, if present in vivo, would be 
expected to increase efficacy. 
Initial experiments aimed to demonstrate that in vivo, ECM ligands promote 
xenograft survival and growth per se in the absence of DNA-damaging agents. 
Matrigel was chosen for the initial experiments (shown above) since, a) it contains 
several extracellular matrix proteins that bind to β1-integrin (including laminin, 
collagen, entactin; see Appendix: Table 9) and produces ECM-mediated protection 
against apoptosis in vitro in an identical manner to laminin and fibronectin 
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experiments shown in chapter 4(Buttery et al, 2004) and b) it has previously been shown to 
support the growth of SCLC xenografts (Yoshida et al., 1997). 
Subsequently, it was planned to test whether ECM proteins protect against the 
apoptotic effects of etoposide or radiotherapy in vivo. It was anticipated that this data 
may proceed into phase I/II trials assessing the combination of genistein with 
chemotherapy or radiotherapy. 
The following hypotheses were initially tested: 
 
1 In vivo, MatrigelTM, a basement membrane preparation containing laminin, 
collagen, entactin and heparan sulphate proteoglycans promotes SCLC 
xenograft survival and growth. 
  
2 This protective effect is β1-integrin dependent and replicates the cell cycle 
effects seen in vitro. 
  
3 Tyrosine-kinase blockade with genistein inhibits ECM-mediated xenograft 
survival in vivo. 
 






5.2  In vivo, extracellular matrix promotes SCLC xenograft survival 
and growth 
In order to identify whether ECM sustains and promotes xenograft survival in vivo, 
200μl aliquots of H69 and H345 SCLC cells suspended in PBS or Matrigel (1:1 vol 
of cells:Matrigel/PBS) were implanted subcutaneously in contralateral flanks of 
Nude nu/nu:Balb(c) mice. Xenograft growth was assessed manually with callipers 
every 3-4 days. 
 






Figure 5.1  5x106 H345 (A) and H69 (B) SCLC cells suspended in PBS or Matrigel (1:1 vol of 
cells:Matrigel/PBS mixed at 40C, total volume 200μl) were implanted subcutaneously in contralateral 
flanks of Nude nu/nu:Balb(c) mice (10 mice per condition). Tumour size was assessed manually with 
calipers and volume calculated by: Volume = (Width2 x Length)/2. Mean ± s.e. shown. Statistical 
analysis: 2-way Anova. 
 
Results: H69 and H345 cells suspended in PBS did not result in measurable 
xenograft growth. When suspended in Matrigel both H69 and H345 implanted cells 
developed into measurable xenografts. H69 cells demonstrated significantly faster 
xenograft growth than H345 cells and for this reason were chosen to perform further 
experiments (Fig 5.1A+B). 
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5.3 Matrigel-mediated xenograft growth is β1-integrin dependent 
Earlier, in vitro data confirmed that extracellular matrix-mediated protection against 
apoptosis was mediated via β1-integrin-dependent alterations in the activity of 
apoptotic 2nd messengers and cell-cycle modulators (see Figs 4.2, 4.3 and 4.5). This 
series of experiments sought to identify whether a similar, β1-integrin-dependent 
mechanism exists in the in vivo setting. 
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Figure 5.2  5x106H69 SCLC cells in PBS or Matrigel (1:1 vol of cells:Matrigel mixed at 40C) were 
implanted subcutaneously in flanks of Nude (nu/nu:Balb(c)) mice with or without the β1-integrin 
blocking antibody 4B4 or IgG1 isotype antibody (20μg/ml in matrigel with cells added 1 hour pre-
implantation) (10 mice per condition).  A Tumour size was measured with calipers and volume 
calculated by Volume = (Width2xLength)/2. Mean ± s.e. shown. Statistical analysis: 2-way Anova. 
Xenograft lysates were protein balanced and submitted to western blot analysis for B cell cycle 





























































Results: H69 cell implants suspended in Matrigel with mouse IgG1 isotype antibody 
developed into measurable xenografts (Fig 5.2A). This rate of growth was not 
significantly different from xenografts grown with matrigel alone (data not shown). 
However, when H69 cells were implanted in matrigel treated with mouse anti-human 
β1-integrin antibody (4B4) xenograft growth was significantly reduced (p=0.0063).  
4B4 treatment did not completely inhibit xenograft growth but induced tumour 
growth delay followed by exponential growth, consistent with a 4B4-mediated 
reduction in the initial number of surviving clones. Continuing xenograft growth 
despite initial 4B4 treatment may be a result of insufficient sustained 4B4 dose or, 
more likely, the presence of additional survival pathways. This confirms that 
Matrigel-mediated xenograft growth is at least partially dependent upon β1-integrin. 
Western blot analysis of expression of proteins responsible for cell cycle control (Fig 
5.2B) showed no difference between matrigel alone, 4B4 or isotype-treated 
xenografts. A possible explanation for this is that the β1-integrin-dependence may be 
a phenomenon which occurs very early in the development of xenografts in this 
model; immediately after implantation cells either survive or die and at this time β1-
integrin signalling can inhibit apoptosis, thus defining the initial number of live cells 
capable of subsequently producing a measurable xenograft. In this way, it would not 
be unexpected for any subsequent xenograft to exhibit similar cell cycling protein 
expression. Similarly, by Western blot analysis, no differences were seen in levels of 
PKB or erk phosphorylation (kinases downstream of β1-integrin), again consistent 
with β1-integrin survival signalling being an early phenomenon. It was anticipated 
that Matrigel/Matrigel + IgG1-derived xenografts may be derived from sub-selected 
clone of cells with high β1-integrin expression and Matrigel + 4B4-derived from 
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clones with low β1-integrin expression. However, Western blot analysis did not 
confirm this (Fig 5.2C). 
In order to identify any morphological differences between untreated, 4B4-treated 
and IgG1-treated xenografts, haematoxylin and eosin (H+E) staining was performed 
on paraffin-embedded sections of xenografts harvested in the above experiments. In 
addition, immunohistochemical staining of Ki67 (proliferation), CD34 



























Figure 5.3 5x106H69 SCLC cells in PBS or Matrigel (1:1 vol of cells:Matrigel mixed at 40C) were 
implanted subcutaneously in flanks of Nude (nu/nu:Balb(c)) mice with or without the β1-integrin 
blocking antibody 4B4 or IgG1 isotype antibody (20μg/ml in matrigel with cells added 1 hour pre-
implantation) (10 mice per condition).  Xenografts were harvested after 41 days and paraffin-embedded 
sections submitted to H+E staining and immunohistochemical staining for Ki67, CD34 and CD56. 
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Results: No difference in the morphological H+E appearance of xenografts was seen 
(Fig 5.3). Sustained neuroendocrine differentiation of xenograft cells was 
demonstrated with high levels of CD56 staining in all sections viewed. No difference 
was observed between treatment conditions. As anticipated in SCLC, high levels of 
Ki67 staining indicating proliferation was observed. No difference was observed 
between treatment conditions. A low level of CD34 staining was identified in all 
treatment conditions indicating minimal angiogenesis (positive controls not shown). 
In summary, no morphological or immunohistochemical differences were seen 
between untreated, 4B4-treated and IgG1-treated xenografts. Again, this is consistent 
with the effect of β1-integrin blockade by 4B4 antibody being an early peri-
implantation phenomenon. 
 
5.4  Genistein inhibits ECM-mediated xenograft survival in vivo only 
when delivered pre-implantation. 
Earlier experiments confirmed that protein tyrosine kinase inhibition with the broad-
spectrum tyrosine kinase inhibitor tyrphostin-25 reversed the anti-apoptotic effects of 
laminin (see Fig 4.3). For the reasons described above genistein was the inhibitor of 
choice for these in vivo experiments and therefore initial in vitro experiments sought 
to  confirm that genistein also abrogated extracellular matrix-mediated protection 













Figure 5.4 In vitro, genistein inhibits laminin-mediated protection against etoposide-induced 
apoptosis. Quiesced H345 cells were seeded into 96-well plates pre-coated with poly-l-lysine 
(10μg/ml) or laminin (10 μg/ml) and treated with (+) or without (-) etoposide (25μg/ml) or genistein 
(50μM)as indicated. Apoptosis was measured after 48 hours using a Caspase-3 activity assay (as 
described in materials and methods). Results normalised to untreated cells on poly-l-lysine. Mean ± 
s.e. of n=5 experiments in triplicate. Data analysis: matched 1-way ANOVA with Bonferroni selected 
post-test. 
 
Results: When SCLC cells were plated on poly-l-lysine, etoposide induced a 
significant increase in apoptosis of 59.3 ± 7.3% (s.e.). This was reduced to 7.4 ± 
5.7% (p<0.001) when plated on laminin. Treatment of H345 cells (and H69, data not 
shown) with the broad spectrum tyrosine kinase inhibitor, genistein, alone did not 
induce a significant increase in apoptosis but did completely abrogate laminin-
mediated protection against etoposide-induced apoptosis (p<0.001). This effect was 
confirmed using a Caspase-3 activity assay (Fig 5.4) and an ELISA-based assay 
based on the quantitative detection of histone-associated DNA fragments in mono- 
and oligonucleosomes (data not shown). 
In order to confirm that a similar, tyrosine kinase-dependent signalling mechanism is 





















































SCLC cells treated with or without the broad-spectrum tyrosine kinase inhibitor, 
genistein. Since the β1-integrin/4B4 experiments above suggested that Matrigel’s 
survival effect may occur at an early timepoint pre- or peri-implantation, genistein 
dosing was performed a) pre + post-implantation (pre = genistein 50μM with the 
Matrigel/cells at the time of implantation, post = by intraperitoneal injection 
50mg/kg/day from days 2-8) or b) post implantation only. Vehicle (10% DMSO in 
PBS) controls were also performed. 
 
A     B    C 
       Genistein pre +            Genistein post 








Figure 5.5  A 5x106H69 SCLC cells in Matrigel (1:1 vol of cells:Matrigel mixed at 40C) with or without 
genistein (50μM with implanted cells) or Vehicle (10% DMSO in PBS) were implanted subcutaneously 
in flanks of separate Nude (nu/nu:Balb(c)) mice (10 mice per condition). Mice subsequently received 
50mg/kg/day i.p. genistein or Vehicle in 200μl injections day2-8.  B 5x106H69 SCLC cells in Matrigel 
(1:1 vol of cells:Matrigel mixed at 40C) were implanted subcutaneously in flanks of separate Nude 
(nu/nu:Balb(c)) mice (10 mice per condition). Mice subsequently received 50mg/kg/day i.p. genistein or 
Vehicle in 200μl injections day2-8. Tumour size was assessed with callipers and volume calculated by 
Volume = (Width2 x Length)/2. Statistical analysis: 2-way ANOVA. C Western blot analysis of 
xenografts harvested at end of experiment A. Probed for global tyrosine phosphorylation, PKB/erk 
phosphorylation, Bax and Bcl-2 expression. 
 





































































































































Results: Xenografts implanted in Matrigel with vehicle (10% DMSO in PBS) grew at 
the same rate as cells implanted in Matrigel alone (data not shown) confirming that 
the DMSO vehicle is not significantly toxic to SCLC xenografts at the dose used in 
these experiments. When genistein was delivered solely by intraperitoneal injection 
from days 2 to 8 after implantation (Fig 5.5B) there was no significant difference in 
xenograft growth. Genistein only inhibited xenograft growth when delivered pre-
implantation as well as on days 2 to 8 after implantation (Fig 5.5A), consistent with 
the earlier data suggesting that Matrigel-mediated xenograft survival is an early 
phenomenon. Western blot analysis of xenograft extracts harvested at the end of the 
experiment shown in Fig A demonstrated no difference in global tyrosine 
phosphorylation (Fig 5.5C). This is not unexpected since the final genistein dose was 
delivered 12 days prior to harvesting the xenografts. There was no difference in 
levels of PKB and erk phosphorylation or in expression of Bax (pro-apoptotic) or 
Bcl-2 (anti-apoptotic) proteins. These results are all consistent with genistein’s action 
representing an early, peri-implantation phenomenon. 
In order to identify any morphological differences between the vehicle-treated and 
genistein-treated xenografts, haematoxylin and eosin (H+E) staining was performed 
on paraffin-embedded sections of xenografts harvested after pre- and post-
implantation delivery of vehicle/genistein. In addition, immunohistochemical 
staining of Ki67 (proliferation), CD34 (angiogenesis) and CD56 (neuroendocrine 
differentiation marker) was performed. 
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Figure 5.6  5x106H69 SCLC cells in Matrigel (1:1 vol of cells:Matrigel mixed at 40C) with or without 
genistein (50μM with implanted cells) or Vehicle (10% DMSO in PBS) were implanted subcutaneously 
in flanks of separate Nude (nu/nu:Balb(c)) mice (10 mice per condition). Mice subsequently received 
50mg/kg/day i.p. genistein or Vehicle in 200μl injections day2-8. Xenografts were harvested after 20 
days and paraffin-embedded sections submitted to H+E staining and immunohistochemical staining for 
Ki67, CD34 and CD56. Representative sections of xenografts from n=4 mice shown. 
 
 
Results: No difference in the morphological H+E appearance of xenografts treated 
with genistein or vehicle was observed (Fig 5.6). Sustained neuroendocrine 
differentiation of xenograft cells was demonstrated with high levels of CD56 staining 
in all sections viewed. No difference was observed between treatment conditions. 
High levels of Ki67 staining indicating active proliferation was again demonstrated. 
No difference was observed between treatment conditions. A low level of CD34 
staining was identified in all treatment conditions indicating minimal angiogenesis 
(positive control not shown). In summary, no morphological or 
immunohistochemical differences were seen between genistein- and vehicle-treated 
xenografts. This is consistent with the effect of β1-integrin blockade by 4B4 
antibody being an early peri-implantation phenomenon. 
Genistein 
Genistein 
Genistein Vehicle Vehicle 
Vehicle Vehicle Genistein 
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5.5 Individual matrix proteins (fibronectin, laminin and collagen) do 
not replicate Matrigel-mediated growth 
In order to identify whether individual matrix proteins were able to support xenograft 
growth, H69 SCLC cells suspended in Matrigel and laminin, fibronectin or collagen 
were implanted subcutaneously in contralateral flanks of Nude mice. Xenograft 
growth was measured with calipers. 
 






Figure 5.7  5x106H69 SCLC cells in Matrigel (1:1 vol of cells:Matrigel mixed at 4oC) or (A) laminin 
(20μg/ml) or (B) fibronectin (40μg/ml) or (C) collagen (20μg/ml) were implanted subcutaneously in 
contralateral flanks of Nude (nu/nu:Balb(c)) mice (10 mice per condition). Tumour size was measured 
with calipers and volume calculated by Volume = (Width2xLength)/2. Mean ± s.e. shown. 
 
Results: H69 cells produced measurable xenograft growth in nude mice when 
implanted in Matrigel. However, the individual ECM proteins; laminin, collagen and 
fibronectin, did not support the growth of H69 xenografts (Figure 5.7). 
 
5.6 Discussion 
I hoped to demonstrate that the ECM-mediated, β1-integrin and PKB/PI3K-
dependent cell survival pathway identified in vitro also exists in vivo in order that 
pathway inhibitors could be tested in vivo with a view to human anticancer 
Matrigel vs Laminin


































































applications. This data does show that Matrigel, a basement membrane preparation 
containing extracellular matrix constituents laminin, collagen, entactin and heparan 
sulphate proteoglycans promotes the development of H69 and H345 SCLC 
xenografts in Nude nu/nu Balb/c mice (Fig 5.1). Tumour growth delay induced by 
function-blocking β1-integrin antibody (but not by IgG1 isotype antibody; Fig 5.2) 
supports the hypothesis that Matrigel-mediated survival signalling is, at least in part, 
β1-integrin-dependent. However, 4B4 treatment did not completely inhibit xenograft 
development. Furthermore, when xenografts were harvested at the end of the 
experiment Western blot and immunohistochemical analysis showed no difference in 
cell cycle modulator protein expression, PKB or erk phosphorylation, β1-integrin 
expression (Fig 5.2 B+C) or H+E, Ki67, CD34 or CD56 staining (Fig 5.3). This is 
consistent with the effect of 4B4 antibody taking place at an early timepoint in 
xenograft development. This may be an artefact of experimental design: in this in 
vivo experiment 4B4 was added exclusively with the cells at the time of xenograft 
implantation and any effect would therefore be likely to be short-lived due to time-
dependent dilution and degradation of antibody. β1-integrin-mediated survival 
signalling may be important in maintaining cell viability at the time of implantation. 
4B4 blockade of this signalling results in increased apoptosis and a reduction in the 
number of surviving cells capable of contributing to the developing xenograft. Thus, 
although 4B4-treated xenografts are initially lower in cell number, they go on to 
develop in an identical manner to untreated/IgG-treated xenografts. It is possible that 
β1-integrin-mediated survival signalling is also a more prolonged factor in xenograft 
development and further experiments utilising repeated dosing of 4B4 antibody 
would address this question. 
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In vitro, genistein replicated the earlier effects of tyrphostin-25 in abrogating 
extracellular matrix-mediated protection against apoptosis (Fig 5.4). In vivo the 
genistein experiments produced similar results to the 4B4 experiments. Broad 
spectrum tyrosine-kinase inhibition did inhibit xenograft development but only if 
delivered at the time of implantation admixed with the cells (Fig 5.5 A+B). When 
genistein was delivered exclusively from days 2 to 8 post-implantation no inhibition 
of xenograft growth was demonstrated. Possible explanations for this include 
insufficient dose or inadequate absorption of genistein into the structure of Matrigel 
implants when delivered via the intraperitoneal route. Western blot confirmation of 
reduced tyrosine phosphorylation of xenografts harvested during the period of 
genistein treatment would address this question though this may be complicated by 
sampling difficulties related to the small size of early implants. An alternative 
explanation is that broad spectrum tyrosine-kinase inhibition may only be an 
important factor in xenograft survival and growth at an early stage of development. 
i.e. analogous to the above explanation for β1-integrin inhibition. Inhibition by 
genistein may result in a reduced number of surviving cells which go on to form a 
smaller, though phenotypically identical, xenograft. Since the final genistein dose 
was delivered on day 8 and xenografts were not harvested until day 20 it is, perhaps, 
unsurprising that Western blot analysis of tyrosine phosphorylation and PKB/erk 
phosphorylation showed no differences between genistein and vehicle-treated 
xenografts (Fig 5.5C). Similarly this hypothesis would be expected to show no 
differences in Bax-Bcl2 levels or immunohistochemical staining for KI67, CD34 or 
CD56 (Fig 5.6). An alternative approach to the timescale of genistein’s effect may be 
to utilise SCLC cells that have been passaged a number of times in vivo. This seems 
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to increase the tumorigenic potential of the cells and may remove the dependence on 
initial matrigel-mediated survival signalling and thus enable assessment of more 
longterm matrigel-mediated effects. 
It appears that cessation of genistein dose at day 8 (Fig 5.5A) is followed several 
days later by exponential growth. Future experiments are intended to continue post-
implant genistein over longer time-courses to confirm long-term inhibition of 
xenograft growth. 
In vitro, individual matrix proteins (laminin, fibronectin and collagen) are capable of 
inducing ECM-mediated survival signalling with broad cell-type specificity. 
However, this was not replicated in vivo (Fig 5.7). Possible reasons for the failure of 
laminin, collagen and fibronectin to propagate xenograft growth in vivo include: i) 
Presence of and requirement for growth factors as an additional signal to survival in 
vivo. Although efforts have been made to eliminate growth factors from Matrigel, 
the Growth Factor-reduced Matrigel used in these studies does contain low levels of 
EGF, bFGF, NGF, PDGF, IGF-1, TGF-β (see Appendix: Table 10). It is possible 
that in the more demanding environs of the in vivo setting, dual (integrin and growth 
factor) signalling is required to sustain xenograft survival. Since xenograft growth 
was produced even in the presence of β1-integrin blockade by 4B4 antibody, GF 
signalling may be the dominant survival signal in vivo. ii) There is some evidence 
that the preservation of 3-dimensional structure produces additional survival 
signalling (Chen et al., 2006),(Campos et al., 2006),(Oloumi., 2000),(Desoize et al., 1998). Matrigel suspended 
cells maintain a formed 3-dimensional mass after implantation. This does not occur 
with the individual extracellular matrices where the implant appears to be absorbed 
and dispersed in the initial hours and days. Further experiments in which individual 
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matrix components are first suspended in agar could address this issue. iii) Nude 
nu/nu Balb/c mice are athymic and thus are lymphocyte-deplete but they do retain an 
innate immune system. It is possible that the solid 3-dimensional structure produced 
by Matrigel acts to prevent entry of innate immune system cells e.g. neutrophils and 
macrophages and thus promotes survival in another β1-integrin-independent 
mechanism. iv) Matrigel contains entactin (also known as nidogen-1), which is a 
150kDa multi-domain basement membrane glycoprotein that may be important in 
basement membrane organisation and assembly. Entactin may act as a  bridge 
between the extracellular matrix molecules laminin-1 and type IV collagen. Thus, in 
vivo it may be critical per se (possibly related to the 3-dimensional integrity of 
Matrigel implants) or may act to converge multiple ECM-mediated cell survival 
signals by approximating individual ECM proteins (Fox et al., 1991). v) It is possible that 
the individual soluble matrix proteins are degraded post implant or are rapidly  
dissipated. The agar experiments described above may clarify this issue by 
sequestration of the ECM proteins. 
 
In summary, this data demonstrates that Matrigel does induce survival pathways to 
promote the development of SCLC xenografts in Nude nu/nu Balb/c mice. It is likely 
that the mechanism of action of Matrigel is multifactorial. It appears that the β1-
integrin-dependent and protein tyrosine kinase-dependent elements of this 
mechanism act early in the development of xenografts, around the time of 
implantation, since no differences in kinase activity, cell cycling protein expression, 
differentiation or angiogenesis can be seen immunohistochemically or by Western 
blot analysis at later timepoints. However, this may be due to the fact that the β1-
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integrin function-blocking antibody (4B4) and genistein were applied several days 
before xenografts were harvested for analysis. Future experiments are planned to 
deliver multiple doses of antibody and to harvest xenograft tissue for 
immunohistochemical and Western blot analysis during the time of treatments to 
confirm ongoing activity at later timepoints. It is not clear why individual 
extracellular matrix proteins (laminin, collagen and fibronectin) did not replicate 
Matrigel in promoting xenograft survival and growth particularly since the earlier 
experiments above did confirm that Matrigel does induce a β1-integrin-dependent 
and protein tyrosine kinase-dependent survival signal. It suggests that, in vivo, 
additional factors are required for ECM-mediated survival signalling. These may 
relate to the presence of additional growth factor signalling in matrigel, the 
requirement for a 3-dimensional matrix, immune system effects, entactin and 
dilution/degradation of the individual, soluble extracellular matrix constituents. 
Future experiments will develop upon this data which demonstrates the presence of a 
β1-integrin-dependent and protein tyrosine kinase-dependent survival pathway in 
xenograft development. Initial experiments will aim to confirm that longer term 4B4 
and genistein inhibit xenograft growth. Subsequently, experiments assessing 
combinations of genistein and etoposide (and other chemotherapeutic agents used in 
SCLC) will be performed to identify whether in vivo synergy exists between these 
agents. Ultimately it is anticipated that combinations of chemotherapy and tyrosine 







Assessment of a GD25 Embryonic Murine Fibroblast 
Model to Investigate Extracellular Matrix-mediated 
Survival Signalling in vitro 
 
6.1 Introduction 
GD25 Null cells are embryonic murine fibroblasts which are stable deletion mutants 
that do not express β1-integrin at the cell membrane. GD25-β1 cells are GD25 Null 
cells stably transfected with mouse β1-integrin in association with a puromycin-
resistance gene. These cell lines have been previously described (Wennerberg et al., 1996). 
Using these cells in an in vitro model system I sought to investigate the identity of 
biochemical messengers involved in extracellular matrix-mediated chemoprotection. 
I hypothesised that GD25-β1 cells would exhibit β1-integrin-mediated outside-in 
survival signalling via adhesion to extracellular matrix proteins (fibronectin and 
laminin) whilst GD25 Null cells would not, due to the absence of β1-integrin 
expression. By confirming this β1-integrin-mediated resistance to chemotherapy-
induced apoptosis it was hoped that further experiments would identify some of the 
intracellular signalling pathways responsible for this process. Initial experiments 
sought to confirm appropriate β1-integrin expression profiles of GD25-β1/GD25 
Null cells and then to demonstrate the presence of extracellular matrix-mediated 
survival signalling in this model system. 
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6.2 GD25 Null and GD25 β1 cell lines: expression of mouse β1-
integrin 
To confirm that the GD25 β1 and GD25 Null cells used in these experiments 
respectively expressed high and absent levels of mouse β1-integrin at the cell 
surface, flow cytometric analysis of cells stained with 9EG7 rat anti-mouse β1-
integrin antibody and isotype antibody was performed (Fig 6.1). 
 
    Anti-IgG1isotype     Anti-β1 integrin  
    Ab + secondary     Ab (9EG7) + secondary 












Figure 6.1 Confirmation of β1-integrin expression profile of GD25 Null and GD25 β1 lines. Flow 
cytometric analysis of β1-integrin expression on the surface of GD25 Null and GD25 β1 cells. 5x105 
cells were trypsinised, washed twice with PBS, resuspended in 100μl PBS and incubated with 1μg of 
rat anti-mouse β1-integrin (9EG7) or rat anti-mouse IgG1 at room temperature for 1 hour. After two 
washes with PBS, cells were incubated with species-specific fluorescein isothiocyanate-conjugated 
secondary antibody (1:50) for 30 min at 4°C and again washed twice with PBS. Samples were finally 
resuspended in PBS at 4°C and analyzed by flow cytometry using FACSCaliburTM (BD Biosciences). 
Typical flow cytometric profiles are shown. 
 
Results: It was confirmed that the GD25 cell lines used for experiments exhibited 
appropriate cell surface expression of β1-integrin (Fig 6.1). This was repeated 











6.3 Fibronectin and laminin do not mediate protection against 
etoposide-induced apoptosis in GD25 cells plated in DMEM with 
10% FCS 
6.3.1 Etoposide-induced apoptosis in GD25 cells plated in serum-
containing media: time and dose response 
In order to identify an optimum etoposide dose and treatment time for demonstration 
of extracellular matrix-mediated survival signalling, GD25 cells were treated with 
etoposide 0-10μg/ml for 0-48 hours and apoptosis and necrosis were assessed by i) 
morphology using fluorescent microscopy of acridine orange and ethidium bromide-
treated cells and ii) flow cytometric analysis of cells labelled with Topro3 (necrosis) 
and AnnexinV-PE (apoptosis). GD25 cells did not tolerate prolonged periods of 
growth in serum-free media and so initial experiments were performed with cells in 




































Figure 6.2 Etoposide-induced Apoptosis: Time and Dose-Response in GD25 cells cultured in 
DMEM with 10% FCS. 2x104 GD25 cells were plated per well of 96 well plates and allowed to adhere 
for 6 hours in DMEM complete media followed by overnight quiescence in GD25 quiescent media. 
They were then treated with 0-10 μg/ml etoposide. The percentage of apoptotic and necrotic cells was 
assessed 12-48 hours later A morphologically by immunofluorescence microscopy after addition of 1μl 
of ethidium bromide (1 mg/ml) and 1μl of acridine orange (1mg/ml). Mean ± s.e. of n=4 experiments in 
triplicate shown. Apoptosis and necrosis was also assessed by flow cytometric analysis of AnnexinV 
and Topro3 staining: A typical example of flow cytometry data is shown in B. AnnexinV/Topro3 time 
and dose-response shown in C. Mean ± s.e. of n=4 experiments shown. 
 
Results: AnnexinV/Topro3 flow cytometry, an objective technique for measurement 
of apoptosis, was performed in addition to the acridine orange/ethidium bromide 
assessment to obviate any potential subjective bias in morphological assessments.  At 
equivalent time-points the morphological assessment (Fig 6.2A) and flow cytometry 
technique (Fig 6.2C) showed similar levels of cell death. A higher rate of necrosis 
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demonstrated at all dose levels and timepoints with the flow cytometry technique and 
this may represent a degree of trauma to the cells during resuspension resulting in 
Topro3 breach of damaged cell membranes. At all dose and timepoints GD25 Null 
cells demonstrated lower levels of etoposide-induced apoptosis and necrosis. Using 
this data 18 and 24 hour timepoints and etoposide doses of 2.5 and 5μg/ml were 



















6.3.2 Fibronectin and laminin do not mediate protection against 
etoposide-induced apoptosis in GD25 cells cultured in DMEM 






























Figure 6.3 Fibronectin and laminin did not mediate protection against etoposide-induced 
apoptosis in GD25 cells cultured in DMEM with 10% FCS. 96 well plates were pre-coated by 
incubation at 37oC for 1 hour with or without 10μg/ml laminin or 20μg/ml fibronectin. 2x104 GD25 cells 
were plated per well and allowed to adhere in GD25 complete media for 6 hours and quiesced 
overnight before treatment with etoposide 0-5μg/ml. The percentage of apoptotic and necrotic cells 
was assessed 0-48 hours later A morphologically by immunofluorescence microscopy after addition of 
1μl of ethidium bromide (1 mg/ml) and 1μl of acridine orange (1mg/ml). 18 and 24 hour timepoints 
shown, mean ± s.e. of n=4 experiments, and B by flow cytometric analysis of AnnexinV and Topro3 
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Results: Whether assessed morphologically (Fig 6.3A) or by flow cytometric 
analysis (Fig 6.3B), at 18 and 24hrs in both GD25 β1 and GD25 Null cells there was 
no statistically significant difference in apoptosis rates at either etoposide dose level 
(2.5 or 5μg/ml) when comparing plastic against fibronectin or laminin. i.e. 
fibronectin or laminin failed to protect GD25 cells against etoposide-induced 
apoptosis irrespective of the presence or absence of β1-integrin expression. 
Furthermore, GD25 β1 cells exhibited greater sensitivity to etoposide-induced 
apoptosis at all dose and time points than GD25 Null cells. A possible reason for the 
failure of ECM to produce chemoprotection in this model was the presence of 
multiple extracellular matrix components in GD25 complete media (containing foetal 
calf serum) that cells were cultured during the initial period of adhesion in these 
experiments. Foetal calf-containing media was used in these experiments since a) 
GD25 cells did not tolerate prolonged periods in quiescent media and b) adhesion did 
not occur in the presence of quiescent media. 
In view of the above results, dose-response and extracellular matrix-mediated 
survival signalling experiments were repeated using SITA, a serum-free medium 








6.4 Fibronectin and laminin do not mediate protection against 
etoposide-induced apoptosis in GD25 cells plated in SITA 
6.4.1  Etoposide-induced apoptosis in GD25 cells plated in SITA: time 
and dose response 
 







Figure 6.4 Etoposide-induced Apoptosis: Time and Dose-Response in GD25 cells cultured in 
SITA. 2x104 GD25 cells were plated per well of 96 well plates in SITA and allowed to adhere overnight 
before treatment with 0-20 μg/ml etoposide. The percentage of apoptotic and necrotic cells was 
assessed 24 hours later by flow cytometric analysis of AnnexinV and Topro3 staining. Time and dose-
response for GD25 β1 and GD25 Null cells are shown in A and B respectively. Mean ± s.e. of n=3 
experiments shown. 
 
Results: After 24 hours etoposide induced a dose-related increase in apoptosis and 
necrosis in GD25 cells (Fig 6.4). As previously demonstrated, GD25 β1 cells were 
more sensitive to etoposide-induced cell death than GD25 Null cells. Since the rate 
of etoposide-induced cell death in GD25 β1 cells was seen to plateau at 5μg/ml this 
dose was chosen for assessment of ECM-mediated chemoprotection. 
  
 





























































6.4.2 Fibronectin and laminin do not mediate protection against 
etoposide-induced apoptosis in GD25 cells plated in SITA 
 








Figure 6.5 Fibronectin and laminin did not mediate protection against etoposide-induced 
apoptosis in GD25 cells cultured in SITA. 96 well plates were pre-coated by incubation at 37oC for 1 
hour with or without 10μg/ml laminin or 20μg/ml fibronectin. 2x104 GD25 cells were plated per well and 
allowed to adhere in SITA overnight before treatment with or without etoposide 5μg/ml. The percentage 
of apoptotic and necrotic cells was assessed 24 hours later A morphologically by immunofluorescence 
microscopy after addition of 1μl of ethidium bromide (1 mg/ml) and 1μl of acridine orange (1mg/ml) and 
B by flow cytometric analysis of AnnexinV and Topro3 staining. Mean ± s.e. of n=4 experiments shown. 
 
Results: In serum-free media, laminin and fibronectin again failed to protect GD25 
cells against etoposide-induced apoptosis (Fig 6.5). 
 
6.5  GD25 β1 cells exhibit faster growth rates than GD25 Null cells 
It is well recognised that cytotoxic agents which target DNA and induce DNA 
double-strand breaks are more effective at inducing apoptosis in rapidly cycling cells 
than slower growing cells (Corvo et al., 2000),(Sharma et al., 2000),(Baguley et al., 1995). In clinical 
practice this is reflected in high initial response rates to chemotherapy in rapidly 
growing cancers such as lymphoma and small cell lung cancer. In order to 
investigate whether this could be a significant factor in the increased sensitivity of 
GD25 β1 - AnnexinV and Topro3 Assessment
of Etoposide-induced Apoptosis at 24hrs
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GD25 β1 cells to etoposide-induced apoptosis, growth curves of GD25 β1 and GD25 









Figure 6.6 GD25 β1 and GD25 Null growth curves on plastic and fibronectin. 10,000 cells were 
plated per 10cm plate, suspended in 15mls of GD25 complete media and incubated at 37oC for 0-15 
days. When counting, media was removed and the adherent cells were washed twice with filtered PBS. 
After resuspension in filtered PBS cells were counted using a Coulter counter. Mean ± s.e. of 4 
experiments shown. 
 
Results: GD25 β1 cells have a significantly faster rate of growth than GD25 Null 
cells (p<0.0001) (Fig 6.6). This is most marked at lower cell densities which is 
important since in the previous experiments (above) cells were initially plated at 105 
cells per ml of media (2x104 cells per 200μl of media) when this difference in growth 
rates is most marked. Cell confluence occurs at approximately 5x105 cells per cm2. 
The reason that at later timepoints GD25 Null cell numbers approach GD25 β1 cell 
numbers is that GD25 Null cells showed a much greater tendency to overgrow and 
carpet the plates whilst GD25  β1 cells appeared to demonstrate a reduction in 
growth rates at high cell densities possibly related to a greater degree of contact 
inhibition. Fibronectin did not significantly alter growth rates of GD25 Null or GD25 
β1 cells. 
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In view of these results it was evident that a comparison of etoposide sensitivity 
between the two cell types would not provide a useful model to assess extracellular 
matrix-mediated survival signalling and no further experiments were performed. 
 
6.6 Discussion 
GD25 β1 and GD25 Null cells offered an appealing model for assessing the 
mechanisms underlying extracellular matrix-mediated survival signalling. Many 
model systems investigating β1-integrin signalling employ function-blocking 
antibodies as negative control arms. Null cells, with a stable deletion of β1-integrin, 
provide an alternative negative control and obviate the problems of antibody 
delivery, isotype controlling and difficulties in performing longer time-course 
experiments with interval antibody dosing. Furthermore, additional stable cell lines 
expressing mutants of β1-integrin have been developed in GD25 cells and these 
provide further opportunities for investigating the β1-integrin-mediated signalling 
involved in extracellular matrix-mediated survival signalling (e.g. GD25β1AY783/795F 
cells have been shown to have a defect in β1-integrin-dependent FAK 
phosphorylation and activation (Wennerberg et al., 2000)). However, experimental 
assessment of this in vitro model system showed that it would not be useful as a tool 
to assess  β1-integrin-mediated protection against chemotherapy-induced apoptosis. 
There was no evidence of extracellular matrix-mediated drug resistance using 
fibronectin or laminin at any dose level or timepoint. This may be a result of a) cell 
type specificity; GD25 cells may not possess the requisite intracellular survival 
signalling pathways, b) insufficient dose of extracellular matrix; however, in some 
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experiments, laminin and fibronectin were used at doses up to 40 and 80μg/ml 
respectively (four times the dose quoted in other published model systems) without 
any evidence of chemoprotection (data not shown), c) over-riding of the effect of 
chemoprotection by culture media: it is possible that insulin (present in SITA) and 
foetal calf serum (in GD25 DMEM complete media) provide survival signalling to 
these cells via β1-integrin-independent pathways (e.g. via PI3Kinase (Gonzalez et al., 
2006),(Su et al., 2006),(Alexia et al., 2006)) and thus cells plated on plastic may already possess 
maximal anti-apoptotic signalling. It would have been preferable to plate GD25 cells 
onto ECM or plastic directly after overnight quiescence. However, cells plated in this 
way failed to adhere and experienced very high apoptotic rates after 24 hours, d) 
undefined survival signalling via other integrins expressed in GD25 cells (αvβ3, 
αvβ5, α6β4 (Retta et al., 2001)) though expected ligand specificity would not predict this. 
In summary, though scientifically appealing, GD25 cells in practice were shown not 
to be a useful tool for the investigation of extracellular matrix-mediated survival 
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Ce: Caenorhabditis elegans 
 


















































Figure 4  Sub-domains of Guanidine Exchange Factors  
RhoGEF PH RasGEF SH3




cNMP PDZ RA RasGEF


















GEF – Guanidine Exchange Factor.
PH - pleckstrin homology.
P - poly-proline-rich sequences, representing SH3 (Src homology 3) domain 
binding sites
Calm - calmodulin binding.
DAG - diacylglycerol binding.
DEP - domain found in Dishevelled (Dvl) proteins.
RA - Ras association.
PDZ - domain found in PSD95, Dlg, ZO1 proteins.
SH2 - Src homology 2 domain, phosphotyrosine binding.
X,Y - phospholipase catalytic domains.
C2 - calcium-dependent lipid binding domain.
cNMP – cyclic nucleotide-binding domain 
EF Hand – helix-turn-helix motif
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EGF - Epidermal Growth Factor
RAM - RBPJκ-associated molecule (binds csl proteins which bind cgtggggaa)
ANK - ankyrin repeats (mediate additional protein interractions and weak csl binding)
OPA - glutamine-rich sequence
PEST - proline, glutamate, serine, threonine-rich sequence
LNR - (Lin-12/Notch) Repeats
DSL - Delta, Serrate, Lag-2 conserved Notch-ligand sequence
NLS - Nuclear Localisation Sequence
TAD - Transactivation Domain
CSL - CBF1/RBPJκ, Su(H), Lag-1
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Bcl-w Bcl-2 Bcl-xL Bfl-1


































Subunit Laminin Fibronectin Collagen Other 
α 1 X  X  
α 2* X X X E-cadherin 
α 3* X X X Thrombospondin, entactin 
α 4  X  V-CAM1 
α 5  X  Fibrinogen, 
α 6* X    
α 7 X    
α 8  X  Tenascin 
α 9    Tenascin 
α 10   X  
α 11   X  
β1 
α V*  X  Vitronectin 
α L1    I-CAM (1-5), JAM-A 
α M2    I-CAM1,Fibrinogen, FactorX, C3bi 
α X    Fibrinogen, C3bi 
Β 2 
α D    V-CAM1 





thrombospondin Β 3 






Β 4 α 6 X    
Β 5 α V  X  Vitronectin 
Β 6 α V  X  Tenascin 
Β 7 α 4  X  V-CAM1 
Β 7 α E    E-cadherin 










Table 1 Integrin heterodimers and Ligands 
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Table 2 Inside-out modulators of integrin affinity 
 
Integrin modulator Integrin 
Ancient Ubiquitous Protein1 (Aup1) αIIb (Kato et al., 2002) 
β3-endonexin β3 (Kashiwagi et al., 1997) 
Ca2+ αIIbβ3 (Hyduk et al., 2007) 
Caspase 12 αIIbβ3 (Kerrigan et al., 2004) 
CD151/Tetraspanins α3β1 (Nishiuchi et al., 2005) 
CD73 αLβ2 (Airas, Niemela, and Jalkanen, 2000) 
CD98 heavy chain β-integrin (Fenczik, Sethi, Ramos, Hughes, and Ginsberg, 
1997),(Cai et al., 2005) 
Chemokines α4β1, αLβ2, αMβ2/Mac-1 (Johnston et al., 2002) 
Calcium and Integrin Binding Protein 
(CIB) 
αIIbβ3 (Tsuboi, 2002) 
Csk β1 (Li et al., 2002) 
Cytohesin 1+3 αLβ2/LFA-1 (Mazerolles et al., 2002) 
Epidermal Growth Factor α2β1 (Genersch et al., 1998) 
Ephrins β1 (Davy et al., 2000) 
FAK β1 (Schaller, 2001) 
FcRs α2β1 (Watson et al., 2000) 
14-3-3 αLβ2 (Nurmi et al., 2006) 
Grb2/SH3 β3, αLβ2/LFA-1 (Saci et al., 2002) 
Hras αIIbβ3, αLβ2/LFA-1 (Hughes et al., 1997),(Hughes et al., 
2002) 
HSP60 α3β1 (Barazi et al., 2002) 
Integrin Associated Protein/CD47 α2β1, αvβ3, αIIbβ3 (Chung et al., 1997) 
IC1n αIIbβ3 (Larkin et al., 2004) 
IGF1 α3β1, αVβ3 (Maile et al., 2002) 
ILK β1, β2+β3 (Pasquet et al., 2002) 
Integrins-transdominant inhibition αIIbβ3, α2β1 (Calderwood et al., 2004) 
Lck αLβ2/LFA-1, α4β1 (Feigelson et al., 2001) 
Lipid raft αLβ2/LFA-1 (Hogg et al., 2002) 
LPL/L-plastin αMβ2/Mac-1 (Wang et al., 2001) 
Mapk α5 and β1 (Hughes et al., 2002) 
Notch4 β1 (Leong et al., 2002) 
PEA 15 β1 (Ramos et al., 1998) 
Phosphorylation β-integrins (Hogervorst et al., 1993) 
PI3K αLβ2/LFA-1, α4β1, α5β1, αIIbβ3, αVβ3 (Cai et 
al., 2005) 
PKC αIIbβ3, αLβ2/LFA-1 (Hauss et al., 1993) 
PLC αIIbβ3, α2β1, α5β1, α6β1, αLβ2/LFA-1 (Hyduk 
et al., 2007) 
Post-translation α7β1, α2-6, αVβ3, β1 (Berthet et al., 2000) 
Rap β-integrin, αIIbβ3, αLβ2/LFA-1 (Bertoni et al., 2002) 
Redox potential β2, αIIbβ3 (Yan et al., 2000) 
Reducing agents α4β1, αIIbβ3 (Chigaev et al., 2004) 
Rras β1 (Keely et al., 1999) 
selectin αMβ2/Mac-1, αLβ2/LFA-1 (Giblin et al., 1997) 
Shc αIIbβ3 (Saci et al., 2002) 
Src αIIbβ3, α4β1 (Saci et al., 2002)  
Syk αIIbβ3, α4β1 (Woodside et al., 2002) 
Talin β1, αIIbβ3 (Calderwood et al., 1999) 
Thrombopoietin αIIbβ3 (Van Os et al., 2003) 
uPA/uPAR αMβ2/Mac-1 (Czekay et al., 2003) 
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Table 4 Proteins that interact with Ras 
 
PROTEIN INTERACTORS PROTEIN INTERACTORS 
AF-6 
Ral guanine nucleotide dissociation 
stimulator 
Angiotensin receptor 1 
cGMP 3`,5`-cyclic phosphodiesterase 
delta subunit 
B-Raf NMDAR2D 
Bcl 2 Ras binding protein Sur 8 
CDC 25A 
Phosphatidylinositol 3 kinase, catalytic 
subunit, delta 
Galectin 1 IRAK2 
Grb2 RAS guanyl nucleotide releasing protein 1 
Insulin receptor Rab acceptor 1 
MEK1 Ras association domain family protein 1 
Neurofibromatosis type I RAS inhibitor 1 
Phosphatidylinositol 3 kinase regulatory 
subunit, alpha 
Zinc finger protein, subfamily 1A, member 
3 
Phosphatidylinositol 3 kinase, catalytic 
subunit alpha 
Ras association (RalGDS/AF-6) domain 
family 5 
Phospholipase C, epsilon 1 LGN protein 




RHOD Ral GDS related protein Rgr 
Ras-GAP RAP1 GTP GDP dissociation stimulator 1 
SOS1 Tetratricopeptide repeat protein 1 
Toll like receptor 2 
Ral guanine nucleotide dissociation 
stimulator like 1 
Toll like receptor 9 Ras interacting protein 1 
VAV1 
Ras association (RalGDS/AF-6) domain 
family 2 
Intersectin 1 RIN 
PDGF beta Zinc finger and BTB domain containing 12 
c-src 
Glutamate receptor, ionotropic, N-methyl 
D-aspartate 1 
Interleukin 1 receptor associated kinase 1 BRAP2 
A_Raf Protein farnesyltransferase alpha subunit 
Guanine nucleotide releasing factor 2 Protein farnesyltransferase beta subunit 
T cell lymphoma invasion and metastasis 
1 Protein kinase C, zeta 
Caveolin 1 Interleukin 3 
Mitogen-activated protein kinase 8 Fyn 
Phosphoinositide 3 kinase, catalytic 
subunit, gamma p73 
SOS2 Retinoic acid receptor responder 3 
Diacylglycerol kinase, zeta  
 














Lag - Lin and GLP 
DLL - Delta-like ligand 
GLP-1 - Germline proliferation 
Su(H) - Suppressor of Hairless 
CSL - Core Binding Factor, Su(H), Lag-1 
CBF - Core Binding Factor  
RBPJκ - recombination signal binding protein for immunoglobulin kappa J region 
TACE - Tumor necrosis factor-alpha-converting enzyme 
Aph1 - Artemia POU-Homeoprotein 
Pen-2 - presenilin enhancer-2 




























Receptor Lin-12  
GLP-1  






Lag-1  Su(H)  CSL 
CBF/RBPJκ  
 
S1 cleavage NK NK Furin convertase 
S2 cleavage SUP-17 Kuzbanian/ADAM10 TACE  

















α1 4.3 ± 0.2 6.1 ± 0.5 4.9 ± 0.8 
α2 2.3 ± 0.3 7.1 ± 0.6 17.4 ± 2.2 
α3 36.4 ± 2.5 38.0 ± 2.2 30.0 ± 1.8 
α4 5.7 ± 0.4 6.5 ± 0.3 3.2 ± 0.1 
α5 3.0 ± 0.2 2.4 ± 0.4 4.4 ± 0.4 
α6 32.4 ± 2.8 22.5 ± 2.5 17.1 ± 2.9 
αV 20.6 ± 3.1 14.7 ± 2.8 26.3 ± 1.2 
    
β1 30.8 ± 3.5 17.1 ± 1.4 42.3 ± 3.9 
β2 5.0 ± 0.3 1.4 ± 0.2 4.2 ± 0.4 
β3 6.8 ± 0.5 6.8 ± 0.6 4.5 ± 0.7 
β4 6.7 ± 0.9 4.6 ± 0.5 6.0 ± 0.1 
β5 5.6 ± 0.8 3.8 ± 0.2 6.8 ± 0.6 
β6 5.6 ± 0.6 5.9 ± 0.4 2.5 ± 0.1 
 
Integrin expression was determined by flow cytometric analysis using monoclonal antibodies 
against integrin subunits. 
 




Corresponds to Fig 4.5A 







Corresponds to Fig 4.5B 
Plastic
Cell cycle phase - - Etoposide XRT - Etoposide XRT
Sub-G0 5.6±1.6 6.1±1.3 4.9±2.4 5.4±1.4 6.3±1.7 5.1±1.1 3.5±1.7
G1 64.8±2.5 65.3±2.8 23.2±2.3 22.1±1.8 67.1±3.1 53.2±1.9 60.1±2.6
S 17.3±2.0 18.2±1.7 25.4±1.6 24.5±2.1 16.7±2.3 22.2±1.7 20.1±1.8
G2/M 8.8±1.0 9.1±0.6 46.2±1.5 47.8±2.1 8.4±2.1 16.8±2.0 16.1±1.9
Poly-L-lysine Laminin
Cell cycle phase - 4B4 Ly294002 Na3V04
Sub-G0 3.6±1.7 4.9±1.1 4.3±0.9 4.5±0.7
G1 24.2±3.9 23.2±2.2 22.1±2.5 39.8±1.8
S 22.6±2.1 20.8±2.8 19.3±1.3 24.5±2.1
G2/M 48.2±3.1 46.9±2.8 52.5±3.0 28.6±2.0
TS2/16 
Cell cycle phase - 4B4 Ly294002
Sub-G0 4.2±2.1 4.3±1.1 3.2±0.9 4.1±2.1
G1 52.3±3.1 22.8±2.0 20.9±1.7 44.2±1.8
S 20.2±1.9 19.7±3.0 16.1±2.4 28.7±2.2




Tables 9 and 10 Extracellular Matrix and Growth Factor composition 
of Growth Factor-reduced MatrigelTM 
 
 






























Growth Factor Typical GF 
Concentration
EGF < 0.5 ng/ml
bFGF n.d.*
NGF < 0.2 ng/ml
PDGF < 5 pg/ml
IGF-1 5 ng/ml
TGF-β 1.7 ng/ml
Concentration of Growth Factors 
(GF) Present in Growth Factor-
reduced BD Matrigel™ Matrix
*n.d. - not determined
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Notch is a central regulator of important cell
fate decisions. Notch activation produces
diverse cellular effects suggesting the presence
of context-dependent control mechanisms.
Genetic studies have demonstrated that Notch
and integrin mutations have related
phenotypes in key developmental processes
such as vascular development and
somitogenesis. We show that the intracellular
domain of mammalian Notch-1 activates
integrins without affecting integrin expression.
Integrin activation is dependent on g -secretase-
mediated intra-membranous cleavage of
membrane bound Notch releasing intracellular
Notch which activates R-Ras, independent of
CSL-transcription. Notch also reverses H-Ras
and Raf-mediated integrin suppression without
affecting ERK phosphorylation. Membrane
bound Notch mutants that are inefficiently
cleaved or intracellular Notch mutants lacking
the ankyrin repeat sequence do not activate R-
Ras or integrins. Co-expression of Msx2-
Interacting Nuclear Target (MINT) protein
with Notch or expression of intracellular
Notch-1 truncation mutants lacking the C-
terminal transactivation/PEST domain
suppresses Notch transcriptional activity
without affecting integrin activation. Notch
ligand, Delta-like ligand-4 stimulates R-Ras-
dependent a5 b1 integrin -mediated adhesion,
demonstrating the physiological relevance of
this pathway. This new CSL-independent
Notch/R-Ras pathway provides a molecular
mechanism to explain Notch, integrin and Ras
cross-talk during the development of multi-
cellular organisms.
The diverse biological processes intrinsic to the
development of multi-cellular organisms are co-
ordinated by communication between adjacent
cells involving a small number of evolutionarily
conserved signalling pathways. The Notch
signalling pathway is an important mechanism for
mediating these intercellular signalling events to
direct cell fate decisions (1). The components of
the Notch pathway have been identified in a broad
range of metazoans and have been extensively
studied in insects, nematodes and mammals (2-4).
Consequently, Notch has been shown to be a key
regulator of many developmental processes
including somitogenesis, vasculogenesis and
neurogenesis (4-6). In addition, the Notch
pathway plays a critical role in mammalian
immune development and carcinogenesis (7,8).
The molecular components of the Notch pathway
have been extensively studied and are highly
conserved between species. Notch encodes a
single-pass heterodimeric transmembrane receptor
with an extracellular domain that contains
epidermal growth factor (EGF)-like repeats (9).
Four Notch homologs (Notch-1-4) and two groups
of ligands (Delta-like (Dll -1, -3 and -4) and
Serrate-like (Jagged 1, 2)) have been identified in
mammals (10,11). Notch-ligand interaction
triggers two distinct proteolytic cleavage events
(S2 and S3) that release the intracellular portion of
Notch (NIC) from the plasma membrane (12-14).
NIC translocates to the nucleus where it binds to a
transcript ional  regulator  CSL (CBF-
1/Su(H)/LAG-1), displacing co-repressors and
recruiting co-activators, thus inducing expression
of Hairy-Enhancer of Split (HES) and HES-
related proteins (HERP) genes (15-18). Data from
several groups suggest that Notch may also signal
without cleavage at S3 or CSL-dependent
transcription (19-21). The molecular components
of this “non-classical” Notch signalling pathway
are not yet fully understood.
Recent genetic studies have indicated important
parallels between the developmental processes
controlled by Notch and integrin-mediated
adhesion.  Integrins are heterodimeric
transmembrane glycoproteins that mediate cell-
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cell and cell-matrix interactions and have been
identified in insects, nematodes and vertebrates
(22). A key feature of integrins is their ability to
modulate ligand-binding affinity in response to
intracellular signals, a process called activation
(23). They are essential for embryogenesis and are
involved in neurogenesis, myogenesis and
angiogenesis, processes also controlled by Notch
(24-26). a6 b1 and a5 b1 integrins are highly
expressed on stem cells and regulate survival,
migration and differentiation (27,28). Notch has
been shown to associate with b1 integrins in
neural stem cells and expression of Notch 4 in
endothelial cells increases adhesion to collagen
(29,30). Additionally, data from Zebrafish
somitogenesis suggests that mutations in the
Notch pathway and integrin a5 subunit can
produce a complementary disruption in somite
formation (31). This suggests the possibility that
Notch may affect integrin activation, modulating
important developmental processes by alterating
cell-matrix interactions (32). We therefore sought
to investigate whether Notch signalling could
activate integrins and define the mechanisms of
this important interaction using an in vitro model
of integrin affinity.
EXPERIMENTAL PROCEDURES
DNA constructs - Mouse Notch-1 constructs: NIC,
NDE, NDE(V1774K) and NLNG in pCS2 (C-
terminal myc-tag) from R. Kopan (Washington
University School of Medicine, St Louis, USA)
(14). Human Notch-1 constructs: ICN1, DTADP,
DEN1 and DANK in pcDNA3.1 from J. C. Aster
(Department of Pathology, Harvard Medical
School, USA) (33), subcloned into pCMV Tag 4A
(Stratagene) to incorporate a C-terminal Flag-tag.
MINT (vector pEF-Bos-Neo, N-terminal Myc tag)
(T. Honjo, Kyoto University, Japan) (34). Tac-a5,
pDCR-H-Ras(G12V) (HA-tagged), pSG5 R-
Ras(WT), R-Ras(T43N) (myc-tagged) and pSG5
R-Ras(G38V) (myc-tagged) as previously
described (35,36). pCDNA3-Raf-CAAX (Flag
tagged) from Dr. C. K. Weber (University of Ulm,
Germany). pGL2 4xCSL (A. Israel, Institute
Pasteur, France) (37). pcDNA3.1 LacZ
(Invitrogen).
Cell Lines/Transfection - CHO(ab-py) cells were
maintained in DMEM (Sigma) with 10% (v/v)
foetal bovine serum (FBS), 1% L-Glutamine
(LG), 1% Penicillin/Streptomycin (PS), 1% non-
essential amino acids and G418 antibiotic at
400mg/ml (Invitrogen). Transient transfection of
a b -py cells was performed with JetPEITM
(Polyplus Transfection Agents, UK) as per
manufacturers instructions. For g-secretase
inhibition, cells were treated with MW167
(50mM) at 36 and 12 hours prior to analysis.
K562 cells (ATCC) were maintained in RPMI
(Sigma) with 10% (v/v) FBS, 1% LG and 1% PS.
K562 cells were transfected by Nucleofector
electroporation (Amaxa, Germany) according to
the manufacturers instructions. K562 cells were
seeded onto human recombinant Delta-like ligand-
4 (DLL-4) (R+D) coated to plastic (10mg/ml in
PBS for 60 min at 37°C) for 12 hours with or
without MW167 (50 mM) or DMSO (Vehicle)
(Calbiochem) as indicated.
Flow Cytometry - CHO(a b-py) cells were
transfected with test DNA together with 0.75mg
Tac-a5 transfection reporter construct. After 48
hours, cells were sequentially labelled with PAC1
antibody (BD Biosciences, UK) (5mg/ml) +/-
5mM EDTA or 100mM MnCl2 in HEPES/NaCl
buffer (20mM HEPES, 140mM NaCl, 1.8mM
CaCl2, 1mM MgCl2 and 2mg/ml Glucose, pH 7.4),
1:25 (v/v) anti-mouse IgM-FITC (Biosource) and
1:50 (v/v) anti-Tac-RPE (ACT-1) (Dako, UK).
ToPro3 (Molecular Probes) was added to each
sample (1mM) and integrin affinity was analysed
by three-colour flow cytometry. PAC1 binding
was determined by gating for live and highly
transfected cells. Integrin activation index (AI)
was calculated (AI = ((FN-FI)/(FA-FI))*100) where
FN is geometric mean (GM) fluorescence intensity
(MFI) of PAC-1 binding of the native integrin, FI
is MFI of PAC-1 binding in the presence of 5mM
EDTA and FA is MFI of PAC-1 binding in the
presence of 100mM Mn2+. AI was used to
calculate percentage integrin suppression ((AI0-
AI)/(AI0)*100). AI0 is the Activation index with
the control vector and AI is the Activation index
with DNA under test. For analysis of b3 integrin
surface expression (independent of integrin
affinity), anti-CD61(b3) antibody (Serotec) was
used in the above conditions.
Gel Electrophoresis and Western Blotting - Cells
were lysed in RIPA buffer, protein balanced by
BCA protein assay (Pierce, USA) and resuspended
in Laemmli sample buffer. Samples were resolved
on 8-12% SDS-PAGE gels (10mg protein per
lane) and transferred onto Hybond C
nitrocellulose (Amersham Pharmacia Biotech).
Immunoblotting: anti-HA (Y-11), anti-Myc
(9E10), anti-ERK2 (C-14), anti-b3-integrin (N-20)
(Santa Cruz Biotech, USA), anti-phospho-ERK1/2
(ERK-PT115), anti-b-actin (AC-40), anti-FLAG
(M2) (Sigma, UK) in 5% non-fat milk, detected
with species specific horseradish peroxidase-
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conjugated antibodies (DAKO, UK) and
chemiluminescence (ECL) (Amersham Pharmacia
Biotech).
CSL-luciferase activity - CSL-luciferase activity
was assayed as previously described (14). In brief,
ab-py cells transfected with test DNA plus pGl2
4xCSL-luc (0.2mg) and pcDNA3.1 LacZ (0.1mg)
were lysed after 48 hours and luciferase activity
was determined using Steady-Glo (Promega)
according to the manufacturers instructions. In
parallel samples, galactosidase activity was
determined using Galacto-Plus (Tropix).
Luciferase activity for each transfection condition
was normalised for galactosidase activity and
expressed as a fold change from that observed
with empty vector.
R-Ras activation assay - R-Ras activity was
determined by binding to the Ras binding domain
(RBD) of Raf as previously described (38). In
brief, ab -py cells were transfected with R-
Ras(WT) or R-Ras(G38V) (0.25 mg) and test
DNA. Cells were quiesced in serum free media
and lysed at 48 hours in buffer (200mM NaCl,
2.5mM MgCl2, 50mM Tris-HCl pH 7.4, 15%
glycerol, 1% NP40 and Complete protease
inhibitor (Boehringer Mannheim, Sussex, UK)) at
4oC for 20 min. The clarified lysate was incubated
with GST-Raf-RBD coupled to glutathione
agarose beads for 2 hours at 4oC. Beads were
washed and eluted protein separated by SDS-
PAGE. Bound R-Ras was detected by western
blotting for myc.
Cell Adhesion Assay - 2x105 K562 cells were
resuspended in HEPES/NaCl buffer and incubated
with 4B4 (Beckman Coulter) (10mg/ml 45 min 37
oC), EDTA (5mM final concentration) or Mn2+
(100mM final concentration) as indicated. Cells
were seeded into plates coated with fibronectin or
poly-l-lysine (10mg/ml in PBS for 60 min 37oC)
and incubated for 30 min at 37°C. Non-adherent
cells were removed by washing with PBS.
Remaining cells were fixed with 3%
paraformaldehyde (5 min) and stained with 0.4%
methylene blue (5 min). Intracellular methylene
blue was eluted with 0.1M HCl and the optical
density (630 nM) of each sample was determined
using an automated plate reader. Cell adhesion per
condition was expressed as a percentage of total
cellular adhesion to poly-l-lysine.
HES-1 expression - Total RNA was extracted
from 1x106 K562 cells using RNeasy kit (Qiagen),
contaminating DNA was removed with RQ1
DNase (Promega) and cDNA was generated by
reverse transcription of 400ng RNA using
TaqMan reverse transcription reagents as per
manufacturer’s instructions (Applied Biosystems).
cDNA quality was verified by PCR amplification
of b -actin. Real time quantitative RT-PCR
analysis was performed with TaqMan reagents
and an ABI 7900HT machine as per manufacturer
instructions (Applied Biosystems). HES-1 for:
CATTCTGGAAATGACAGTGAAGCA; HES-1
rev: CAGCGCAGCCGTCATCT; HES-1 probe:
CTCCGGAACCTGCAGCGGGC fam labelled.
Triplicate measurements were performed and
analyzed with ABI sequence detector software
(version 2.1) using the 2-DDCt method. HES-1
expression for each condition was normalised for
18S expression and represented as a fold change
from control cells.
Statistical analysis - Data were analysed by one-
way analysis of variance and the appropriate post-
test analyses were applied. p values < 0.05 were
considered to be significant.
RESULTS
Notch-1 activates integrins and reverses H-
Ras/Raf-mediated integrin suppression - To
investigate whether Notch signalling could
modulate integrin activation, we used a well-
established model of integrin affinity (39). This
utilises a CHO cell line (ab -py) that stably
expresses an active chimeric integrin (aIIb a6 b3
b1), which has the ligand binding properties of
a IIb b3 but is activated through the a 6 b1
cytoplasmic domains. We assessed the activation
status of the chimeric integrin expressed on the
a b -py cells using flow cytometry to detect
binding of a monoclonal antibody specific for the
active confirmation of aIIb b3 (PAC-1). A cell
surface marker encoding the extracellular domain
of the IL-2 receptor, termed Tac, and the
intracellular domain of the a5 integrin (Tac-a5)
was used as a marker for DNA transfection.
Transfection of ab-py cells was detected by flow
cytometry using an antibody against the IL-2
receptor, Tac-R-PE (R-phycoerythrin). We
routinely observed transfection efficiencies of 70-
80%. Using this model we were able to determine
integrin activation status (geometric mean
fluorescence intensity of FITC-labelled PAC-1
binding) in highly transfected cells (Tac-R-PE
positive cells) allowing accurate assessment of the
effects of transfected test DNA on integrin
affinity. For each DNA transfection we compared
PAC1 binding under ‘native’ conditions to those
in the presence of EDTA (maximally inhibited
integrins) or manganese (maximally activated
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integrins) allowing calculation of an integrin
activation index as described in experimental
procedures.
We found that expression of the intracellular
domain of mouse Notch 1 (designated NIC),
which constitutively activates the Notch signalling
pathway (14), increased integrin activation in ab-
py cells compared to vector control. This was
demonstrated by a rightward shift in PAC-1
binding in highly transfected cells (vector 49.8%,
NIC 75% cells in right upper quadrant) (Fig.1a).
There was no change in PAC-1 binding in the
untransfected cells. Correspondingly, NIC
expression increased integrin activation index
(88.4 +/- 5.7%) compared to expression of vector
alone (67.3 +/- 2.2%) (Fig.1b).
The chimeric integrin in ab-py cells is relatively
activated in the resting state. Therefore, we sought
to suppress integrin affinity and determine
whether Notch signalling would reverse integrin
suppression. The small GTP-binding protein H-
Ras has been shown to suppress integrin activation
(39). We found that transfection of constitutively
active H-Ras(G12V) alone caused marked
inhibition of PAC1 binding; however co-
transfection with NIC completely reversed
suppression of integrin activation (Fig.1 a and b).
These effects were not produced by alterations in
H-Ras(G12V) or NIC expression when the
constructs were co-transfected, nor was expression
of the chimeric integrin in the ab-py cells affected
(Fig.1c).
Hughes et al. (1997) have previously shown that
H-Ras-mediated suppression of the chimeric
integrin in a b -py CHO-K1 cells is not a
consequence of a decrease in integrin expression
levels (39). To confirm that Notch expression did
not alter surface integrin expression we used flow
cytometry to detect surface expression of b3
integrins. Using an anti-b3 integrin antibody
whose binding was not dependent on integrin
activation status we found that neither H-
Ras(G12V), NIC or R-Ras(G38V) expression
altered surface expression of b3 integrins in ab-py
cells (Fig.1d). Thus changes in PAC1 binding are
due to alterations in integrin activation not
expression.
H-Ras suppresses integrin activation via its
downstream effector kinase Raf-1 (39). We
therefore tested the ability of active Notch to
reverse integrin suppression by an activated
membrane-targeted variant of Raf, Raf-CAAX.
Similar results were observed to those found with
H-Ras(G12V) (Fig.2a-c). Thus NIC reversed the
suppressive effect of activated H-Ras or Raf-1 on
integrin affinity, suggesting that Notch signalling
can over-ride integrin inactivation caused by the
H-Ras dependent suppression pathway.
Previous work has suggested that suppression of
integrin activation by H-Ras and Raf-1 is
dependent upon ERK1/2 function but does not
correlate with bulk phosphorylation of ERK (40).
However, reversal of integrin suppression by the
small death effector domain-containing protein
PEA-15 depends upon its capacity to bind ERK1/2
(40,41). Notch signalling has previously been
shown to have differing effects on ERK
phosphorylation depending upon cellular context
(42,43). Therefore, we investigated whether Notch
signalling could reverse suppression of integrin
activation by H-Ras through effects on ERK1/2.
We found that transfection with NIC alone did not
affect ERK phosphorylation. Furthermore NIC did
not affect phosphorylation of ERK induced by H-
Ras(G12V) or Raf CAAX (Fig. 1c and 2c). In
addition, we were unable to demonstrate a
physical association between NIC and ERK1/2 by
co-immunoprecipitaion (data not shown). This
suggests that Notch modulation of integrin affinity
is distinct from the Ras/Raf pathway.
Activation of b 1 integrins by Notch-1 requires
intramembrane cleavage at S3 to release the
intracellular domain - Classically, Notch
activation requires ligand-induced cleavage of the
Notch receptor approximately 12 amino acids N-
terminal to the transmembrane domain (S2),
which allows intramembrane cleavage (S3) by the
protease complex g-secretase (13,14,44). However
analysis of the role of Notch in patterning of the
Drosophila embryo dorsal epidermis suggest that
Notch may signal without membrane cleavage
(45). We therefore determined whether activation
of b1 integrins by Notch was dependent on intra-
membrane cleavage.
Mutants of mouse Notch-1 that are membrane
bound and show differing efficiencies of
processing by g -secretase were used (14)
(summarised in Figure 3) to assess rescue of H-
Ras(G12V)-induced integrin suppression. All
subsequent ab-py assays are represented as levels
of integrin suppression. The Notch mutant NDE
consists of the transmembrane and intracellular
domains of mouse Notch-1 with a short
extracellular segment and is cleaved by the g-
secretase complex to yield active intracellular
Notch. Transfection of ab-py cells with NDE
yielded a fragment of similar molecular weight to
NIC and reversed H-Ras-mediated integrin
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suppression without affecting H-Ras expression or
ERK1/2 activation (Fig.4 a and b). The effect on
integrin activity was less pronounced than
observed with NIC, presumably as a result of a
lower yield of intracellular Notch from NDE
(Fig.4a). To investigate this, two Notch mutants
were used which are inefficiently processed by g-
secretase and do not yield detectable levels of
intracellular Notch; an NDE variant with a point
mutation at amino acid 1774, NDE(V1774K); and
NLNG which has identical transmembrane
/intracellular domains to NDE but an extracellular
domain containing LNG repeats. Transfection of
ab-py cells with NDE(V1774K) or NLNG did not
yield detectable intracellular Notch and did not
significantly reverse H-Ras suppression of
integrins (Fig.4a). Furthermore, pre-treatment of
ab-py cells with the g-secretase inhibitor MW167
blocked the processing of NDE to intracellular
Notch and prevented integrin activation without
altering H-Ras(G12V) expression or ERK1/2
phosphorylation (Fig.4b).
We confirmed the transcriptional activity of the
Notch mutants by measuring CSL-dependent
luciferase activity (14). CSL-luciferase activity
was significantly stimulated by NIC and NDE
(Fig.4c). However, transfection of the Notch
mutants NDE(V1774K) or NLNG, which are
inefficiently cleaved, stimulated CSL-luciferase
activity significantly less than NIC (Fig.4c).
Furthermore, inhibiting g-secretase with MW167
significantly reduced the capacity of NDE to
activate CSL (Fig.4d). Co-transfection of H-
Ras(G12V) with the Notch mutants did not affect
CSL-luciferase activity (data not shown). Taken
together this data indicates that S3 cleavage is
essential for both classical Notch activation and
Notch-mediated integrin activation.
Activation of b 1 integrins by Notch-1 is not
dependent on CSL-mediated transcription - S3
cleavage releases the intracellular portion of the
Notch receptor, which associates with CSL (46).
In the resting state CSL binds to DNA acting as a
transcriptional repressor, but upon interaction with
Notch, co-repressors are displaced and CSL
activates transcription leading to up-regulation of
downstream target genes (e.g. HES-1) (47,48).
However, Notch may also signal independently
from CSL-mediated transcription (49). We
therefore sought to determine the role of
transcription in Notch activation of integrins using
two approaches: inhibition of Notch-CSL
interaction and deletion of the transactivation
domain of Notch-1.
We used Msx2-interacting nuclear target protein
(MINT), which has been shown to compete with
the intracellular region of Notch for binding to
CSL, suppressing the transcriptional activity of
Notch (34). Transfection of MINT into ab-py
cells did not affect integrin affinity or the ability
of H-Ras to suppress integrins/phosphorylate
ERK1/2 (Fig.5 a and b). Available MINT
antibodies are ineffective for Western blot
analysis, therefore expression of MINT was
confirmed by immunofluorescence microscopy
(Fig.5c-j) (34). Importantly, MINT expression did
not block NIC activation of integrins despite
significantly reducing CSL-luciferase activity
(Fig.5k). This suggests that Notch activation of
integrins is not dependent upon transcriptional
activity.
To confirm our transcriptional activity data we
used intracellular Notch-1 truncation mutants
(Fig.3). The C-terminal transactivation/PEST
(TADP) domain of Notch-1 is important for Notch
transactivation and CSL-dependent transcription
(33). Transfection of human intracellular Notch-1
(ICN1) into ab-py cells reversed H-Ras-mediated
integrin suppression in a similar manner to mouse
NIC (Fig.5l). Furthermore, transfection of an
ICN1 truncation mutant, lacking the TADP
domain (DTADP) also reversed H-Ras-mediated
integrin suppression to a similar degree as ICN1
(Fig.5l). We confirmed that removal of the TADP
region from the intracellular domain of Notch-1
significantly reduced CSL-dependent transcription
(Fig.5m). This data confirms that integrin
activation by Notch is not dependent on CSL-
dependent transcription.
Activation of b1 integrins by Notch-1 requires the
ankyrin repeat domain - The intracellular domain
of the Notch receptor consists of the RAM
domain, two nuclear localisation sequences, TAD,
PEST and ankyrin repeat regions (48,50). We
sought to investigate whether the integrin
activating function of Notch could be mapped to
one of these regions using deletion mutants (Fig.3)
(33). We used a membrane bound Notch mutant
(DEN1) that consists of a short extracellular
segment, the transmembrane region and
intracellular domain of human Notch-1 (Fig.3),
which is processed by g-secretase and is
constitutively active. We found that this mutant
reversed H-Ras suppression of integrins in ab-py
cells (Fig.6a). In addition a DEN1 mutant (DRAM)
lacking the 23RAM domain and the DT A D P
mutant (lacking TAD, PEST or NLS domains)
were able to activate integrins (Fig.6 a and b).
However a mutant of DEN1 (DANK), which was
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lacking the ankyrin repeats, was unable to reverse
H-Ras suppression of integrins (Fig.6a). We
confirmed the previously described transcriptional
activity of these mutants in ab-py cells (Fig.6c)
(33). This data specifically implicates the ankyrin
repeats in Notch activation of integrins.
Activation of b1 integrins by Notch is mediated by
R-Ras - The CSL-independent effectors of Notch
are not fully defined. However, our data suggests
that Notch may regulate integrin activity by
activating effectors that antagonise H-Ras
signalling to integrins. R-Ras is a small GTP-
binding protein homologous to H-Ras that can
activate integrins and reverse H-Ras/Raf-initiated
integrin suppression without affecting bulk ERK
phosphorylation (36,51). We found that
transfection of low doses of NIC (0.25mg) had a
minimal effect on integrin suppression mediated
by H-Ras(G12V) (Fig.7a left). Importantly, whilst
transfection of wild type R-Ras alone did not
affect integrin affinity, co-transfection of wild
type R-Ras with 0.25 mg of NIC reversed H-Ras-
mediated integrin suppression, without affecting
H-Ras expression or ERK1/2 phosphorylation
(Fig.7a left, right). This suggests that activation of
integrins by Notch is potentiated by R-Ras.
To demonstrate a specific role for R-Ras in Notch-
mediated integrin activation we used a dominant-
negative R-Ras mutant, R-Ras(T43N) (52).
Transfection of R-Ras(T43N) alone had a minimal
suppressive effect on integrin affinity; however
co-transfection of R-Ras(T43N) with NIC blocked
the ability of active Notch to increase integrin
affinity (Fig.7b left). Furthermore R-Ras(T43N)
prevented NIC from reversing H-Ras(G12V)-
mediated integrin suppression but did not affect
integrin suppression when co-transfected with H-
Ras(G12V) alone (Fig.7b left). These effects
occurred without alterations in expression of H-
Ras, Notch or dominant-negative R-Ras (Fig.7b
right). In addition transfection of R-Ras(T43N)
did not alter integrin expression in the ab-py cells
or H-Ras stimulation of  ERK1/2 phosphorylation
(Fig.7b right).
To determine whether Notch signalling can
directly activate R-Ras, we used the Ras-binding
domain (RBD) of Raf, linked to GST, to pulldown
GTP-bound (active) R-Ras from CHO cell lysates
(38). We found that transfection of NIC or NDE
stimulated an increase in active GTP-bound R-Ras
in ab-py cells, in comparison to wild type R-Ras
alone, without affecting R-Ras expression levels
(Fig.7c left). Furthermore, DTADP, which did not
activate transcription, was also able to activate R-
Ras (Fig.7c right). However, the Notch mutant
NDE(V1744K), which did not yield detectable
intracellular Notch, or DANK, which lacked the
ankyrin repeats, were not able to stimulate an
increase in active R-Ras (Fig.7c left, right). These
results indicate that the intracellular domain of
Notch can specifically activate R-Ras in CHO
cells and this requires the ankyrin repeats but not
CSL-dependent transcription. These results
demonstrate that the ability of Notch signalling to
regulate integrin affinity is mediated through R-
Ras.
Notch-1 activates native a5 b1 integrins in an R-
Ras dependent manner to increase cellular
adhesion to fibronectin - To investigate the
physiological relevance of the above findings, we
examined the effect of Notch on the fibronectin
receptor a5 b1 integrin, in the human myeloid cell
line K562 (53). Transfection of K562 cells with
NIC significantly increased adhesion to
fibronectin in comparison to empty vector
(Fig.8a). Similar increases in cellular adhesion
were observed with ICN1 and DTADP (results not
shown). Adhesion of K562 cells transfected with
either Notch or vector was significantly blocked
by prior incubation with the b1 integrin-blocking
antibody 4B4 (Fig.8a). Furthermore, co-
expression of dominant-negative R-Ras blocked
the effect of NIC on adhesion of K562 cells to
fibronectin (Fig.8b). This occurred without
alterations in Notch or b1 integrin expression. We
confirmed that NIC activated Notch signalling in
K562 by realtime PCR measurement of HES-1
expression and that HES-1 expression was
unaffected by co-transfection of dominant-
negative R-Ras (Fig.8c). These results indicate
that active Notch signalling can regulate natively
expressed integrin affinity through R-Ras
activation.
K562 cells express Notch-1 receptors in the
undifferentiated state and previous data has shown
that Notch signalling can be activated in vitro by
recombinant Notch ligand coated to tissue culture
plastic (54,55). Human recombinant Delta-like
ligand-4 (DLL-4) significantly increased adhesion
of K562 cells to fibronectin (Fig.7d right). This
adhesion was blocked by EDTA and increased by
Mn2+ (Fig.8d). DLL-4 increased HES-1 expression
in K562 cells and this was prevented by MW167
(Fig.8e). Crucially, pre-treatment of K562 cells
with MW167, or pre-incubation with the b1
integrin blocking antibody 4B4, prevented DLL-4
from increasing adhesion to fibronectin (Fig.8f).
Furthermore, DLL-4 induced activation of a5 b1
integrins was blocked by transfection of
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dominant-negative R-Ras (Fig.8g). These data
indicate that ligation of Notch receptors by
naturally occurring Notch ligands can activate b1
integrins increasing cellular adhesion to ECM
through R-Ras.
DISCUSSION
We show here that Notch-1 signalling in
mammalian cells activates b 1 integrins.
Furthermore we demonstrate the physiological
relevance of our findings by showing that ligation
of native Notch-1 receptors by Notch ligand
increases cellular adhesion to fibronectin through
a5 b1 integrins. Crucially our data provides a
mechanism for previous observations
demonstrating key interactions between Notch and
integrins in somitogenesis and vascular
development.
Somitogenesis is the process whereby segmented
precursors of the skeletal muscle and vertebral
column are generated during vertebrate
embryogenesis (32). Mutations in zebrafish
integrin a5 disrupt anterior somite formation,
giving a complementary phenotype to the
posterior defects seen in Notch pathway mutants
(31). Analysis of integrin:notch double mutants
revealed redundancy between integrin and Notch
pathways in promoting somite border
morphogenesis, suggests a regulatory relationship
between Notch and integrins (32). Our data
demonstrates that Notch regulates integrin affinity
and provides a mechanism for this interaction that
is crucial to vertebrate development.
Genetic studies in mice have suggested that Notch
signalling is important for formation of the
vasculature. Mutations in Jagged-1, Notch-1 and
Notch-1 / Notch-4 in mice result in embryonic
lethality with severe vascular defects (56). Genetic
analyses also indicate a central role for integrins in
vascular development - antagonists of b1 integrins
inhibit angiogenesis in the chick chorioallantoic
membrane, and Notch 4 increases endothelial cell
adhesion preventing endothelial sprouting (30).
Notch may therefore regulate vascular
development through interaction with integrins.
Interestingly, R-Ras knockout mice demonstrate
defects in angiogenesis in response to vascular
injury and tumour growth (57). We provide direct
evidence of a link between Notch and b1 integrins
involving R-Ras activation that may represent a
central mechanism for regulation of vascular
development and angiogenesis. Notch-1 and DLL-
4 expression on vascular endothelial cells is
regulated by vascular endothelial growth factor
and thus our findings of integrin activation by
DLL-4 may be particularly relevant (5).
We showed that Notch-1 overrides H-Ras-
mediated integrin suppression via R-Ras
activation. Studies of vulval development in
Caenorhabditis elegans and the Drosophila eye
have indicated important interactions between
Notch and Ras (58,59). The Notch pathway can
antagonise Ras signalling (60,61). Inhibitory
cross-talk between Notch and H-Ras regulates
Drosophila bristle patterning, C. elegans vulva
formation and may be important in T-cell positive
selection (62-64). These interactions occur in part
because each pathway can affect the expression or
activities of components of the other pathway
(65). Our data provides a new mechanism for
Notch antagonism of H-Ras through activation of
R-Ras. This does not require CSL/transcription
and may therefore allow for rapid changes in
cellular signalling in response to interaction with
Notch ligands expressed on adjacent cells. The
importance of this signalling cascade in worms
and insects remains to be demonstrated as these
organisms have a simpler repertoire of small GTP-
binding proteins and therefore may lack the
essential signalling components (i.e. R-Ras) for
this interaction (66).
The mechanisms by which R-Ras might
antagonise H-Ras functions have not yet been
defined. Previous work has demonstrated that
reversal of H-Ras-mediated integrin suppression
by R-Ras is not due to competition for
downstream effectors or Raf-induced MAP kinase
activation (36). Furthermore, specific mutations in
the effector binding loop of R-Ras impaired the
ability of R-Ras to reverse H-Ras-mediated
integrin suppression but did not correlate with
their ability to activate known R-Ras effectors
(67). Recent data has indicated that targeting of R-
Ras to focal adhesions at the cell surface is critical
for its ability to regulate integrin activation (68).
Interestingly H-Ras has also been found to be
associated with focal adhesions and data has
suggested that Notch can interact with b1 integrins
involving lipid rafts (29,69). Therefore, a better
understanding of the interaction between Notch,
the small GTPases and integrins at the cell surface
may help to explain crucial processes in integrin
activation and Notch antagonism of H-Ras.
Our data indicates that Notch-1-mediated integrin
activation requires cleavage of the Notch receptor
at S3 to release the intracellular domain but is
independent of CSL-transcription. Importantly we
showed that integrin activation by Notch is not
inhibited by MINT, which prevents Notch binding
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to CSL (34). CSL-independent Notch signalling
has been suggested by previous analysis of Notch
mutant phenotypes in Drosophila - two gain of
function classes of Notch alleles were defined
which prevent development of sensory bristles,
one of which is not rescued by removing Su(H)
(19). In vivo evidence for CSL-independent
signalling in vertebrates was provided by
experiments examining Delta-1 activated signals
in the developing avian neural crest (70). In vitro
studies have shown that Notch can prevent
differentiation of C2C12 mouse myoblasts into
myotubes. Myoblast differentiation is not blocked
by a dominant negative CSL protein and can be
mimicked by truncated forms of Notch, which
cannot activate a CBF-1-dependent promoter (20).
The mediators of these pathways are not well
defined. We provide direct evidence of CSL-
independent Notch signalling and demonstrate that
R-Ras is a key signalling moiety in this pathway.
We show that intracellular Notch specifically
activates R-Ras and that dominant-negative R-Ras
blocks Notch integrin activation. R-Ras has
important cellular effects including survival,
transcription and adhesion but the physiological
activators are poorly understood (66). Thus our
data defines a novel Notch signalling pathway and
describes a new R-Ras activator.
We show here that Notch activation of integrins
requires the ankyrin repeat domain of intracellular
Notch. Recent studies indicated that this region is
essential for all known Notch functions (50).
Genetic analyses in Drosophila utilising Notch
deletion mutants have indicated that deletion of
the RAM-ANK region abolishes the ability of full
length Notch to transduce a Su(H)-dependent
signal (71). Point mutations within the ankyrin
repeats of full length Notch produce strong
dominant negative phenotypes, whereas mutations
that eliminate RAM activity do not abolish Notch
signalling (3,71). Studies of mouse Notch-1 have
shown that the ankyrin repeats are responsible for
binding to CSL and transactivation (48); Notch
mutants consisting of the TAD/PEST region were
unable to activate transcription but this could be
rescued by co-expression of the ankyrin repeat
domain. Our data concurs with these genetic and
in vitro studies. In addition we show that the
ankyrin repeats have a previously undefined
function not related to CSL binding. Therefore
analysis of ankyrin repeat point mutations should
enable dissection of Notch CSL -dependent and
–independent signalling pathways.
In conclusion, the data presented in this paper
demonstrates clear evidence for a new Notch
signalling pathway. We show that ligand-induced
cleavage of the Notch-1 receptor at S3 releases the
Notch intracellular domain. This activates R-Ras,
in a CSL-independent manner involving the
ankyrin repeats, anatgonises H-Ras-mediated
integrin suppression and increases integrin
affinity. Activation of Notch could enable a cell to
respond to its environmental context, which may
be particularly important in the control of stem
cell fate decisions, as these cells express high
levels of Notch-1, b1 integrins and are frequently
found in an ECM rich niche (28). Thus, our data
defining an interaction between Notch, the Ras
family of GTPases and b1 integrins adds a new
level of complexity to the Notch signalling
pathway and has important implications for the
future understanding of development and disease.
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FIGURE 1: Notch activates integrins and reverses H-Ras-mediated suppression of integrin
affinity.
(a) CHO(ab-py) cells transfected with Tac-a5 (0.75mg), intracellular Notch-1 (NIC) (1 mg) and H-
Ras(G12V) (0.375mg). Integrin activation state was analysed by flow cytometry (n=7 independent
experiments). The representative dot blots display PAC1-FITC binding (integrin activation status) on
the x-axis and Tac-R-PE antibody binding (transfection efficiency) on the y-axis. The quadrant marker
on each dot blot differentiates on the x-axis, cells with high and low integrin affinity status and on the
y-axis, highly transfected cells (upper quadrants) against cells transfected to a lesser extent (lower
quadrants). The quadrant marker separating highly transfected cells was set for individual experiments
to contain 20-25% of Tac-a5 positive cells. The figure in the right upper quadrant of each dot blot
represents the percentage of highly transfected cells present in that quadrant (i.e. cells with high
integrin affinity). Representative dot blots are shown. H-Ras(G12V) induced a left shift in PAC1
binding in transfected cells indicating integrin suppression. Co-transfection of NIC increased PAC1
binding and reversed the left shift, indicating integrin activation. (b) Mean percentage integrin
activation +/-SEM is shown. Inset: Dose-dependent effect of NIC on H-Ras(G12V) (0.375mg)-
mediated integrin suppression. (c) Representative immunoblot of NIC, H-Ras, b3 integrin, ERK2,
phospho-ERK and b actin expression. (d) CHO(ab-py) cells were transfected with Tac-a5 (0.75mg)
and either intracellular Notch-1 (NIC) (1mg), H-Ras(G12V) (0.375mg) or R-Ras(G38V) (0.5mg).
Surface expression of b3 integrins was determined by flow cytometry. Representative overlay
histograms of anti-b3 integrin (white) or isotype control (black) staining on highly transfected cells are
shown. Statistically significant differences between results are indicated by * (p<0.05) or ** (p<0.01).
FIGURE 2: Notch reverses Raf-mediated suppression of integrin affinity.
(a) PAC1 binding in ab-py cells transfected with Tac-a5 (0.75mg), NIC (1 mg) and Raf-CAAX (0.5
mg) (n=5 independent experiments, representative dot blots shown). (b) Mean percentage integrin
activation +/-SEM. (c) Representative immunoblot analysis of NIC, Raf-CAAX, b3 integrin, ERK2,
phospho-ERK and b-actin expression. Statistically significant differences between results are
indicated by * (p<0.05) or ** (p<0.01).
FIGURE 3: Description of Notch constructs.
Mouse (a) and Human (b) Notch-1 constructs used in this study. Key defines important structural
components and mutations/deletions in the intracellular domain of each construct.
FIGURE 4: Notch activation of integrins requires intramembranous (S3) cleavage.
(a) The effect of Notch mutants NIC, NDE, NDE(V1744K) and NLNG (1mg) on H-Ras(G12V)
(0.375mg)-mediated integrin suppression (mean+/-SEM, n=4 independent experiments).
Representative immunoblot of Notch, H-Ras(G12V) and b actin expression. (b) NDE (1mg) reversal of
H-Ras(G12V) (0.375mg)-mediated integrin suppression in the presence of MW167 (50 mM) (o) or
vehicle (n) (mean+/-SEM, n=4 independent experiments). Representative immunoblot of Notch, H-
Ras(G12V), ERK2, phospho-ERK and b actin expression. (c) The effect of NIC, NDE, NDE(V1744K)
or NLNG (1mg) on CSL-luciferase activity in ab-py cells (mean fold increase compared to empty
vector +/-SEM, n=4 independent experiments). (d) The effect of NIC or NDE (1mg) in the presence of
MW167 (50 mM) (o) or vehicle (n) on CSL-luciferase activity (mean fold increase compared to
empty vector +/-SEM, n=3 experiments). Statistically significant differences between results are
indicated by * (p<0.05).
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FIGURE 5: Notch activation of integrins is independent of CSL-transactivation.
(a) The effect of NIC (1mg) and MINT (2m g) on H-Ras(G12V) (0.375mg)-mediated integrin
suppression (mean+/-SEM, n=3 independent experiments). (b) Representative immunoblot of NIC, H-
Ras(G12V), phospho-ERK and ERK2 expression. (c-j) Expression of MINT (2mg) and NIC (1mg) in
ab-py cells shown by immunofluoresence microscopy. (c-d) ab-py cells expressing NIC-GFP (green),
and phase contrast; (e-f) ab-py cells expressing myc-MINT (labelled with alexafluor 568) (red), and
phase contrast; (g-h) ab-py cells expressing NIC-GFP (green) and myc-MINT (alexafluor 568) (red);
(i) Merge of green (NIC) and red (MINT) channels; (j) Phase contrast of (g-i). (k) The effect of NIC
(1mg) and MINT (2mg) on CSL-luciferase activity (mean fold increase compared to empty vector +/-
SEM, n=3 independent experiments). (l) The effect of Notch mutants, ICN1 and DTADP (1mg), on H-
Ras(G12V) (0.375mg)-mediated integrin suppression (mean +/-SEM, n=3). Representative
immunoblot of Notch, H-Ras(G12V) and b actin expression. (m) The effect of ICN1 and DTADP
(1mg) on CSL-luciferase activity (mean fold increase compared to empty vector +/-SEM, n=4
independent experiments). Statistically significant differences between results are indicated by *
(p<0.05).
FIGURE 6: Notch activation of integrins requires the ankyrin repeats.
(a) The effect of Notch mutants DEN1 and DANK (1mg) on H-Ras(G12V) (0.375mg)-mediated
integrin suppression (mean+/-SEM, n=4 independent experiments). Representative immunoblot of
Notch, H-Ras(G12V) and b actin expression. (b) The effect of Notch mutants ICN1, DTADP and
DRAM (1mg) on H-Ras(G12V) (0.375mg)-mediated integrin suppression (mean+/-SEM, n=5
independent experiments). Representative immunoblot of Notch, H-Ras(G12V) and b  actin
expression. (c) The effect of ICN1, DEN1, DRAM, DTADP and DANK (1mg) on CSL-luciferase
activity (mean fold increase compared to empty vector +/-SEM, n=3 independent experiments).
Statistically significant differences between results are indicated by * (p<0.05).
FIGURE 7: Notch activation of integrins is mediated by R-Ras.
(a) Left: The effect of NIC (0.25mg) and R-Ras(WT) (0.5mg) on H-Ras(G12V) (0.375mg)-mediated
integrin suppression in ab-py cells (mean +/-SEM). Right: Representative immunoblot of NIC, H-
Ras(G12V), R-Ras(WT), b3 integrin, ERK2, phospho-ERK (p-ERK) and b actin expressiom (n=4
independent experiments). (b) Left: The effect of R-Ras(T43N) (1mg) on NIC (1mg) reversal of H-
Ras(G12V) (0.375mg)-mediated integrin suppression in ab-py cells (mean +/-SEM). Right:
Representative immunoblot of NIC, H-Ras(G12V), R-Ras(T43N), b3 integrin, ERK2, phospho-ERK
(p-ERK) and b actin expression (n=4 independent experiments). (c) Left: The effect of Notch mutants,
NIC, NDE and NDE(V-K) (1mg), on R-Ras activation in ab-py cells. Right: The effect of Notch
mutants, DTADP and DANK (1mg), on R-Ras activation in ab-py cells. Representative immunoblots
of myc-tagged active R-Ras (from Ras binding domain of Raf), total R-Ras (from whole cell lysates)
and Notch (n=4 independent experiments). Statistically significant differences between results are
indicated by * (p<0.05). NS indicates no significant difference.
FIGURE 8: Notch increases adhesion in a b1 integrin/R-Ras dependent manner.
(a) The effect of NIC (1mg) on K562 cell adhesion to fibronectin with (o) or without (n) 4B4 (mean
percentage adhesion compared to poly-l-lysine +/-SEM, n=4 independent experiments). (b) The effect
of NIC and R-Ras(T43N) on K562 cell adhesion to fibronectin (mean percentage adhesion compared
to poly-l-lysine +/-SEM). Representative immunoblot of NIC, R-Ras(T43N), b1 integrin and b-actin
expression (n=5 independent experiments). (c) The effect of NIC and R-Ras(T43N) (1mg) on HES-1
expression in K562 cells (mean fold increase in HES-1+/-SEM, normalised for 18S and compared to
empty vector, n=3 independent experiments). (d-g) K562 cells incubated for 12 hours with
recombinant human Delta ligand 4 (Dll-4) with or without MW167 (50 mM). (d) Dll-4 effect on K562
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cell adhesion to fibronectin with or without EDTA (5mM) or Mn2+ (100mM) (mean percentage
adhesion +/-SEM compared to poly-l-lysine, n=4 independent experiments). (e) The effect of Dll-4 +/-
MW167 or 4B4 (10 mg/ml) on K562 cell adhesion to fibronectin (mean percentage adhesion +/-SEM
compared to poly-l-lysine, n=3 independent experiments). (f) The effect of Dll-4 +/- MW167 on HES-
1 expression in K562 cells (mean fold increase in HES-1+/-SEM, normalised for 18S and compared to
empty vector, n=3 independent experiments). (g) The effect on K562 cell adhesion to fibronectin of
cells transfected with R-Ras(T43N) or empty vector, and +/-Dll-4 (mean percentage adhesion +/-SEM
compared to poly-l-lysine, n=3 independent experiments). Statistically significant differences between
results are indicated by * (p<0.05). NS indicates no significant difference.
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Leader Peptide Ankyrin Repeats
LNG Repeats Transactivation Domain
Transmembrane Domain PEST Sequence
RAM Domain 6x MYC TAG
Nuclear Localisation Sequence 1x FLAG TAG
 by on A


























































































































 by on A











































































































-+ - - + ++-NIC
+ +H-Ras(G12V) - - + - H-Ras(G12V) - - + - + -
MINT - - +- - ++ + - -MINT +- - ++ +
c d e f












 by on A






































































































 by on A















































-+ - + - +-
- - + - +
+0.25 µg NIC
+H-Ras(G12V)











































































































 by on A































































- - - -






















































































 by on A









ECM overrides DNA damage-induced cell cycle arrest
and apoptosis in small-cell lung cancer cells through
b1 integrin-dependent activation of PI3-kinase
PS Hodkinson1,2, T Elliott1,2, WS Wong1, RC Rintoul1,
AC Mackinnon1, C Haslett1 and T Sethi*,1
1 MRC Centre for Inflammation Research, Queen’s Institute of Medical
Research, University of Edinburgh, 51 Little France Crescent, Edinburgh EH16
4SA, UK
2 These authors contributed equally to this work.
* Corresponding author: T Sethi, MRC Centre for Inflammation Research,
Queen’s Institute of Medical Research, University of Edinburgh, 51 Little
France Crescent, Edinburgh EH16 4SA, UK. Tel: þ 00 44 131 242 6550;
Fax: þ 00 44 131 242 6479; E-mail: t.sethi@ed.ac.uk
Received 13.7.05; revised 07.11.05; accepted 24.11.05; published online 27.1.06
Edited by M Oren
Abstract
The emergence of resistance to chemotherapy remains a
principle problem in the treatment of small-cell lung cancer
(SCLC). We demonstrate that extracellular matrix (ECM)
activates phosphatidyl inositol 3-kinase (PI3-kinase) signaling
in SCLC cells and prevents etoposide-induced caspase-3
activation and subsequent apoptosis in a b1 integrin/PI3-
kinase-dependent manner. Crucially we show that etoposide
and radiation induce G2/M cell cycle arrest in SCLC cells prior
to apoptosis and that ECM prevents this by overriding the
upregulation of p21Cip1/WAF1 and p27Kip1 and the down-
regulation of cyclins E, A and B. These effects are abrogated
by pharmacological and genetic inhibition of PI3-kinase
signaling. Importantly we show that chemoprotection is not
mediated by altered SCLC cell proliferation or DNA repair.
Thus, ECM via b1 integrin-mediated PI3-kinase activation
overrides treatment-induced cell cycle arrest and apoptosis,
allowing SCLC cells to survive with persistent DNA damage,
providing a model to account for the emergence of acquired
drug resistance.
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doi:10.1038/sj.cdd.4401849; published online 27 January 2006
Keywords: cancer; extracellular matrix; cell cycle; apoptosis;
chemoresistance
Abbreviations: CDK, cyclin-dependent kinase; DNA-PKcs,
DNA-dependent protein kinase catalytic subunit; ECM, extra-
cellular matrix; FCS, fetal calf serum; GSK-3, glycogen synthase
kinase-3; Gy, Gray; MDR, multi-drug resistance; Na3VO4, sodium
orthovanadate; PI3-kinase, phosphatidyl inositol 3-kinase; PKB,
protein kinase B; Rb, retinoblastoma protein; SCLC, small-cell
lung cancer; Topo II, topoisomerase II; XRT, radiation; z-VAD,
z-valine–alanine–aspartate
Introduction
Lung cancer is the most common fatal malignancy in the
developed world.1 Small-cell lung cancer (SCLC), which
constitutes 25% of all lung tumors, has a very poor prognosis
(2-year survival less than 5%). Etoposide-based chemo-
therapeutic regimens and radiotherapy are the main stay of
treatment.2 Although impressive initial responses are seen, in
the majority of patients, recurrent disease refractory to further
treatment results in tumor relapse and ultimately death. This
phenomenon, known as multi-drug resistance (MDR), is the
major cause of cancer treatment failure.2 New therapeutic
strategies are urgently needed, which will require an in-depth
understanding of the mechanisms of MDR in SCLC.
We have previously shown that SCLC is surrounded by an
extensive stroma of extracellular matrix (ECM) at both primary
and metastatic sites and that high levels of expression
correlate with poor patient prognosis.3 Cells interact with
ECM components via heterodimeric cell surface proteins
called integrins.4 ECM–integrin interaction stimulates signal
transduction pathways that regulate a number of cellular
processes important in cancer growth, including cell cycle
transition and protection from apoptosis.4 We have shown that
adhesion of SCLC cells via b1 integrins to ECM components
promotes cell survival and confers resistance to chemo-
therapeutic agents.3 This has now been demonstrated to be a
general mechanism for acquired drug resistance in a number
of malignancies including myeloma, breast and colon can-
cer.3,5–7 However, the intracellular signals activated by ECM
components in cancer cells, which influence response to
chemotherapy and radiotherapy, have not been fully eluci-
dated. A clear understanding of these mechanisms is
essential to the development of rational therapeutic strategies
to overcome acquired MDR and enhance the effects of
chemotherapy and radiotherapy.
Central to the cellular response to chemotherapy and
radiation-induced DNA damage is cell cycle arrest, predomi-
nantly at the G1/S and G2/M checkpoints.8 Alterations in
expression of genes that control progression through the cell
cycle have been demonstrated to affect chemosensitivity. The
best described in cancer cells are alterations in expression of
p53 and the retinoblastoma protein (Rb). Mutated forms of
p53 and/or Rb have been shown to be associated with
increased resistance of tumor cells to various anticancer
drugs and irradiation, mainly because of disruption of cell
cycle checkpoints.9 Alterations in other cell cycle regulators
such as the cyclins, cyclin-dependent kinases (CDKs) and
their inhibitors, p21Cip1/WAF1 and p27Kip1, may also play an
important role in the regulation of drug sensitivity.10
Anchorage to ECM is required for proliferation of all
untransformed cells and the development of anchorage
independence is an important stage in transformation.11
Regulation of the cell cycle by mitogens and cell adhesion in
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untransformed cells is restricted to the G1/S transition.12,13
Progression through the G1 phase is mediated by CDK 2, 4
and 6, whose activities are controlled by their associated
cyclins and CDK inhibitors, p21Cip1/WAF1 and p27Kip1.14
Accumulation of cyclin D, which associates with and activates
CDK 4 and 6, initiates progression through G1.15 The cyclin
D–CDK 4 and 6 complex also prevents transcriptional
repression of cyclin E and the de-repression of cyclin A,
promoting the onset of S phase.16 Cells in suspension have
higher levels of CDK 2 inhibitors than do attached cells,
leading to impaired cyclin E–CDK 2 activity with resultant cell
cycle arrest in late G1.14,17 These results suggest that the
regulation of cyclin E–CDK 2 activity is an important
mechanism by which anchorage to ECM controls progression
through the G1/S transition in untransformed cells. Regulation
of cyclin E–CDK 2 activity may also represent how ECM
protects cancer cells from chemotherapy-induced cell cycle
arrest and subsequent apoptosis.
The phosphatidyl inositol 3-kinase (PI3-kinase) signaling
pathway has been demonstrated to be an essential survival
signal in SCLC cells, and is a key regulator of cell cycle
progression.18,19 Integrin activation by ECM couples integrin
cytoplasmic tails to focal adhesion kinase and activates PI3-
kinase, which phosphorylates inositol lipids, leading to
activation of protein kinase B (PKB) and phosphorylation of
glycogen synthase kinase 3b (GSK3b).19,20 PKB phosphory-
lates and inactivates proapoptotic factors such as caspase 9
and Bad, preventing apoptosis.19 Phosphorylation of GSK3b
stabilizes cyclin D1, promoting progression through G1 phase
of the cell cycle, and prevents apoptosis by altering gene
expression through NF-kB and AP-1.21–23 Therefore, preven-
tion of cell cycle arrest and subsequent apoptosis through
integrin activation of PI3-kinase may represent an important
mechanism by which ECM proteins protect SCLC cells from
chemotherapy and radiation.
In this paper, we demonstrate that ECM proteins can
override etoposide-induced G2/M cell cycle arrest and
apoptosis in SCLC cells through b1 integrin activation of
tyrosine kinase/PI3-kinase signaling. Furthermore, we show
that ECM-mediated protection from etoposide occurs despite
topoisomerase II (Topo II) inhibition and DNA double-strand
break formation allowing the survival of DNA damaged cells.
Thus, integrin activation by ECM proteins may provide a
central mechanism for the emergence of MDR in cancer.
Results
ECM proteins protect SCLC cells from
chemotherapy- and radiation-induced apoptosis
via b1 integrin activation
We have previously shown that SCLC ceslls are surrounded
by the ECM proteins laminin and fibronectin in vivo, and
that the degree of expression of ECM adversely affects
patient prognosis.3 To elucidate the mechanism by which
ECM promotes SCLC cell survival, we investigated the
effect of specific ECM proteins in vitro on apoptosis induced
in SCLC cells by etoposide and ionizing radiation. H345
SCLC cells were adhered to poly-L-lysine, fibronectin or
laminin and treated with etoposide (25mg/ml). The percentage
of apoptotic cells was assessed by acridine orange/ethidium
bromide staining at time points over a period of 72 h.
Apoptosis induced by etoposide was first evident at 24 h in
H345 SCLC cells adhered to poly-L-lysine, reaching a
maximum at 48–72 h (Figure 1a). No significant difference
was observed whether cells were plated onto tissue culture
plastic or adhered to poly-L-lysine (data not shown). However,
adhesion to both laminin and fibronectin significantly pro-
tected H345 SCLC cells from apoptosis at all time points
(Figure 1a). This effect was not due to a physical interaction
between etoposide and ECM, as medium that had been
treated with etoposide and incubated with laminin-coated
plastic for 72 h was still able to induce apoptosis when added
to SCLC cells adhered to poly-L-lysine (Figure 1b). Further-
more, adhesion of H345 SCLC cells to ECM proteins
protected SCLC cells against the proapoptotic effect of
ionizing radiation (Figure 1c and d), further confirming that
ECM protection is not caused by a physical effect on
chemotherapeutic agents. Similar results were seen with
H69 and H510 cells (data not shown). These results were
confirmed using two other methods for assessing apoptosis: a
cell death detection ELISA kit which is based on the
quantitative detection of histone-associated DNA fragments
in mono- and oligonucleosomes (Figure 1e) and annexin V
expression (data not shown). To determine whether this
survival benefit was due to an increase in the growth rate of
cells on ECM, we compared the growth of H345 SCLC cells
adhered to laminin or poly-L-lysine (Figure 1f). ECM proteins
stimulated a small increase in cellular growth over 9 days.
However, there was no significant difference in cell number
between H345 cells grown on ECM or on poly-L-lysine at the
early time points corresponding to when apoptosis was being
assessed. These results indicate that the ECM-mediated
protection of SCLC cells from chemotherapy is due to an
antiapoptotic effect and not increased growth.
We have previously characterized integrin expression on
SCLC cells and the b1 integrin subunit is highly expressed.3
To investigate whether the antiapoptotic effect of ECM
proteins was mediated by the activation of b1 integrins on
SCLC cells, we used specific b1 integrin function blocking and
stimulating antibodies to manipulate ECM chemoprotection.
H345 SCLC cells were adhered to poly-L-lysine or laminin,
treated with etoposide (25 mg/ml), and apoptosis was
assessed at 48 h by acridine orange/ethidium bromide
staining (Figure 1g) and annexin V (Figure 1h). The basal
level of apoptosis in H345 SCLC cells on poly-L-lysine was
872%, and this was increased to 5574% in the presence of
etoposide (n¼ 3 independent experiments in quadruplica-
te7S.E.M.). Adhesion of H345 SCLC cells to the ECM
proteins laminin or fibronectin significantly reduced apoptosis
caused by etoposide at 48 h from 5574 to 771.7 and
871.4%, respectively (n¼ 3 independent experiments in
quadruplicate7S.E.M.). ECM-mediated protection from eto-
poside-induced apoptosis was completely abolished by
preincubation of H345 SCLC cells with the b1 integrin
function-blocking antibody (4B4 10 mg/ml). Furthermore, the
b1-stimulating antibody TS2/16 (10 mg/ml) and the broad-
spectrum phosphatase inhibitor sodium orthovanadate
(Na3VO4) both reproduced the effects of ECM proteins.
Taken together, these results indicate that ECM proteins
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prevent apoptosis in SCLC cells through activation of b1
integrins and tyrosine kinase signaling pathways.
Laminin and Na3VO4 stimulate PI3-kinase activity,
PKB phosphorylation and activity, and increase
glycogen synthase kinase-3 (GSK-3)b
phosphorylation
Integrin-dependent cell adhesion triggers an increase in
tyrosine phosphorylation and PI3-kinase activation.19
PI3-kinase has also been shown to mediate matrix-induced
survival in normal epithelial cells.24 Therefore, we examined if
ECM proteins activated PI3-kinase signaling pathways in
SCLC cells. Adhesion of H345 cells to ECM proteins laminin
and fibronectin stimulated a marked increase in PI3-kinase
activation (average 3.1 and 2.9 increases in PI3-kinase
activity, respectively, n¼ 3 independent experiments in
quadruplicate) (Figure 2a). Furthermore, the b1 integrin-
stimulating antibody TS2/16 (10mg/ml) and Na3VO4 (200 mM)
increased PI3-kinase activity by a similar amount to ECM
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Figure 1 ECM-mediated protection from etoposide- and radiation-induced apoptosis in SCLC cells is b1 integrin-dependent. (a) H345 SCLC cells were seeded into
96-well plates precoated with poly-L-lysine (10 mg/ml) (K), laminin (10 mg/ml) (J) or fibronectin (20 mg/ml) (n), and treated with etoposide (25 mg/ml). The percentage
of apoptotic cells was determined at the times indicated by staining cells with acridine orange/ethidium bromide and subsequent fluorescent microscopy (mean of n¼ 3
independent experiments in quadruplicate7S.E.M.). (b) Quiesced H345 SCLC cells were seeded into 96-well plates precoated with poly-L-lysine (10 mg/ml) and treated
with etoposide (25 mg/ml) (K) or seeded on poly-L-lysine in a medium that had been conditioned by incubation for 72 h in laminin-coated (10 mg/ml) six-well plates with
(&) or without (’) etoposide (25 mg/ml). The percentage of apoptotic cells was determined as above (mean of n¼ 3 independent experiments in
quadruplicate7S.E.M.). (c) Quiesced H345 SCLC cells were seeded into 96-well plates precoated with poly-L-lysine (10 mg/ml) (K), laminin (10 mg/ml) (J) or
fibronectin (20 mg/ml) (n), and treated with ionizing radiation (2 Gy). The percentage of apoptotic cells was determined as above (mean of n¼ 3 independent
experiments in quadruplicate7S.E.M.). (d) Quiesced H345 cells were adhered to poly-L-lysine (10 mg/ml) (black bar) or laminin (10 mg/ml) (white bar), treated with
ionizing radiation (0–4 Gy) as indicated, and the percentage of apoptotic cells was determined at 48 h (mean of n¼ 3 independent experiments in
quadruplicate7S.E.M.). (e) H345 cells were adhered to poly-L-lysine (black bar) or laminin (white bar) and treated with etoposide (25 mg/ml). Apoptosis was assessed at
the time indicated using a cell death ELISA kit. The graph represents the mean absorbance at 405 nm from n¼ 3 experiments7S.E.M. Increase in absorbance
indicates increased apoptosis. (f) H345 SCLC cells were plated into 24-well plates coated with poly-L-lysine (K) or laminin (J) and cell numbers were counted at times
indicated (mean n¼ 4 independent experiments7S.E.M.). (g) Quiesced H345 cells were incubated with (þ ) or without () the function blocking anti-b1 integrin
antibody 4B4 (10 mg/ml) for 30 min at 371C as indicated, and then seeded into 96-well plates precoated with poly-L-lysine (PLL) (10 mg/ml), laminin (Ln) (10 mg/ml),
fibronectin (Fn) (20 mg/ml) or the integrin-activating antibody TS2/16 (10 mg/ml). Cells were treated with (þ ) or without () etoposide (Etop) (25 mg/ml) or Na3VO4
(200 mm) as indicated. The percentage of apoptotic cells was determined at 48 h as above (mean of n¼ 3 independent experiments in quadruplicate7S.E.M.). (h) H345
cells were treated as above and the percentage of apoptotic cells was assessed by surface expression of annexin V using flow cytometry (mean of n¼ 3
experiments7S.E.M.)
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independent experiments in quadruplicate). As predicted,
LY294002 reduced basal levels of PI3-kinase activity. PKB
and GSK-3b, which are downstream effectors of PI3-kinase
and regulate cell survival, may also participate in overriding
chemotherapy- and radiation-induced apoptosis in SCLC
cells. Adhesion of H345 SCLC cells to laminin caused a time-
dependent increase in PKB activity, noted first at 5 min with
maximum activity at 10 min (Figure 2b). An increase in GSK3b
phosphorylation was also noted at 5 min, rising to a plateau at
15 min (Figure 2c). Similar results were seen with fibronectin
and TS2/16 (results not shown). Furthermore, Na3VO4
(200mM) stimulated PKB and GSK3b phosphorylation in
H345 cells adhered to poly-L-lysine (Figure 2d and e). The
ECM-mediated increase in phosphorylation of PKB and
GSK3b was sensitive to PI3-kinase inhibition with LY294002
(10 mM) and was not affected by etoposide treatment (25 mg/
ml) (Figure 2d and e). In addition, the inhibition of PKB
phosphorylation by LY294002 was prolonged in H345 cells,
being observed up to 48 h after treatment (Figure 2f). Similar
effects were seen in H69 SCLC cells (data not shown).
ECM protection against etoposide-induced
apoptosis is dependent on tyrosine kinase and
phosphotidyl inositol 3-kinase activation
To specifically investigate the role of PI3-kinase signaling in
ECM-mediated chemoprotection, we initially used a pharma-
cological inhibitor of PI3-kinase activity, LY294002. Analysis
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Figure 2 ECM activates PI3-kinase signaling in SCLC cells. (a) H345 cells were adhered to 6-well plates precoated with poly-L-lysine (10 mg/ml), laminin (10 mg/ml),
fibronectin (20 mg/ml) or TS2/16 (10 mg/ml). In addition, cells on poly-L-lysine were treated with Na3VO4 (200 mm) or LY294002 (30 mM) as indicated. PI3-kinase activity
was assayed after 10 min as described in Materials and Methods. (b) Quiesced H345 cells were adhered to laminin for the times indicated and PKB activity was
determined as described in Materials and Methods. (c) Quiesced H345 cells were adhered to laminin for the times indicated and expression of phosphorylated GSK3b
was determined by Western blot analysis. Relative protein expression was quantified using Image J software (mean of n¼ 3 experiments7S.E.M.). (d) H345 cells were
adhered to six-well plates precoated with poly-L-lysine (10 mg/ml) or laminin (10 mg/ml) and treated with (þ ) or without () etoposide (25 mg/ml), Na3VO4 (200 mM) or
LY294002 (30 mM) as indicated. Cells were lysed after 10 min, and expression of phosphorylated protein kinase B (p-PKB), total PKB, phosphorylated glycogen
synthase kinase 3b (p-GSK3b) and glycogen synthase kinase 3a/b (GSK 3a/b) was determined by Western blot analysis. Representative blots from n¼ 3 experiments.
(e) Relative expression of phospho-PKB from cells treated as above. Graph represents the mean fold increase in phospho-PKB expression normalized to untreated
controls (n¼ 3 experiments7S.E.M.). (f) H345 cells were quiesced, plated onto laminin or poly-L-lysine, and treated as indicated. Cells were lysed after 48 h and
phospho-PKB (p-PKB) and total PKB expression was determined by Western blot. Representative blot from n¼ 3 experiments
ECM overrides G2/M arrest and apoptosis in SCLC
PS Hodkinson et al
1779
Cell Death and Differentiation
poly-L-lysine revealed that inhibition of PI3-kinase with
LY294002 produced a small increase in the degree of
apoptosis both with and without etoposide (Figure 3a).
Furthermore, the protection of H345 SCLC cells against
etoposide-induced apoptosis mediated by ECM was comple-
tely reversed by the addition of LY294002 (Figure 3a). In
addition, chemoprotection resulting from specific b1 integrin
stimulation with TS2/16 or stimulation of the tyrosine
kinase pathway with Na3VO4 was abrogated by LY294002.
Similar results were seen in H69 and H510 SCLC cells. As
expected, z-valine–alanine–aspartate (z-VAD), which inhibits
caspase activity, prevented apoptosis induced by etoposide
(Figure 3a).
PI3-kinase activates downstream PKB, which phosphory-
lates proapoptotic factors such as caspase-9 and Bad,
preventing cell death.21–23 Thus, we investigated whether
ECM could alter Bad phosphorylation and etoposide-induced
caspase-9 activation in a PI3-kinase-dependent manner. We
found that adhesion of H345 SCLC cells to ECM stimulated
phosphorylation of Bad and prevented cleavage of caspase-9
induced by etoposide after 24 h (Figure 3b). These effects
were prevented by treatment with LY294002. Activation of
caspase-9 initiates cleavage of the ‘effector’ caspase-3, which
ultimately results in apoptosis. We found that etoposide could
induce caspase-3 cleavage in H345 cells adhered to poly-
L-lysine, but not in cells adhered to laminin. However,
treatment with LY294002 prevented laminin from blocking
caspase-3 cleavage without affecting caspase-3 activation in
cells adhered to poly-L-lysine (Figure 3b). In parallel experi-
ments, caspase-3 activity was measured (Figure 3c). Etopo-
side induced an increase in caspase-3 activity in H345 SCLC
cells, which, as expected, was blocked by z-VAD. Adhesion to
laminin and stimulation of the tyrosine kinase pathway with
Na3VO4 overcame etoposide-induced caspase-3 activation,
preventing cells undergoing apoptosis. Furthermore, the
ECM- and Na3VO4-mediated inhibition of etoposide-induced
caspase-3 activation was prevented by the tyrosine kinase
inhibitor tyrophostin-25 and the PI3-kinase inhibitor LY294002
(Figure 3c). These results indicate that PI3-kinase signaling,
through phosphorylation of Bad and modulation of caspase
activity, is critical for ECM-mediated resistance to etoposide-
induced apoptosis in SCLC cells.
ECM proteins override etoposide- and radiation-
induced G2/M cell cycle arrest via PI3-kinase
modulation of cell cycle regulators
DNA damage is central to the cellular response to chemo-
therapy and radiation and results in cell cycle arrest predomi-
nantly at the G1/S and G2/M checkpoints.8,14 Subsequent,
activation of checkpoint signaling cascades can result in
apoptotic cell death preventing accumulation of genetic
damage. Modulation of cell cycle checkpoints may therefore
play an important role in sensitivity to radiation and chemother-
apy. We investigated whether ECM proteins could override cell
cycle arrest induced in SCLC cells by etoposide and radiation.
H345 SCLC cells were adhered to poly-L-lysine or laminin,
treated with etoposide (25mg/ml) or ionizing radiation (2Gray
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Figure 3 ECM-mediated protection from caspase-3 activation and apoptosis
requires PI3-kinase signaling. (a) Quiesced H345 cells were seeded into 96-well
plates precoated with poly-L-lysine (10 mg/ml), laminin (10 mg/ml) or TS2/16
(10 mg/ml), allowed to adhere for 1 h and then treated with (þ ) or without ()
etoposide (25 mg/ml), Na3VO4 (200 mM) or LY294002 (30 mM) as indicated. The
percentage of apoptotic cells was assessed at 48 h by flow-cytometric analysis of
surface annexin V staining (mean of n¼ 3 independent experiments7S.E.M.).
(b) Quiesced H345 cells were seeded into six-well plates precoated with poly-L-
lysine (10 mg/ml) or laminin (10 mg/ml) and treated with (þ ) or without ()
etoposide (25 mg/ml) or LY294002 (30 mM) as indicated. After 24 h the cells were
lysed and the expression of phospho-Bad (p-Bad), Bad, cleaved caspase-9 (p10)
and caspase-3 was determined by Western blot. Representative blots from n¼ 3
experiments are shown. Actin is shown as a loading control. (c) Quiesced H345
cells were seeded into six-well plates precoated with poly-L-lysine (10 mg/ml) or
laminin (10 mg/ml) and treated with (þ ) or without () etoposide (25 mg/ml), z-
VAD (100 mM), LY294002 (30 mM), tyrphostin-25 (tyrpho-25) (25 mM) or Na3VO4
(200mM) as indicated. Caspase-3 activity was measured after 48 h as described
in Materials and Methods, and normalized to untreated cells on poly-L-lysine
(mean of n¼ 3 experiments7S.E.M.)
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flow-cytometric analysis of propidium iodide staining. H345
SCLC cells showed similar cell cycle profiles whether grown in
suspension or adhered to poly-L-lysine or laminin (Figure 4a). At
24 h after treatment with etoposide (25mg/ml) or ionizing
radiation (2 Gy), H345 SCLC cells adhered to poly-L-lysine
showed a significant increase in the percentage of cells in the S
and G2/M phases of the cell cycle, with a reciprocal reduction in
the percentage of cells in G1 (Figure 4a and Table 1). In
contrast, H345 cells adhered to laminin and treated with
etoposide or ionizing radiation showed only a small increase
in the percentage of cells in S and G2/M phase, with a minimal
reciprocal reduction in the percentage of cells in G1. Similar
results were observed with fibronectin (data not shown).
To investigate whether ECM proteins protect against cell
cycle arrest via activation of b1 integrin/PI3-kinase signalling,
we treated H345 SCLC cells adhered to poly-L-lysine or
laminin with etoposide for 24 h in the presence of the b1


























































Figure 4 ECM overrides etoposide- and radiation-induced cell cycle arrest via b1 integrin-mediated PI3-kinase activation. (a) H345 cells were quiesced overnight,
washed twice and seeded into a six-well tissue culture plate, uncoated (plastic) or precoated with poly-L-lysine (10 mg/ml) or laminin (10 mg/ml). Cells were treated as
indicated: no further treatment (), etoposide (25 mg/ml) or ionizing radiation (2 Gy) (XRT). Progression through the cell cycle was assessed 24 h later by flow-cytometric
analysis of DNA content using CELL Quest software. Representative histograms are shown from n¼ 5 independent experiments. (b) Quiesced H345 SCLC cells were
seeded into six-well tissue culture plates precoated with poly-L-lysine (10 mg/ml) or laminin (10 mg/ml) and treated with etoposide (25 mg/ml). In addition, cells were
treated as indicated: blockade of b1 integrin function with 4B4 (10 mg/ml), stimulation of b1 integrins with TS2/16 (10 mg/ml), inhibition of PI3-kinase with LY294002
(30 mM) or activation of tyrosine kinase with Na3VO4 (200 mM). Progression through the cell cycle was assessed 24 h later by flow-cytometric analysis of DNA content
using CELL Quest software. Representative histograms are shown from n¼ 5 independent experiments. (c) H345 SCLC cells were seeded into six-well plates
precoated with poly-L-lysine (10 mg/ml) (PLL), laminin (10 mg/ml) or TS2/16 (10 mg/ml). Cells were treated with (þ ) or without () etoposide (25 mg/ml), LY294002
(30 mM) or Na3VO4 (200 mM) as indicated. Cells were lysed after 24 h and the expressions of p21
Cip1/WAF1, p27Kip1, phosphorylated CDK1 (p-CDK1), phosphorylated
CDK2 (p-CDK2) and cyclins D, E, A and B were determined by Western blot analysis. Representative blot from n¼ 3 experiments. Actin is shown as a loading control
Table 1 ECM protects SCLC cells from etoposide- and radiation-induced cell cycle arrest
Plastic Poly-L-lysine Laminin
Cell cycle phase — — Etoposide XRT — Etoposide XRT
Sub-G0 5.671.6 6.171.3 4.972.4 5.471.4 6.371.7 5.171.1 3.571.7
G1 64.872.5 65.372.8 23.272.3 22.171.8 67.173.1 53.271.9 60.172.6
S 17.372.0 18.271.7 25.471.6 24.572.1 16.772.3 22.271.7 20.171.8
G2/M 8.871.0 9.170.6 46.271.5 47.872.1 8.472.1 16.872.0 16.171.9
H345 cells were quiesced overnight, washed twice and seeded into a six-well tissue culture plate, uncoated (plastic) or precoated with poly-L-lysine or laminin. Cells
were treated as indicated: no further treatment (), etoposide or ionizing radiation (XRT). Progression through the cell cycle was assessed 24 h later by flow cytometric
analysis of DNA content using CELL Quest software. Mean percentage of total cells in each phase of the cell cycle is shown from n¼5 experiments 7S.E.M.
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stimulating antibody TS2/16, Na3VO4 or LY294002, and
assessed progression through the cell cycle (Figure 4b and
Table 2). Blockade of b1 integrins with 4B4 completely
abrogated laminin-mediated protection from G2/M cell cycle
arrest induced by etoposide in H345 SCLC cells without
affecting cell cycle arrest in cells adhered to poly-L-lysine.
Furthermore, laminin-mediated protection from etoposide-
induced G2/M cell cycle arrest was blocked by inhibition of
PI3-kinase with LY294002. In addition, stimulation of b1
integrins on H345 SCLC cells with TS2/16 or activation of
tyrosine kinase with Na3VO4 reduced etoposide-induced G2/
M cell cycle arrest, simulating the effects of ECM. These
results indicate that protection of SCLC cells from etoposide-
induced cell cycle arrest by ECM proteins is mediated via b1
integrin activation of PI3-kinase signaling.
DNA damage can activate p21Cip1/WAF1 and p27Kip1 and
inhibit Cdc25s (activator of CDK1) to cause G1/S and G2/M
arrest.8 PI3-kinase has been shown to induce expression of
D-type cyclins and to increase stability of cyclin-D1 through
PKB-dependent phosphorylation of GSK3b.21 Therefore, we
investigated whether ECM proteins could modulate cell cycle
regulators through PI3-kinase and thus prevent G2/M cell
cycle arrest. After 24 h of etoposide treatment, H345 SCLC
cells showed an increase in expression of the CDK inhibitors
p21Cip1/WAF1 and p27Kip1 and phosphorylated CDK1 (inactive
form) with decreased expression of phosphorylated CDK2
(active form) and cyclins E, A and B (Figure 4d). Adhesion of
H345 SCLC cells to laminin increased cyclin D expression and
blocked the etoposide-induced changes in p21Cip1/WAF1,
p27Kip1, phosphorylated CDK1 and 2, and cyclins E, A and
B. Similar results were seen with fibronectin (data not shown).
Furthermore, the effects of ECM were simulated by TS2/16
antibodies, but with less pronounced effects due to the
bivalent nature of antibody binding, which will produce less
integrin clustering and three-dimensional changes than
laminin. The ability of laminin or TS2/16 to overcome
etoposide-induced changes in cell cycle regulators was
blocked by the PI3-kinase inhibitor LY294002. These results
indicate that ECM proteins via b1 integrins can override
etoposide-induced G2/M cell arrest by modulating expression
of cyclins, CDKs and CDK inhibitors in a PI3-kinase-
dependent manner.
Expression of a dominant-negative PKB mutant
prevents, and a constitutively active PKB mutant
mimics, ECM-mediated protection from apoptosis
and cell cycle arrest
Although LY294002 is accepted as a specific inhibitor of PI3-
kinase/PKB signaling at the doses used, it can inhibit other
pathways that may affect cell survival. Therefore, we sought
to genetically interfere with PI3-kinase signaling in SCLC cells
to confirm the effects of LY294002 on ECM-mediated
chemoprotection. We have shown that binding of SCLC cells
to ECM leads to activation of PI3-kinase, which activates
PKB. Thus, to specifically examine downstream PKB signal-
ing, we interfered with the activity of PKB through the
expression of both constitutively active (PKB CA) and
dominant-negative (PKB DN) PKB mutants. We found that
transient expression of PKB DN in H345 SCLC cells markedly
inhibited phosphorylation of downstream GSK3b, whereas
expression of PKB CA increased phospho-GSK3b levels, in
accordance with the expected activity of these mutants on
PKB signaling (Figure 5a). Importantly, expression of PKB CA
protected H345 cells adhered to poly-L-lysine from etoposide-
induced apoptosis (Figure 5b). Expression of PKB DN
produced a small increase in apoptosis both with and without
etoposide treatment in cells adhered to poly-L-lysine. How-
ever, PKB DN markedly increased etoposide-induced apop-
tosis in cells adhered to laminin (Figure 5b). Similar results
were obtained with H69 cells (data not shown).
To confirm the results obtained with LY294002 on
ECM-mediated protection from G2/M arrest, we transiently
expressed PKB DN and PKB CA in H345 cells adhered to
poly-L-lysine or laminin and analyzed progression through the
cell cycle. In cells adhered to poly-L-lysine, transient expres-
sion of PKB CA reversed etoposide-induced G2/M arrest
(Figure 5c and Table 3). Transient expression of PKB DN in
cells adhered to poly-L-lysine caused a modest increase in the
G2/M population with and without etoposide treatment.
Importantly, expression of PKB DN in cells adhered to laminin
significantly reversed protection from etoposide-induced G2/
M arrest and caused a small, but significant, increase in G2/M
arrest without etoposide treatment (Figure 5c and Table 3).
Taken together, the results observed with LY294002 and the
PKB mutants suggest a central role for PI3-kinase/PKB
signaling in ECM-mediated chemoprotection in SCLC cells.
Adhesion to ECM proteins does not modulate
ongoing etoposide- and radiotherapy-induced
DNA damage or repair
In order to confirm that the antiapoptotic and cell cycle effects
of ECM were not due to a reduction in etoposide activity or
altered repair of etoposide- and radiation-induced DNA
Table 2 ECM overrides etoposide- and radiation-induced cell cycle arrest via
b1 integrin-mediated PI3-kinase activation
Poly-L-lysine
Cell cycle phase — 4B4 LY294002 Na3VO4
Sub-G0 3.671.7 4.971.1 4.370.9 4.570.7
G1 24.273.9 23.272.2 22.172.5 39.871.8
S 22.672.1 20.872.8 19.371.3 24.572.1
G2/M 48.273.1 46.972.8 52.573.0 28.672.0
Laminin TS2/16
Cell cycle phase — 4B4 LY294002 —
Sub-G0 4.272.1 4.371.1 3.270.9 4.172.1
G1 52.373.1 22.872.0 20.971.7 44.271.8
S 20.271.9 19.773.0 16.172.4 28.772.2
G2/M 18.472.5 51.272.2 58.873.1 21.772.6
H345 SCLC cells were seeded into six-well tissue culture plates precoated with
poly-L-lysine, laminin or TS2/16 and treated with etoposide. In addition, cells
were treated as indicated: blockade of b1 integrins with 4B4, inhibition of PI3-
kinase with LY294002 or activation of tyrosine kinase with sodium orthovana-
date (Na3VO4). Progression through the cell cycle was assessed 24 h later by
flow cytometric analysis of DNA content using CELL Quest software. Mean
percentage total cells in each phase of the cell cycle is shown from n¼5
independent experiments 7S.E.M.
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damage, we assessed Topo II activity and DNA double-strand
break formation and repair. Topo II resolves sister chromatid
entanglement by binding to DNA, cleaving both strands and
passing a second duplex through the first before reannealing
the cleavage site.25 Etoposide blocks the reannealing action
of Topo II after the enzyme has created a double-strand break
leading to activation of DNA damage signaling pathways and
ultimately apoptosis.25 We measured Topo II activity by the
ATP-dependent de-catenation of high-molecular-weight
DNA. While etoposide was able to inhibit Topo II activity,
adhesion to the ECM protein laminin did not affect etoposide
inhibition of Topo II activity or Topo II expression. The PI3-
kinase inhibitor LY294002 had no effect on either Topo II
expression or activity (Figure 6a).
To determine the amount of DNA damage induced by
etoposide and radiation, H345 cells were seeded onto plastic
precoated with poly-L-lysine or laminin and then treated as
specified. The cells were washed, allowed to recover, and the
amount of DNA double-strand breaks in cell nuclei was
determined by immunofluorescence staining of phosphory-
lated H2AX (gH2AX). The foci of gH2AX represent actual DNA
double-strand breaks and correlate closely with cell death in
response to DNA damage (Figure 6b and c).26 DNA double-
strand breaks were also confirmed by Western blotting for
gH2Ax and DNA-dependent protein kinase catalytic subunit
(DNA-PKcs) (Figure 6d). A very marked and equal increase in
gH2Ax foci was seen 2 h after etoposide (30 min after
radiotherapy – data not shown). Over the following 24-h
period, there was a decrease in the number of double-strand
breaks as DNA damage was repaired (Figure 6b–d). Crucially
there was no difference in the amount of DNA damage or rate
of repair in response to etoposide or radiation between cells
plated on laminin or nonspecifically adhered to plastic by poly-
L-lysine. Interestingly, while nearly all of the DNA damage was
repaired, there were still a significant number of gH2Ax foci
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Figure 5 Expression of a dominant-negative PKB mutant prevents, and a constitutively active PKB mutant mimics, ECM-mediated protection from apoptosis and cell
cycle arrest. (a) H345 SCLC cells were transfected with equal amounts of empty vector (pUSEamp), dominant-negative PKB (PKB DN) or constitutively active PKB (PKB
CA). After 48 h, cells were lysed and expression of the myc-tagged PKB mutants, GSK3 a/b and phospho-GSK3a (p-GSK3a) was determined by Western blot. (b) H345
cells were transfected with equal amounts of PKB DN (þ ) PKB CA (þ ) or empty pUSEamp () as indicated. After 24 h cells were quiesced, resuspended in SITA,
plated onto poly-L-lysine or laminin and treated with etoposide as indicated. After 48 h the percentage of apoptotic cells was determined by flow-cytometric analysis of
annexin V. (c) H345 cells were transfected with equal amounts of dominant-negative PKB (PKB DN) (þ ), constitutively active PKB (PKB CA) (þ ) or pUSEamp ().
After 24 h the cells were quiesced, seeded into six-well plates precoated with poly-L-lysine or laminin and treated with etoposide as indicated. Progression through the cell
cycle was assessed 24 h later by flow-cytometric analysis of DNA content using CELL Quest software. Representative histograms are shown from n¼ 5 independent
experiments
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Discussion
Our results show for the first time that ECM proteins activate
b1 integrins to protect SCLC cells against the proapoptotic
effects of the DNA damaging agents, etoposide and ionizing
radiation through tyrosine kinase-mediated PI3-kinase activa-
tion. Etoposide, which inhibits the re-annealing activity of
Topo II causing DNA damage, upregulates CDK inhibitors
p21Cip1/WAF1 and p27Kip1, increases CDK 1 phosphorylation
and downregulates cyclins D, E, A and B and CDK 2
phosphorylation, causing G2/M cell cycle arrest. In SCLC
cells b1 integrin-mediated PI3-kinase activation via phosphory-
lation of PKB and GSK-3b leads to maintenance of cyclins D,
E, A and B, increases expression of phosphorylated CDK2
and downregulates CDK inhibitors, p21Cip1/WAF1 and p27Kip1
despite the presence of etoposide. This leads to continued
progression through the cell cycle, overriding etoposide-
induced G2/M arrest. Furthermore, adhesion of SCLC cells to
ECM via b1 integrin/PI3-kinase signaling results in phosphory-
lation of Bad and reduced caspase-9 cleavage, in response to
etoposide, preventing apoptosis. The interrelationship of ECM
effects on G2/M progression and apoptosis is not clear, but it
is likely that through PI3-kinase ECM overrides these
processes in parallel, to effect cell survival and proliferation.
Importantly, the effects of ECM occur despite etoposide-
induced Topo II inhibition and extensive DNA damage.
As a consequence, SCLC cells in the presence of ECM
are resistant to chemotherapeutic agents and continue to
cycle despite genetic abberations, possibly leading to the
Table 3 Expression of dominant-negative PKB prevents, and constitutively
active PKB mimics, ECM-mediated protection from G2/M cell cycle arrest
Poly-L-lysine Etoposide treatment
Cell cycle phase — PKB CA — PKB CA
Sub-G0 4.370.7 4.170.8 8.371.3 3.670.9
G1 63.272.9 60.173.3 19.672.1 49.871.8
S 15.671.8 17.371.6 27.371.4 21.573.1
G2/M 12.271.1 14.271.1 53.573.0 22.672.3
Poly-L-lysine Etoposide treatment
Cell cycle phase — PKB DN — PKB DN
Sub-G0 3.270.7 4.170.8 7.572.3 8.971.7
G1 61.373.9 51.673.3 24.671.9 27.671.9
S 17.372.1 20.471.9 26.872.4 26.872.7
G2/M 14.272.1 23.273.1 47.573.1 43.67 3.8
Laminin Etoposide treatment
Cell cycle phase — PKB DN — PKB DN
Sub-G0 4.071.8 4.271.9 3.170.7 8.171.1
G1 64.573.0 47.671.5 55.372.2 20.872.2
S 16.271.7 24.572.9 20.671.1 27.771.7
G2/M 11.672.1 21.272.0 15.271.0 49.272.1
H345 cells were transfected with equal amounts of dominant-negative PKB
(PKB DN), constitutively active PKB (PKB CA) or empty vector (). After 24 h,
the cells were quiesced, seeded into six-well plates precoated with poly-L-lysine
or laminin and treated with etoposide as indicated. Progression through the cell
cycle was assessed 24 h later by flow cytometric analysis of DNA content using
CELL Quest software. Mean percentage of total cells in each phase of the cell
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Figure 6 Adhesion to ECM does not affect etoposide-induced Topo II inhibition
or DNA double-strand break formation and repair. (a) H345 cells were adhered to
poly-L-lysine or laminin and treated with (þ ) or without () etoposide (25 mg/ml),
LY294002 (30 mM) or tyrphostin-25 (25 mM) as indicated. Nuclear extracts were
prepared and Topo II activity was determined by ATP-dependent decatenation of
kinetoplast DNA (kDNA) as described in Materials and Methods. A representative
UV gel is shown (from n¼ 3 independent experiments): MC – decatenated
individual DNA mini-circles (active Topo II), NW – high-molecular-weight
interlocking kDNA network (inactive Topo II)). In parallel samples, Topo II
expression was determined by Western blot analysis. (b) Quiesced H345 SCLC
cells were adhered for 1 h to eight-well coverslides precoated with poly-L-lysine
(10 mg/ml) or laminin (10 mg/ml) and treated with etoposide (25 mg/ml) for 2 h.
Cells were washed twice and the medium was replaced with RPMI containing
10% FCS. Cells were fixed at 0–24 h after removal of etoposide as indicated,
stained with anti-gH2Ax antibody and foci viewed by fluorescence microscopy.
Representative images of gH2Ax foci from n¼ 4 independent experiments.
Untreated cells are shown for comparison. (c) H345 SCLC cells were seeded into
eight-well coverslips precoated and treated with poly-L-lysine (closed bars) or
laminin (open bars) and allowed to adhere for 1 h. The cells were treated with
etoposide (25 mg/ml) for 2 h, washed and allowed to recover in RPMI with FCS.
Cells were fixed at 0–24 h after removal of etoposide as indicated, stained with
anti-gH2Ax antibody and foci viewed by fluorescence microscopy The intensity of
gH2Ax staining in 10 high-power fields was quantified with Openlab image
analysis software for each condition and normalized to untreated cells (mean
relative gH2Ax foci of n¼ 4 experiments). (d) H345 cells were adhered to
poly-L-lysine () or laminin (þ ), treated with etoposide (25 mg/ml) and lysed
at the times indicated. Expression of DNA-PKcs and gH2Ax was deter-
mined by Western blot analysis. Representative blot from n¼ 3 independent
experiments
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emergence of drug-resistant clones. As the DNA damage is
random, genetic drug resistance can be achieved as a result
of a wide variety of insults, explaining why no unifying
mechanism for the emergence of MDR in SCLC has been
defined.
The development of MDR is a major cause of treatment
failure in cancer.2 Central to the cellular response to DNA
damage is cell cycle arrest at regulated checkpoints with
subsequent activation of cell death by apoptosis.8 MDR is a
multi-factorial phenomenon, and therefore it may be more
effective to target the processes which enhance survival and
prevent apoptosis induced by initial drug treatment in cancer
cells, preventing the emergence of acquired drug resis-
tance.27 Resistance mechanisms in vitro differ from those in
vivo, suggesting that the local cellular environment plays a
significant role in selection for in vivo drug resistance. Our
previous results in SCLC suggest that in vivo interactions
between tumor cells and ECM proteins in the microenviron-
ment are involved in the early stages of drug selection,
providing a survival advantage to ECM adherent SCLC cells,
and promote the acquisition of the classical forms of drug
resistance.
Detachment of anchorage-dependent cells results in
apoptotic cell death.28 This can be prevented by constitutive
activation of integrin-dependent signaling pathways such as
PI3-kinase and PKB.29 While anchorage-independent growth
is a major step in cellular transformation leading to cancer and
metastases, cancer cells may still use integrin survival
signals. Our work and results from other groups show that a
number of cancers, including SCLC, breast, prostate, colon
cancer and hematological malignancies, all use ECM adhe-
sion for survival to evade the cytotoxic effects of chemo-
therapy or radiotherapy.3,5–7 While this appears to be a
general and important phenomenon, the actual intracellular
mechanisms coupling integrin activation to protection from
chemotherapy- and radiotherapy-induced apoptosis may be
cancer cell type specific. The mechanisms described here for
SCLC differ from those reported previously, particularly
myeloma cells. This may reflect cell type specificity potentially
relating to differing integrin behavior between hematological
malignancies and solid tumors. Previous studies in hema-
poeitic tumor cells have demonstrated that adhesion to
fibronectin protected against chemotherapeutic agents
through increased expression of p27Kip1 and G1 cell cycle
arrest.30 Furthermore, integrin-mediated adhesion in hema-
poeitic cancer cells reduced DNA double-strand breaks and
apoptosis caused by chemotherapeutic agents such as
mitoxantrone and etoposide.31 This primarily a5b1-mediated
reduction in DNA damage correlated with decreased topo-
isomerase-II enzymatic activity. However, the a5b1 integrin is
not found in SCLC cells and is reduced in other carcino-
mas.3,32 Furthermore, our results show that, in SCLC cells
grown in suspension or adhered to ECM proteins such as
laminin and fibronectin, the enzymatic activity of topoisome-
rase-II and the amount of etoposide- or radiation-induced
DNA double-strand breaks remain unchanged. In addition, the
rate of proliferation is also unaffected by adhesion to ECM
proteins. These results demonstrate that decreased prolifera-
tion and changes in Topo II activity are not the mechanisms of
integrin-mediated drug resistance in SCLC cells.
The PI3-kinase/PKB pathway contributes to the pathogen-
esis of cancer and confers resistance to apoptosis.19,33
Activated PI3-kinase phosphorylates inositol lipids, resulting
in the activation of the serine/threonine kinase PKB that
phosphorylates caspase-9 and BAD, promoting cell survi-
val.19 Activated PKB can also regulate cellular proliferation by
interaction in the nucleus with cell cycle regulators governing
G1/S and G2/M checkpoints.34 In this study, we have shown
that inhibition of PI3-kinase prevents b1 integrins from
overriding etoposide-induced G2/M cell cycle arrest and
apoptosis, indicating that PI3-kinase is crucial for ECM-
mediated chemoprotection in SCLC cells. Previous work has
indicated that inhibition of growth factor stimulated PI3-kinase
activity, promotes apoptosis and enhances sensitivity of
SCLC cells to chemotherapy.18 Primarily, we found that
pharmacological and genetic inhibition of PI3-kinase/PKB
signaling dramatically reversed ECM-mediated chemoprotec-
tion. However, we did observe an increase in apoptosis
measured by annexin V staining at 48 h with inhibiton of PI3-
kinase signaling both with and without etoposide. These
results confirm previous data by Krystal et al. (2002), but the
effects on apoptosis were less pronounced in our system,
possibly due to differences in experimental design and cell
types examined. This small effect on apoptosis is in keeping
with previous data published on the use of LY294002.18,35
Integrins and growth factors in untransformed cells only
regulate cell cycle progression at the G1/S checkpoint.11
Current evidence suggests a central role for PI3-kinase
signaling pathway in regulating cell cycle progression. PI3-
kinase activation can be sufficient to induce G1 transit in
fibroblasts.34 Thus, downstream targets of PI3-kinase/PKB-
dependent pathways that regulate normal cell cycle progres-
sion may also participate in overriding etoposide- and
radiation-induced cell cycle checkpoints. PI3-kinase activity
has been shown to induce expression of D-type cyclins and to
increase cyclin D1 stability through PKB-dependent phos-
phorylation of GSK-3b.21 G1 progression depends on the
sustained expression of D type cyclins. The cyclin D–CDK 4
and 6 complex sequesters the CDK inhibitors p21Cip1/WAF1
and p27Kip1, which allows cyclin E–CDK 2 to drive the cell
cycle through late G1, allowing the derepression of cyclin A at
the onset of S phase.16 Deletion of the p27Kip1 gene restores
the growth phenotype of cyclin D1 null mice.36 Furthermore
cells, which overexpress cyclin E, still depend on cyclin D1
accumulation to sequester the enhanced p21Cip1/WAF1 levels,
suggesting that a major function of cyclin D1 in cell cycle
control is the redistribution of CDK inhibitors.37 PI3-kinase
effects on G1-phase progression may also be mediated
through the downregulation of expression and function of
p27Kip1.38 Thus, adhesion to ECM via integrin-mediated
activation of PI3-kinase may reduce levels of p21Cip1/WAF1
and p27Kip1, allowing cells to progress through the G1/S
phase of the cell cycle.
SCLC cells have previously been shown to have a defective
G1/S checkpoint, which correlates with mutant inactive p53.39
We confirm the reports of others that etoposide and ionizing
radiation lead to G2/M cell cycle arrest in SCLC cells.
Furthermore, our data clearly demonstrate that the b1
integrin/PI3-kinase pathway in SCLC cells regulates progres-
sion through the G2/M checkpoint. The ability of b1 integrins to
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override etoposide-induced G2/M arrest in SCLC cells could
result from increased DNA repair, thus removing signals for
cell cycle arrest. Importantly, we found no difference in the
degree of DNA damage induced by etoposide or XRT in cells
adhered to either laminin or poly-L-lysine. Furthermore, when
cells were allowed to recover, we observed identical rates of
DNA repair. This suggests that ECM-mediated protection
from G2/M arrest is not caused by alterations in the amount of
DNA damage or the kinetics of DNA repair. The finding of
identical DNA repair is interesting because laminin, by driving
cells through the G2/M cell cycle checkpoint, might reduce the
time scale for effective DNA repair, resulting in increased
amounts of damaged DNA. However, previous data have
demonstrated that DNA repair can occur at all stages of the
cell cycle and cells have mechanisms for tolerating damaged
DNA, allowing replication of the genome.40 Therefore, it is
possible that, in cells driven through the G2 checkpoint by
laminin, damaged DNA is tolerated, to be repaired during
other phases of the cell cycle. This could result in similar
apparent levels of DNA double-strand break repair between
cells adhered to laminin and poly-L-lysine. Importantly,
tolerating mechanisms are more likely to introduce point
mutations, increasing the likelihood of long-term genetic
damage.
Crucially, what we have demonstrated in this paper is that
etoposide treatment of SCLC cells adhered to poly-L-lysine
induces DNA double-strand breaks causing G2/M cell cycle
arrest and ultimately apoptotic cell death via caspase
activation. However, although etoposide induces identical
DNA damage in cells adhered to ECM, b1 integrin/PI3-kinase
activation by ECM proteins prevents prolonged G2/M arrest
by downregulating p21Cip1/WAF1 and p27Kip1, reduces phos-
phorylation of CDK1, maintains expression of cyclin D, E, A
and B and phosphorylates CDK2. Thus, adhesion to ECM
allows SCLC cells to survive following significant treatment-
induced DNA damage, increasing the likelihood of propaga-
tion of genetic mutations, providing an explanation for the
acquisition of MDR following initial therapy.
b1 integrin-mediated adhesion between tumor cells and the
ECM in their environment confers a survival advantage to
SCLC cells, protecting from apoptosis and allowing cells with
damaged DNA to drive through the cell cycle. This may lead to
the propagation of further transforming genetic mutations,
which may ultimately cause acquired MDR in what were
initially chemo-sensitive cells. Thus, the environmental con-
text and specificity of cancer cells may have important
consequences on the acquisition of MDR and therapies
designed to disrupt specific interactions between cells, and
their environment may be important targets in the circumven-
tion of MDR. This has important implications for the role of
dose intensification and adjuvant treatment by inhibiting b1
integrin/PI3 kinase signaling to enhance the cytotoxic effects
of chemotherapy. However, integrins play a key role
particularly in the immune system and protection against
infection; thus targeting b1 integrins may have deleterious
side effects. Our initial observations on cell-adhesion
mediated drug resistance have been shown to be widely
applicable in a number of cancers including breast, colon and
hematological cancers. We believe the mechanisms outlined
in this article will also have broad implications, particularly in
cancers that are initially sensitive to cytotoxic treatment and
then become resistant. A better understanding of the b1-
specific mechanisms mediating integrin protection against the
proapoptotic effect of DNA damaging drugs may lead to the




All experiments used NCI-H69, NCI-H345 and NCI-H510 cell lines from
ATCC (Rockville, MD, USA) which were grown in HEPES buffered RPMI
1640 medium (Invitrogen) supplemented with 10% (v/v) heat-inactivated
fetal calf serum (FCS) (Labtec), 5mg/ml L-glutamine, 100 U/ml penicillin
and 100mg/ml streptomycin (Invitrogen Ltd, UK). For experiments, cells
were cultured overnight in quiescent media (RPMI supplemented with
0.25% (w/v) BSA, 100 U/ml penicillin and 100 mg/ml streptomycin), and
then resuspended in SITA media (RPMI supplemented with 30 nM
selenium, 5 mg/ml insulin, 10mg/ml transferrin, 0.25% (w/v) BSA, 100 U/ml
penicillin and 100 mg/ml streptomycin). FCS contains fibronectin (25 mg/
ml), which will stimulate b1 integrin/PI3-kinase signaling, and therefore it
was necessary to remove FCS prior to and during experiments examining
the effects of ECM on SCLC cells.
Transfection of cell lines
Plasmids encoding myc-tagged constitutively active PKB-pUSEamp myr-
Akt1/PKBa and myc-tagged dominant-negative PKB-pUSEamp Akt1/
PKBa (K179M) were obtained from Upstate Biotechnology. pUSEamp
was used as an empty vector control. Plasmid inserts were sequenced
prior to use. For transfection H345 and H69 cells were washed twice,
resuspended in antibiotic free culture RPMI (0.5 106 cells/ml) and
transfected with 1 mg of DNA/106 cells using Lipofectamine 2000 (1 : 5
ratio) according to the manufacturer’s instructions.
Apoptosis
SCLC cells were quiesced by overnight incubation at 371C in quiescent
medium. Cells were washed twice and seeded (4 104 cells in 200ml of
SITA per well) into 96-well plates which had been precoated by incubation
at 371C for 1 h with poly-L-lysine (10 mg/ml) (Sigma), laminin (10 mg/ml)
(Sigma), fibronectin (20 mg/ml) (Sigma) or TS2/16 (10 mg/ml) (BioLegend)
as specified. Cells were allowed to settle for 1 h at 371C and then treated
with Na3VO4 (200mM) (Sigma), LY294002 (30 mM) (Calbiochem),
tyrphostin-25 (25 mM) (Calbiochem) or etoposide (25 mg/ml) (Sigma) as
specified. Cells were treated with ionizing radiation (1–4 Gy) as specified
using a 6 MV linear accelerator. In experiments using 4B4 to block b1
integrin function, cells were incubated with 4B4 (10 mg/ml) (Beckman
Coulter) at 37oC for 30 min prior to seeding onto ECM. Apoptosis was
assessed 0–72 h later by the addition of 1ml of ethidium bromide (1 mg/ml)
(Sigma) and 1 ml acridine orange (1 mg/ml) (Sigma) and the percentage of
apoptotic cells was determined by fluorescent microscopy as described
previously.5 Apoptosis was also determined using a cell death detection
ELISAt kit (based on the quantitative detection of histone-associated
DNA fragments in mono- and oligonucleosomes) according to the
manufacturer’s instructions (Roche Diagnostics) and by flow-cytometric
analysis of Annexin V staining according to the manufacturer’s instructions
(Annexin V-PE BD Bioscience).
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PI3-kinase activity assay
PI3-K activity was measured as described previously.29 Briefly, cells were
spun onto six-well plates precoated with poly-L-lysine (10 mg/ml) (Sigma),
laminin (10 mg/ml) (Sigma), fibronectin (20 mg/ml) (Sigma) or TS2/16
(10 mg/ml) (BioLegend) as specified and lysed. PI3-kinase was
immunoprecipitated from protein-equilibrated cell lysates using a 10 mg
1 : 1 mixture of anti-phosphotyrosine antibodies PY20 and PY99 (Upstate
Biotechnology, Lake Placid, USA) and assayed for activity using
[g-32P]ATP and a mixture of phosphatidyl inositol and phosphatidyl serine
as substrate. 3-Phosphorylated lipids were resolved using thin-layer
chromatography after Folch extraction. PIP3 was identified by auto-
radiography and quantified by liquid scintillation counting.
PKB activity
PKB activity was measured as described previously.29 In brief, cells were
quiesced overnight, gently disaggregated and then treated as specified.
Cells were lysed, PKB was immunoprecipitated with anti-PKBa
conjugated to protein G-sepharose beads (41C for 90 min) and assayed
for activity using [g-32P]ATP and crosstide substrate (Upstate Biotechnol-
ogy). Radioactive incorporation was quantified by liquid scintillation
counting.
Caspase-3 activity
Quiesced SCLC cells were adhered to poly-L-lysine (10mg/ml) (Sigma),
laminin (10mg/ml) (Sigma), fibronectin (20mg/ml) (Sigma), or TS2/16
(10mg/ml) (BioLegend) as specified and treated with Na3VO4 (200mM)
(Sigma), LY294002 (30mM) (Calbiochem), tyrphostin-25 (25mM) (Calbio-
chem), etoposide (25mg/ml) (Sigma) or z-VAD (100mM) (Promega) as
indicated. Cells were lysed at 48 h and caspase-3 activity was assessed
using a caspase-3 cellular activity kit according to the manufacturer’s
instructions (Cat. no. 235419 Calbiochem). Specific caspase-3 activity (pmol/
min/mg protein) in each experiment was normalized to untreated cells.
Western blotting
Cells were treated as specified, lysed in RIPA buffer and protein balanced
by BCA protein assay (Pierce). Samples were resolved on 10, 12 or 14%
acrylamide gels (10 mg protein/lane) and separated proteins were
transferred onto nitrocellulose membranes. Blots were probed with the
following antibodies overnight at 41C in either 5% milk or 3% BSA in TBS
Tween: rabbit anti-actin (Sigma); rabbit anti-phospho-PKB (Sigma),
mouse anti-GSK-3a/b (Biosource International), rabbit anti-phospho-
GSK-3b (pS9) (Biosource International); mouse anti-p21Cip1/WAF1 (clone
CP74) (Sigma); mouse anti-p27Kip1 (clone DCS-72) (Sigma); mouse anti-
cyclin A (Oncogene Research Products) mouse anti-cyclin B (BD
Transduction Labs, USA); mouse anti-cyclin D1 (clone AM29) (Zymed);
mouse anti-cyclin E (clone HE12) (Upstate); rabbit anti-phospho-CDK2
(Thr160), rabbit anti-phospho-CDK1 (Tyr15) (both Cell Signaling
Technology, USA); mouse anti-gH2Ax (Upstate); mouse anti-DNA-PKcs
(p350 clone 6) (BD Biosciences); rabbit anti-phospho-Bad (Ser136); rabbit
anti-Bad (9292) (Cell Signaling Technology); rabbit anti-cleavage site-
specific caspase-9 antibody (CCSA 315/316) (Biosource); mouse anti-myc
(9E10) (Abcam); and rabbit anti-caspase-3 (Asp179) (5A1). Species-
specific horseradish peroxidase-conjugated antibodies (Dako) were used
as secondary labels and bands were visualized using ECL (Amersham)
according to manufacturer’s instructions. Relative protein expression was
quantified using Image J software.
Cell cycle analysis
Cells were quiesced overnight and seeded into six-well plates precoated
with laminin, fibronectin or TS2/16 and treated as specified. Cells were fixed
0–24 h later in 70% ice-cold ethanol (for at least 2 h), stained with propidium
iodide and subjected to flow-cytometric analysis (pulse processing) with a
FACS Calibur (BD Biosciences) flow cytometer. Cell cycle parameters from
10 000 events were analyzed using CELLQuest software.
Topo II activity
Topo II activity was measured as described previously.3 Briefly, nuclei were
extracted from SCLC cells treated as specified and lysed. The supernatant
was used in a Topo II assay, which measures Topo II activity by the ATP-
dependent de-catenation of high-molecular-weight kinetoplast DNA (kDNA).
Each sample was incubated for 30 min at 371C in reaction buffer (50 mM
Tris-HCl (pH 7.5), 10 mM MgCl2, 100 mM KCl, 0.5 mM EDTA, 30mg/ml
BSA, 1 mM ATP, 0.5 mM dithiothreitol and 100mg/ml kDNA (TopoGEN)).
The reaction products were separated by 1% agarose gel electrophoresis,
stained with ethidium bromide and photographed under UV light.
Visualization of DNA double-strand breaks
Cells were quiesced overnight and seeded into eight-well coverslides
(Nalge NUNC) at a density of 2.5 105 cells/cm2 precoated with laminin or
poly-L-lysine. Cells were allowed to adhere for 1 h at 371C and then treated
with etoposide (25mg/ml) for 2 h. Cells were then washed and allowed to
recover in RPMI with FCS. Cells were fixed at 0–24 h after etoposide
treatment with 3% paraformaldehyde for 5 min, washed twice with PBS,
permeabilized with 0.1% Triton and blocked with 0.2% fish skin gelatin.
Cells were incubated with 1 : 500 dilution of anti-gH2Ax (Upstate) for 2 h at
room temperature and washed with PBS. Secondary antibody labeled with
ALEXAflour 488 (1 : 500) was applied for 1 h at room temperature. The
slides were viewed using a Zeiss Axioskop 2 microscope. Image analysis
was performed using Openlab software from Improvision.
Statistical analysis
Data were analyzed by one-way analysis of variance and the appropriate
post-test analyses were applied. P-values o0.05 were considered to be
significant.
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